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The objectives of the present study were to design and evaluate elastic liposomes in 
comparison to simple drug solution and conventional liposomes, and in delivering a 
model NSAID, Ibuprofen (IBU) across human epidermis after topical application. The 
scope of the project included formulation development, characterization, and 
optimization based on their physical characteristics and determination of IBU 
penetration when incorporated in conventional and elastic liposomes through human 
epidermis after topical application, and finally to establish the relationship between the 
formulation variables and skin penetration of IBU loaded liposomes.  
A thin film hydration method was chosen to prepare liposomes where the hydrophilic 
molecule sodium fluorescein (NaFl) and poorly water soluble drug IBU were selected as 
molecules of interest for liposome development and evaluation. Conventional liposomes 
were prepared from phosphatidylcholine (PC) and cholesterol, and elastic liposomes 
were prepared from PC and surfactant (Tween 80 and sodium cholate) with 7% ethanol 
in the system. Process variables such as the solvent system, hydration medium, and 
method of size reduction were carefully selected for initial formulation development. 
Vesicles were optimized based on their physical characteristics (i.e. particle size and 
size distribution, zeta potential, entrapment efficiency (EE)) and bilayer elasticity. 
Morphology of different liposomes was examined by using a Transmission Electron 
Microscope (TEM). The in vitro release of both model drugs from various optimized 
formulations was investigated by dialysis method. The effects of formulation variables 
such as, type and concentration of surfactant, and ethanol on transdermal penetration of 
IBU loaded liposomes were investigated using Franz type diffusion cells under non-
occluded condition. 
Findings of the current study showed that the formulation variables and type of 
compound to be entrapped into liposomes have significant effect on the physical 
characteristics of both conventional and elastic liposomes. For example, inclusion of 
both cholesterol and surfactant showed a reduction in particle size of liposomes, 
irrespective of the type of molecule entrapped. However the impact of cholesterol on 
IV 
 
drug loading is complex.  Cholesterol increased the EE of NaFl loaded conventional 
liposomes but reduced EE in IBU loaded conventional liposomes. However, the 
inclusion of surfactants reduced the EE in both NaFl and IBU loaded liposomes. The 
zeta potential values of different liposomes were largely dependent on the composition 
of formulation and the type of molecule entrapped. Under TEM, all vesicles were found 
to be regular and spherical with the exception of those with a higher content of 
surfactant where vesicular structures were absent. The storage stability of NaFl loaded 
conventional liposomes was dependent on cholesterol content. Liposomes containing 
30% w/w cholesterol, showed maximum stability against particle fusion and 
aggregation. However all elastic liposomes showed maximum deformability at 15% 
w/w surfactant. Further increase in the surfactant content reduced elasticity considerably 
due to the formation of micelles, which lack the propensity for curved structure.  
Results of the in vitro release study of NaFl and IBU from liposomes showed that the 
release rate was biphasic in nature and was dependent on liposome composition. In the 
case of NaFl release, 30% w/w of cholesterol containing liposome had the slowest 
release rate compared to that of free drug and elastic liposomes. IBU release from 20% 
w/w cholesterol containing liposome was the slowest compared to all IBU loaded 
conventional and elastic liposomes. 
The skin penetration study in vitro showed significantly improved permeation of IBU by 
elastic liposomes compared to that of the conventional liposome and the control (free 
drug solution) due to the self penetration enhancing ability of elastic vesicles provided 
by individual functional components. The improvement in transdermal flux, 
permeability coefficient, enhancement ratio, and drug deposition in the skin from elastic 
liposomes indicate that these vesicles are a better delivery system for topical delivery of 
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1.1. Skin drug delivery system 
The ultimate objective of a successful drug delivery system is to deliver the drug 
effectively and specifically to the target site at a rate and concentration which will 
achieve greater efficacy and reduced toxicity than that of the conventional 
formulation of the same drug
1
. 
Among various routes of drug administration, drug delivery into and through the 
skin has established itself as a unique and useful method. Topical and transdermal 
drug delivery have played a vital role in the history of primitive remedies
2
.  
Transdermal drug delivery uses the skin as an alternative route for the delivery of 
systemically acting drugs whereas topical or dermal drug delivery is the topical 
application of drugs to the skin for treating local skin diseases. Drug delivery into 
(dermal) or via (transdermal) the skin offers many benefits over other routes of 
administration, which include providing continuous drug delivery
3
 with avoidance of  
hepatic first pass effect
4
, no gastrointestinal (GI) irritation as it bypasses the GI 
tract
4
, and reduced fluctuations in plasma drug levels
2
. Moreover drugs with short 
biological half-lives can be utilized. Overall dermal drug delivery system targets the 
drug for a local effect
2
, avoids variable absorption and metabolism associated with 
oral treatment, and enhances and maintains drug concentration in the skin. 
Furthermore it improves patient compliance
3
. 
1.1.1. Dermal drug delivery system 
Dermal  or topical drug delivery system can be defined as the application of a topical 
drug formulation to the skin to directly treat a dermatological condition (e.g. acne, 
skin cancer, eczema, and microbial infections) or the cutaneous manifestations of a 
general disease (e.g. psoriasis) with the intent of providing the pharmacological 
effect of the drug to the skin surface or within it
5
.  This delivery system has received 
serious attention in the past years due to its influence on enhanced dermal 
penetration. Dermal drug delivery system contains not only active drug but also 





. These formulation components all together are of utmost importance 
for successful dermal delivery. In dermal drug administration the primary step is the 
release and partitioning of the drug from the delivery system into the skin, which to 
certain extent, is governed by the drug partition coefficient. A vehicle utilized for 
such delivery usually has high active holding capacity. Penetration enhancers 
utilized in such vehicle influence drug release, drug diffusion and partition in the 
skin. 
1.2. Skin physiology and barrier function 
The skin is the largest organ of human body (up to 10% of body weight), which 
forms a barrier against the external environment, protecting the body from unwanted 
influences
2
. It is structured with three layers: epidermis (<100 µm), dermis (<4000 
µm), and subcutaneous layer. The pH of the skin varies from 4.5 to 6.0
7
. It is 
suggested that the acidity of the skin helps in limiting or preventing the growth of 
pathogens and other organisms
8
. A typical diagrammatic cross-section of human skin 
is shown in Figure 1.1.  
 
1.2.1. The epidermis 
The epidermis, the outermost layer of the skin, is covered with an emulsified lipid 
film with an acidic pH and is referred to as the “acid mantle”
9
. This acidic pH can be 
attributed to having glucose as the energy provider for the lower part of epidermis 
and also lactic acid as the end product of metabolism. These contribute to the skin 
pH being less than 6 
5
. The epidermis is composed of four strata: the stratum 
germinativum (the basal layer), the stratum granulosum (the malpighian layer), the 
stratum lucidum (the granular layer) and the stratum corneum (the horny layer).  
 
1.2.2. The dermis 
The dermis lies between the epidermis and the subcutaneous fatty region. It is 
composed of a network of loose connective tissue principally of collagen fibrils 
(provide support) and elastic tissue (provides flexibility) embedded in 
mucopolysaccharides
10
. Numerous structures are embedded within it, for example, 
nerves, blood vessels, hair follicles, sebaceous and sweat glands. Mast cells, 
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macrophages, melanocytes, leukocytes, and endothelial cells are also found in this 
region. However sebum from sebaceous gland is composed of free fatty acids, waxes 
and triglycerides, which maintain the surface pH around 5. Also eccrine glands 
secrete sweat, a dilute salt solution which is of pH around 5 
2
. Therefore the overall 
pH of dermis is around 5. Depending on body area, the dermis can be 10-40 times 
thicker than the epidermis and is viewed as gelled water layer providing a minimal 
resistance to most polar drug delivery
2
. The function of the dermis is to nourish the 
epidermis and to anchor it to the subcutaneous tissue
11
. 
1.2.3. The subcutaneous tissue/hypodermis 
This resides between the dermis and the underlying body constituents
2
. The deeper 
hair follicles and sweat glands originate in this layer and principal blood vessels and 
nerves are carried to the skin
12
. The subcutaneous tissue provides a receptacle for the 
generation and storage of fat which in turn acts as both heat regulator and shock 
absorber
13




Figure 1.1: A diagrammatic cross-section through full thickness human skin 






Despite many advantages in skin drug delivery, a limited number of drugs can be 
designed as topical, transdermal delivery products due to the barrier function of the 
stratum corneum, which limits  the passage of nearly all but  smallest lipophilic 
compounds
15







Moreover, achieving a high and constant drug flux through the skin is a difficult task 




1.2.4. The stratum corneum as a permeability barrier 
The stratum corneum, the outermost layer of the epidermis is a quasi-passive and 
very thin anatomical barrier with a thickness between 5 and 8 µm, exceptionally up 
to just above 20 µm
18
 and when hydrated up to 40 µm
19
. It consists of 10-15 layers 
of keratin-filled dead flattened cells, the corneocytes
20
. The stratum corneum is a 
“brick and mortar”-like structure of corneocytes. “Brick” represents corneocytes and 
“mortar” is the intercellular matrix
21
; corneocytes are more than 90% of all cells in 
the stratum corneum 
17
.  
Keratin is a fibrous protein, which is produced by the epidermis beneath. The cell 
boundary, the cornified envelope, runs perpendicular to the skin surface and is 
entirely surrounded by crystalline lipid lamellar regions
20
 which is not only abundant 
but also highly organized and thus acts as an extra intercellular “glue” sealing the 
empty spaces between the cells
22
. Such architecture of the stratum corneum is 
extremely impermeable but to the smallest compounds. 
The thickness of the average mammalian corneocyte is approximately 0.3µm
23, 24
 but 
values up to 0.8 µm have also been reported
25
. The average number of corneocytes 






. Each flat superficial 
corneocyte covers 1100-1200 µm
2
 of the skin, but deep in the dermis, the cells are 




. Groups of up to a dozen 
corneocytes columns in the stratum corneum form clusters which represent the basic 






The stratum corneum is neither continuous, nor homogenous. Some regions 
(especially the finger tips, bottom of the toes, the palmar and plantar surfaces) show 
extensive lines and ridges or dermatoglyphics, whereas the rest of the skin is 
comparatively smooth
20
. Again the resistance to molecular diffusion varies according 
to quality, crystallinity and total quantity (<15 wt %) of lipids in the stratum 
corneum, body sites, gender and species and is higher in human or pig than in 
rodent
17
. Although some researchers have suggested that sweat pores and hair ducts 
penetrating through the stratum corneum could be utilized to traverse the barrier, it 
seems that the cross sectional area of the pores is so small as to be negligible
20
. 
Moreover the outward movement of the sweat or sebum would tend to flush out 
everything which did penetrate
20
.  
The major lipid classes in the stratum corneum are long chain ceramides (40%), 
cholesterol (25%), free fatty acids (FFA; 25%), triglycerides, cholesterol sulphate, 
and sterol or wax esters
21,27,28
. These are called „skin lipids‟ and are arranged in 
bilayer sheets filling the intercellular space in the stratum corneum creating a 
compact structure. Lipid synthesis occurs in the corneocytes during epidermal 
differentiation, and they are extruded into the extracellular domains and form 
extracellular lipid enriched layers
29
. Altogether the stratum corneum provides a 
greater resistance unit to drug penetration. 
 
1.3. Skin penetration pathways 
A penetrant that is applied to the skin surface has three potential pathways by which 
it may traverse intact stratum corneum: via appendages (shunt routes), through the 
intercellular lipid domain, or via a transcellular route.  
1.3.1. Shunt route 
The pores of the appendages (hair follicles, sweat ducts) bypassing the barrier of the 
stratum corneum occupy only around 0.1% of the total skin surface
19
. Though 
eccrine sweat glands are numerous in palms and soles, their openings onto skin 
surface are also very small. Moreover, beyond this surface area, they either evacuate 
or secrete sweat that is expected to reduce inward diffusion of topically applied 
substances. The hair follicular pore openings are considerably larger than that of the 
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eccrine glands but are less numerous. The sebaceous gland ducts are also filled with 
sebum which is lipoidal
2
. Hence at a pseudo-steady state, penetration through the 
appendages makes a negligible contribution to total drug flux
30
. Shunt routes were 
found to be minor contributors at steady state flux of steroids through excised human 
skin
31
. Still, it can be utilized to contribute in the early time period between drug 
application and the establishment of steady state flux
32
; in the application of finite 
doses of medicine to skin in vivo for short time; the passage of large polar molecules 
and ions
2




Figure 1.2: A typical diagram representing macro-routes of drug penetration: 
(1) via the sweat ducts; (2) through the hair follicles with their associated 
sebaceous glands (Figure adapted from Barry
3
 and slightly modified) 
1.3.2. The intercellular route 
The only continuous domain within the stratum corneum is formed by the 
intercellular lipid matrix
34, 35
 which is generated by corneocytes in the mid to the 
upper part of the stratum granulosum, discharging their lamellar contents into the 
intercellular space
36
. This route is highly tortuous where penetrants pass through the 
continuous lipid domains between the corneocytes. The pathway the molecule has to 
traverse is considerably greater (ranging from 150-500 µm)
2
. Yet this route is 
considered to show much faster absorption due to the high diffusion coefficient of 
most drugs within the lipid bilayers as this route provides both hydrophilic and 
lipophilic regions. Such junctions between corneocytes clusters often reach several 
micrometers into the skin and each junction in the stratum corneum is a “hot spot” 
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for dermal and transdermal drug delivery
17
. Therefore this route is the principal 




1.3.3. The transcellular route 
The transcellular route is often regarded as a polar route and is suitable for highly 
hydrophilic compounds at a pseudo-steady state
2
. A penetrant traversing the intact 
stratum corneum via this route faces many hurdles. Firstly, it has to partition into the 
corneocytes, then diffuse through the hydrated keratin and then again partition into 
the lipid bilayer to reach the next corneocyte. In this traversing through multiple lipid 
bilayers, the molecule has to partition into and diffuse across the hydrophobic chains 
and hydrophilic head groups of the lipids
20
. With this route, the pathway is directly 
across the stratum corneum and hence the path length for permeation is usually 
regarded as the thickness of the stratum corneum. Considering all these factors, this 
route is usually not considered as a preferred route for dermal invasion. However 
when a penetration enhancer (for example, urea) was used, this route gained 




Figure 1.3: Simplified diagram of stratum corneum and two micro-routes of 






1.4. Penetration enhancement techniques 
The main difficulty in topical application of drug is to cross the stratum corneum, the 
major permeability barrier. Many strategies have been investigated to overcome this 
barrier which can be achieved chemically, physically or by use of vesicular 
components
40
. Combination of both chemical and physical methods or by 




1.4.1. Chemical penetration enhancers 
Chemical penetration enhancers basically enhance skin permeability by reversibly 
altering the physicochemical nature of the stratum corneum 
44, 45
. They disrupt the 
highly ordered structure of stratum corneum lipid, interact with intercellular proteins, 
and improve permeant partition into it with a view to reduce its diffusional 
resistance
46
. Solvents and surfactants are suitable examples of this. Good solvents 
are water, methanol, ethanol, dimethyl sulfoxide, alkyl homologs of methyl 
sulfoxide, dimethyl acetamide, dimethylformamide, glycerol, propylene glycol, 
isopropyl palmitate, Azone, N-methyl-2-pyrrolidone, pyrrolidones-2-pyrrolidone
47
. 
Surfactants that act as chemical enhancers can be either anionic (e.g. dioctyl 
sulphosuccinate, sodium lauryl sulphate, decodecylmethyl sulphoxide), cationic (e.g. 
cetyltrimethyl ammonium bromide) or non-ionic (e.g. Pluronic F127, Pluronic F68)
2, 
48
. Cationic surfactants damage human skin and are therefore not suitable for skin 
penetration
48
. Besides surfactants, bile salts (e.g. sodium taurocholate, sodium 
deoxycholate, sodium tauroglycocholate), binary systems (e.g. propylene glycol-
oleic acid, 1, 4-butane diol-linoleic acid) and miscellaneous chemicals (e.g. urea, N, 





1.4.2. Physical methods 
There are a few physical techniques which are applied to enhance skin permeation of 
topically applied agents. Iontophoresis, electroporation, ultrasound, microfabricated 
microneedle techniques cover the majority of approaches
32
. Iontophoresis works by 
electrically (≤ 0.4 mA/cm
2
) opening the stratum corneum by nanoporating the skin 
on a time scale of an hour by enlarging the pre-existing pores (pores of appendages, 
 
9 
already described under section 1.3.1) with an initial diameter of 0.5 nm
49
. The drug 
is briefly, applied under an electrode of the same charge as the drug, and a counter 
electrode is positioned elsewhere on the body. The active electrode effectively repels 
the drug and forces it into the skin
50
. Electroporation (or electropermeabilisation) is 
quasi-catastrophic electrical skin break-through, giving rise to relatively wider pores 
in the skin organ. These wide pores induce a dramatic and reversible increase in 
transmembrane transport. A relatively high potential (150 to 600 V) is applied to the 
membrane for a short time (micro to milli seconds)
51
 leading to transitory structural 
perturbation of lipid bilayer membranes. The skin resistance drops by several orders 
of magnitude during high voltage pulsing. Electroporation is widely used in 
introducing genetic material into bacterial cells and transcutaneous flux for small 




. Electroporation, however, when applied 
repeatedly, will result in strong skin damage, becoming an irreversible process and 
compromising the skin‟s function as barrier protection. In microneedles, needles 
(with an array of 20 x 20 needles with height of 150 µm, spaced 100 µm apart
53
)  are 
applied on skin and then removed  to form pores within the stratum corneum where 
the drug solution is to be added later. Alternatively drug loaded microneedle tips can 
be used for immediate delivery where the drug is delivered by application of 
pressure or electrical means
2
. Sonophoresis is the application of ultrasound to the 
skin on which a drug, most preferably proteinaceous in nature, alone or in 
combination with a carrier, has been applied. It significantly enhances the 
transdermal transport of drugs. Sonophoresis produces an effect made up of a 
combination of high-frequency heat and motion energy, which is generated by sound 
waves at millions of cycles a minute (up to 3 million hertz). This method enhances 
transdermal transport in two ways: (i) enhanced diffusion through structural 
alterations of the skin (i.e, formation of transient pores in skin) and (ii) convection 
induced by ultrasound. Transdermal transport enhancement induced by this type of 
sonophoresis decreases after ultrasound is turned off, therefore the process is 
reversible.  Charged and larger biomolecules are generally transported by the 








1.4.3. Formulation approaches  
Penetration enhancement with special formulations is mainly based on the use of 
colloidal carriers where submicron-sized particles are intended to transport entrapped 
active molecules into the skin. Such carriers include traditional liposomes, elastic 
liposomes, ethosomes, niosomes, nanoemulsions, and solid-lipid nanoparticles
54
. 
The first two types of liposomes will be discussed in this chapter in detail. 
Ethosomes are one sort of liposomes composed of mainly phospholipid, relatively 
high concentration of alcohol, sometimes glycerol and water
55
. Niosomes are 
vesicles composed of nonionic surfactants that have been evaluated as carriers for a 




1.5. Liposomes for skin drug delivery system 
In order to deliver drugs into or through the skin, numerous methods have been 
investigated. One of the most studied approaches to enhance penetration of drugs is 
the use of vesicular systems such as liposomes
57
. Liposomes were first invented by a 
British physician, Alec D. Bangham in 1965
58
. He discovered phospholipid vesicles, 
which he initially called tiny fat bubbles, and later named liposomes. However the 
use of vesicles for skin delivery was first introduced by Mezei and Gulasekharam, 
who reported a four to five-fold greater permeation of topical application of 
liposomal lotion of triamcinolone acetonide as compared with an ointment 
containing same drug concentration
59
. Thus they concluded that liposome use might 
be beneficial for increased local activity while diminishing systemic absorption. 
Liposomes literally mean “fat body” are nano- and micro lipoidal vesicles
58
 (tiny 
spheres), which have diameters ranging from 50 nm to few microns and are formed 
as concentric bimolecular layers separated from its aqueous environment
32
. They are 
biocompatible and capable of incorporating both hydrophilic (in the aqueous zone) 
and lipophilic drugs (in the lipid domain). Liposomes may show significant 
improvement in apparent aqueous solubility of a lipophilic drug, consequently 
making possible delivery of a dose much higher than its water solubility
60
. Moreover 
drugs can be encapsulated within liposomes without further chemical modification 
that could interfere with the drugs‟ therapeutic activity. Improved stabilization of 
unstable drugs by liposome encapsulation is possible
61
. Furthermore, liposomes are 
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non-toxic at any concentration of usual administered doses, biodegradable and can 
be richly biofunctionalized with antibodies, protein receptors, and other biosensor 
molecules 
62
. Therefore liposomes have been investigated as parenteral drugs and 
antigen carrier systems and more recently have been extensively researched as 
topical and transdermal drug delivery systems
63-67
.  
Liposomes were found to be markedly superior to conventional dosage forms in a 
few areas, especially for intravenous and topical administration of drugs
28
. The 
rationale for using liposomes for skin delivery lies in the unique structural and 
functional properties of liposomes by which they can encapsulate and store drugs  of 
widely varying polarities including various cargoes, such as enzymes, proteins, and 
DNA
60
. Their functional properties is such that they facilitate their entry into the skin 
where they form depots to enhance and extend the pharmacodynamic effects of the 
incorporated drug
68
. They may act as penetration enhancers (especially deformable 
liposomes), which aid in the penetration of the individual lipid components into the 
stratum corneum and subsequently alter the intercellular lipid lamellae
69
. Moreover 
topically applied liposomes, especially those prepared with skin lipids may provide 
an effective delivery system for skin diseases. These vesicles can act as a drug 
reservoir and have been shown to help sustain regular release of dermally active 
compounds into the skin
70
, even to the deeper strata
28
, releasing encapsulated drugs 
of half-lives ranging from 0.6 to 11 days
71
. Prolonged release from liposomal 
delivery systems can be useful in the treatment of a variety of skin lesions
45
. 
Furthermore liposomes are easy to apply on the skin, enhance the local therapeutic 
index
72
 and reduce serious side effects and incompatibilities that may arise from 
undesirable high systemic absorption of drugs
28
. However a suitable modification in 
barrier function of the stratum corneum can be brought by a favourable interaction 
between liposomal phospholipids and lipid bilayers of the skin
73
. Vesicular 
deformability, size, shape, lamellarity, lipid composition and surface charge facilitate 









1.5.1. Classification of liposomes 
Liposomes are classified by their lamellarity and size. Liposomes can be subdivided 
by lamellarity into multilamellar and unilamellar vesicles. They can also be 
subdivided by size into small unilamellar vesicles (SUVs) and large unilamellar 
vesicles (LUVs).  
Multilamellar vesicles (MLVs) (size from 100-1000 nm) form spontaneously when 
an excess volume of aqueous medium is added to dry lipid film
75
 and under gentle 
agitation (by mechanical dispersion or by hand shaking). Each vesicle generally 
consists of five or more concentric lamellae in an onion-like arrangement and are 
more suitable for lipophilic drugs. They are very simple to prepare, can easily be 
scaled up and are usually mechanically stable upon long storage period
76
.  Due to the 
slow degradation of the concentric lamellae, MLVs give a more gradual and 
sustained release of entrapped material
76
. However MLVs were found not suitable 
for hydrophilic compounds as the percentage captured by aqueous components is 
usually low (~5-10%)
77
 for 0.2µ MLVs with lipid concentration of 30 mg/mL. 
 
Figure 1.4: Schematic illustration of liposomes of different size and number of 
lamellae (Figure adapted from Daniels
78
 and modified).   
Unilamellar vesicles however are single bilayer liposomes. SUVs reviewed by 
Bangham
79
, are at the lowest limit of size (25-50 nm; according to some authors up 
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to 100 nm) possible for phospholipid vesicles. However size differs slightly 
according to the ionic strength of the aqueous medium and the lipid composition of 
the membrane
60
. Usually MLVs are subjected to sonication to form SUVs. They are 
the only well characterized vesicles homogenous in size and lamellarity
76
. But these 
vesicles also have some disadvantages. Their production usually requires a high 
energy input (for example, sonication or homogenization power) and they are 
thermodynamically unstable and are susceptible to aggregation and fusion on 
storage, particularly below the phase transition temperature (Tc, the temperature at 
which the lipid passes from gel state to liquid state). In addition to this, the entrapped 
volume is small, and thus the percentage entrapment of water soluble molecules is 
correspondingly low
76
. LUVs however are a very heterogeneous group of vesicles 
having the diameters ranging from 100 nm to cell size
80
. They can be formed by the 
reverse phase evaporation (REV) technique and by detergent dialysis
81
. Unlike 
SUVs, they have a high aqueous-lipid compartment ratio; thus a high entrapment for 
hydrophilic solutes can often be achieved with very economical use of membrane 
lipids. They also show reproducible drug release rates
76
. However the presence of 
only a single bilayer makes the vesicles not highly mechanically stable and retention 
of entrapped compound is not high
60
. 
1.5.2. Conventional liposomes 
Conventional liposomes can be prepared from many amphiphilic ingredients. The 
most common liposome composition is phosphatidylcholine (PC), a phospholipid 
from soybean or egg yolk
82
 with or without cholesterol.  Conventional liposomes can 
also be prepared from other phospholipids to impart a charge, for example 
phosphatidylserine and phosphatidylinositol (for positive charge) and 
phosphatidylglycerol and phosphatidic acid (for negative charge)
76
. The type of lipid 
utilized in a liposome is very important. For example, the presence of net charged 
lipids (for some bioactive compounds) not only prevents spontaneous aggregation of 
liposomes but also influences the effectiveness of solute entrapment into the 
vesicles
1
. The two primary components (phospholipid and cholesterol) of 





Phospholipids are amphiphilic molecules which are mostly constructed from the 
combination of a polar head group (negatively charged phosphate group) and a 
glycerol backbone moiety substituted with either one or two acyl or alkyl chains 
(PC), or an N-acylated sphingoid base (sphingomyelin) which is hydrophobic in 
nature. Phospholipids from natural sources are classified into phosphodiglycerides 
and sphingolipids
60
. PCs are the major phosphodiglycerides that can be obtained 
from natural (egg or soybean) and synthetic sources, and when extracted from plant 
and animal sources, they are known as “lecithins” (unpurified form).  
 
R1 and R2= Fatty acid residues 
Figure 1.5: Chemical structure of Phosphatidylcholine (PC) 
 
The reasons for choosing PC in liposome formulations are many. In the corneocytes 
of the stratum corneum, cellular membranes account for 50% of the dry mass and 
consist mainly of PC and sphingomyelin. The intercorneocyte matrix is rich in 
phospholipids
83
. As phospholipids share a high structural similarity with skin lipids 
and have many advantages such as strong tissue affinity, biodegradability, and very 
little toxicity they are widely used in topical and transdermal delivery systems
83
. 
Moreover, PC is comparatively cheap and chemically inert. Due to the double chain 
tail, PC molecules have an overall tubular shape, and form lamellar bilayer vesicles 
(Figure 1.6(a)) in the presence of aqueous medium, in contrast to most other 
amphiphilic molecules (e.g. detergents and lysolecithin) whose geometry (a conical 
shape with single tails) lead to the formation of micelles
60




                                          (a)                                                 (b) 
Figure 1.6(a): Double chain Phosphatidylcholine (PC) turned into liposome; (b): 




1.5.2.2. Penetration enhancement effect of phospholipid 
Phospholipids containing unsaturated fatty acids are strong permeation enhancers for 
percutaneous delivery of some topically applied drugs
85
. There are few concepts 
which are thought to be applied in the penetration enhancement effect of 
phospholipid. Phospholipids possess the property of surfactants. They may penetrate 
the intercellular lipid bilayers of the stratum corneum and reduce its crystallinity and 
increase the permeability of drugs
86
. Moreover phospholipids may occlude the skin 




Phospholipid vesicles can either disrupt the bilayer fluidity in the stratum corneum 
or fuse with the stratum corneum lipids. The latter will collapse the structure and 
liberate the permeant  from the phospholipid vehicles. If the drug is poorly soluble in 
the vehicle the thermodynamic activity will be raised which will result in facilitated 
permeation
2
. Moreover, phospholipids may mix with the stratum corneum lipids 
creating a lipid-enriched environment. This lipid depot is preferred by lipophilic 





Few studies, however, have used phospholipids in a non-vesicular form as 
penetration enhancers. For instance, theophylline penetration was enhanced through 
hairless mice skin by 1% egg PC in propylene glycol (a concentration at which 
liposomes did not form)
88
. On the other hand, various studies demonstrated that 
phospholipids can exhibit their enhancing effect on skin in the presence of organic 




Cholesterol and its derivatives are the most important and predominant sterols in 
animal tissues. Incorporation of cholesterol into liposome bilayers was found to 
bring major changes in membrane properties
60
. However cholesterol does not form a 
bilayer structure of liposomes by itself. As it is amphipathic in nature; it can be 
incorporated into phospholipid membranes at very high concentrations (up to 2:1 
molar ratios of cholesterol to PC). In phospholipid liposomes, cholesterol enters the 
membrane by orienting its hydroxyl group towards the aqueous surface; the tricyclic 
ring sandwiched between the first few carbons of the fatty acyl chains, into the 
hydrocarbon core of bilayer, with the aliphatic chain aligned parallel to the acyl 




Figure 1.7: Chemical structure of cholesterol 
Cholesterol acts as a fluidity buffer (both in biological membranes and in synthetic 
vesicles) due to their ability to interact with the phospholipid head groups and tail 
groups by hydrogen bonding and hydrophobic interactions respectively
60
. 
Cholesterol  can broaden the bilayer transition considerably, and at high 
concentration (50 mol %) may completely abolish the heat of transition
91
. In the 
presence of cholesterol, above Tc, the freedom of molecular motion of the bilayer is 
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increased thus suppressing the tilts and shifts in membrane structure specifically at 
phase transition. Consequently at ambient temperature, cholesterol fluidizes bilayers 
containing saturated phospholipids, but decreases the fluidity of bilayers containing 
unsaturated phospholipids
60
. Thus the overall effect of cholesterol is to moderate the 
difference between gel and liquid crystalline phases.  
Cholesterol in liposomes improves bilayer characteristics
81
 by increasing micro 
viscosity of the bilayers by filling empty spaces among the phospholipid molecules, 
by reducing permeability of the membrane to water soluble molecules, and by 
stabilizing the membrane
92
. Moreover it increases the rigidity of the vesicles and 
helps to form smaller and more uniform liposomes. Lastly it prevents phase 
separation. 
1.5.2.4. Mode of action of conventional liposomes on skin penetration 
There has been a large amount of extensively reviewed research work carried out 
with conventional liposomes to improve skin delivery of drugs
2, 93-97
. Four possible 
mechanisms by which conventional liposomes may enhance skin delivery of drugs 
are the intact vesicular skin penetration, the penetration enhancing effect, the 




The intact vesicular skin penetration concept was first suggested by Mezei and 
Gulasekharam
59,99
 who showed that intact liposomes penetrated up to the vascular 
dermis. Being large, intact liposomes were unable to enter the capillary circulation 
and thus acted as a drug reservoir at the site of action. However it was unexpected 
that large vesicles could penetrate the densely packed stratum corneum in great 
numbers
97
. Therefore many attempts were taken to find out the actual scenario. 
Foldvari et al
100
 showed the presence of intact unilamellar liposomes in the dermis 
after application of MLVs, concluding that MLVs lost their external bilayers during 
epidermal penetration. They added that these liposomes could be adsorbed intact on 
the skin surface before penetration, with a possibility of some vesicle rupture. SUVs 
produced better input of aqueous radiolabelled inulin and radiolabelled lipid bilayer 
components
101
 into deeper skin strata compared with large MLVs, suggesting that 
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vesicle size affects skin deposition. This all in turn supported the concept of intact 
vesicular penetration as a possible mechanism for improved skin accumulation. 
While Du Plessis et al investigated the effect of vesicle size on skin deposition of 
cyclosporin, they showed that intermediate size and not the small size vesicles 
resulted in higher skin deposition. This indicated that intact liposomes did not 
penetrate the skin because greater flux is expected from smaller vesicles in case of 
intact vesicular penetration
102
. Similar improvement in stratum corneum penetration 
was observed when a fluorescent marker was applied onto skin after pre-treatment 
with empty vesicles and vesicles encapsulating the marker
95
. This suggested that 
improved delivery was not due to intact vesicular penetration, and suggested a 
possible second mode of action, the penetration enhancing effect, proposed by 
Kirjavainen et al
94
, who suggested that liposomes penetrated the stratum corneum by 
adhering onto the surface of the skin and subsequently destabilizing, fusing or 
mixing with the lipid matrix. Therefore, conventional liposomes may act as 
penetration enhancers by altering the lipid structure of stratum corneum and 
promoting impaired barrier function of these layers to the drug. This ultimately 
creates a less well-packed intercellular lipid structure with subsequent increased skin 
partitioning of the drug. However the extent of interaction between liposomes and 
skin is highly dependent on the lipid composition of liposomes revealing that dermal 
delivery with skin-lipid liposomes is more effective than delivery with non-skin lipid 
vesicles
94
. Du Plessis et al studied the influence of skin pre-treatment with liposomes 
on topical absorption of inulin and hydrocortisone. They found that pre-treatment did 
not give advantage of encapsulated drug, showing no penetration enhancement for 
both. Therefore they concluded that liposome-stratum corneum interaction 
hypothesis was invalid, suggesting that liposomes must at least be applied along with 
the drug or the drug must be encapsulated within them
103
.  
The third mechanism, adsorption and fusion of liposomes onto the skin surface was 
demonstrated by Hofland et al
104
 and Abraham and Downing
105
, who showed that 
lamellae and rough structures formed on the top of the outermost layers of stratum 
corneum. This probably increased the driving force for permeation of liberated 
molecules. However, when the vesicles collapse on the skin surface they may form 
an additional barrier, which could reduce the permeation of hydrophilic molecules 
 
19 
encapsulated in the aqueous core. This mechanism also cannot account for the 
increased delivery of macromolecules
2
. Mechanism of enhancement via the 
transappendageal route was suggested by Du Plessis
106
. Recently this route has been 




Although some authors have suggested conventional liposomes as suitable carriers 
for skin delivery of some drugs
108-110
, after intensive research it has become evident 
that traditional liposomes are of little or no importance as dermal drug carriers, 
because they do not deeply penetrate the skin, but rather remain accumulated in the 
upper layers of the stratum corneum
94
. The widest pores in the stratum corneum are 
around 30 nm in diameter or less
111
 and inhibit the entry of conventional liposomes 
with a minimum diameter of 100 nm
22
. To push large entities across the intact skin, 
one must therefore depend on the „penetration‟ mechanism, rather than on simple 
„permeation‟ (diffusion-based transport). In order to squeeze through the small pores, 
the membrane elasticity of liposomes becomes important
22
. As membrane elasticity 
is lacking in conventional liposomes, a second type of liposome has emerged called 




1.5.3. Elastic liposome 
Elastic liposomes, also called deformable or ultra flexible vesicles, were introduced 
by Cevc and Blume in 1992
112
 who termed them as „Transfersomes‟. In composition, 
elastic liposomes differ from conventional liposomes as they contain an edge 
activator (10-25%) as well as a low concentration of ethanol (3-10%). An edge 
activator is often a single chain surfactant with a high radius of curvature that 
destabilizes vesicular bilayer and increases bilayer elasticity
22, 69, 113
 by lowering the 
interfacial tension
114
. Various surfactants which were employed to formulate elastic 
liposomes are sodium cholate, sodium deoxycholate, Span 60, Span 65, Span 80, 
Tween 20, Tween 60, Tween 80 and dipotassium glycyrrhizinate
115-119
.  
Due to the self adaptability and high deformability of elastic liposomes, it is 
suggested that they can efficiently penetrate even through the pores of stratum 
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corneum that would be difficult for other particulates of same size
22
. The 
concomitant presence of stabilizing (phospholipid) and destabilizing molecules 
(surfactants) in bilayers of elastic liposomes and their tendency to redistribute in the 
non-uniformly stressed bilayer structure allow these vesicles to be several orders of 
magnitude more elastic than conventional liposomes and thus are suited for skin 
penetration
22
. However to be elastic, an optimal balance between the amount of lipid 
and surfactant is required. If surfactant level is too low, vesicles still remain rigid, if 





Figure 1.8: Location of drug molecules inside liposome; charged hydrophilic, 
amphiphilic and lipophilic drug molecules can be associated with the bilayer, 
whereas hydrophilic compounds can also be entrapped in the aqueous core of 
liposomes. Rigid vesicles may consist of double chain lipids in the presence or 
absence of cholesterol (left image). Elastic vesicles may consist of double chain 








1.5.3.1. Penetration enhancement effect of ethanol and surfactants 
Elastic liposomes show enhanced dermal penetration because of the presence of 
surfactants and ethanol in their structure. Therefore these two components are 
described in brief here. 
1.5.3.1.1. Ethanol 
Ethanol is a known efficient penetration enhancer and is commonly believed to act 
by affecting the intercellular region of the stratum corneum
120, 121
. The penetration 
enhancing effect of ethanol can be attributed to two main factors: (a) “push effect” 
and (b) “pull effect” in which penetration of drug molecule is increased due to 
reduction in barrier property of stratum corneum
86, 122
. When a finite dose of drug is 
applied on the skin, due to the evaporation of ethanol, drug concentration reaches 
beyong its saturation solubility which possibly modifies the thermodynamic activity 
of the drug. This leads to a supersaturated state which allows greater driving force 
for penetration. This is how the “push effect” works. The “push effect” is negatively 
correlated with the solubility parameter of the donor phase. The second mechanism 
is the “solvent drag” effect or “pull effect”. In this effect ethanol rapidly permeates 
across the skin carrying the permeant
123
 altering the solubility properties of the 
tissue, thereby reducing the barrier property of the stratum corneum with a 
consequent improvement of drug partitioning into the membrane. It is reported that 











 through rat skin and estradiol through human skin in 
vivo
127
. However the enhancement effect of ethanol is concentration dependent. For 
example salicylic acid diffusion across human epidermis was promoted up to 




Surfactants are generally composed of a lipophilic alkyl or aryl fatty chain, together 
with a hydrophilic head group. They are often defined in terms of the nature of the 
hydrophilic moiety
129
. Many traditional topical formulations contain ionic 
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surfactants that enhance skin penetration of drug molecules in a variety of ways. For 
example, they are widely known to interact with proteins, thus inactivate enzymes 
and bind well within the stratum corneum
2
.  Anionic surfactants (for example, 
sodium laury sulphate; SLS) swell the stratum corneum possibly by uncoiling the 
keratin fibers and altering the α-helices to a β-sheet conformation
2
. They are also 
able to expose more water binding sites to the stratum corneum, are able to extract 
lipids from it and disrupt the lipid bilayer packing
130
.  
While surfactants usually possess low chronic toxicity
2
 cationic surfactants were 
reported to have potential to damage skin; SLS is a powerful irritant and increased 
the transepidermal water loss in human volunteers in vivo
48
. However cationic 
surfactants are still widely used in cosmetic formulations with no apparent side 
effects
131
. Non-ionic surfactants (nonoxynol series) and anionic surfactants are 
regarded as safe. The polysorbates were shown to enhance the permeation of 
hydrocortisone, lignocaine and methanol
132, 133
. On the contrary naloxone and 
naproxen permeation were not improved by non ionic surfactants
134
. 
Polyoxyethylene alkyl ethers and esters were shown to be more effective permeation 
enhancers than the polysorbates
134
. In order to provide enhancement by altering the 
lipid region of stratum corneum, the surfactants have to permeate, a phenomenon 
strongly dependent on the partition coefficient and solubility of the surfactants
135
. 
The more lipophilic is the surfactant, the greater the enhancement potential. 
 
1.5.3.2. Mode of action of elastic liposome 
Two mechanisms were proposed by which elastic vesicles can improve skin delivery 
of drugs
114
. They are 1) as drug carrier systems; 2) as penetration enhancers.  
1.5.3.2.1. As drug carrier system 
This mechanism was first put forward by Cevc and his colleagues
112, 136-138
 where 
vesicles were proposed to act as drug carrier systems. In this system, intact vesicles 
enter the stratum corneum by transdermal hydration gradient
3
 which exists across 
human skin in vivo from around 20% at the outer surface to nearly 100% within the 
skin at the epidermal/dermal junction
2
. The osmotic force for the vesicles entering 





when elastic liposomes are applied on the skin surface non-occlusively, phospholipid 
tends to avoid dry surroundings and requires hydration to remain in maximum 
swollen state. The gradient operating from the skin towards water-logged viable 
tissues drives them to squeeze between the cells in the horny layer
3
, despite the large 
average vesicle size
138
. Moreover, the surfactant accumulates at the high stress sites 
within the vesicles and forms a highly curved area of the vesicle. Thus elastic 
liposomes deposited on the skin surface will evaporate and partially dehydrate, 
follow the local hydration gradient and trespass the strongly hydrated and deeper 
skin layers spontaneously
3
 and intact without permanent disintegration
138
.  
The inter-cluster pathway and the inter-corneocyte pathway (honeycomb-like 
system) contain structural irregularities within the intercellular lipid lamellae. These 
irregularities can act like virtual channels through which elastic liposomes do 
penetrate 
23
. In non-invasive transdermal immunisation when elastic liposomes 
labeled with a radio-active marker was applied, radioactivity was observed in the 
liver indicating the presence of these particles in systemic circulation, which might 
suggest that elastic liposomes permeate across the skin
139, 140
. The important 
difference between elastic and conventional liposomes is the high and stress-
dependent adaptability of the former. When conventional vesicles are applied on the 
skin non-occlusively they are unable to deform, confine themselves to the upper 
layers of the stratum corneum, where they dehydrate and fuse with skin lipids
112
. 
1.5.3.2.2. As penetration enhancer 
van den Bergh et al showed that hairless mouse skin pretreated with elastic vesicles 
increased the diffusion of 
3
H2O compared to pre-treatment with a buffer control, 
indicating a possible penetration enhancing mechanism
141
. In this mechanism, 
phospholipid vesicles, after entering the stratum corneum modify the intercellular 
lipid lamellae, facilitate penetration of free drug molecules into and across the 
stratum corneum
141
. Moreover elastic liposomes were reported to carry both 
entrapped and non-entrapped carboxyfluorescein into the stratum corneum and 
possibly to deeper layers of the skin
63
, suggesting a possible penetration enhancing 
effect. In another study, elastic liposomes with ketotifen only outside the vesicles 
significantly improved drug permeation and deposition over elastic liposomes with 
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ketotifen only entrapped inside the vesicles, suggesting that the penetration 
enhancing effect may be of great importance in enhanced skin delivery of ketotifen 
by elastic liposomes
142
. However penetration enhancement is markedly influenced 
by the type, concentration and state of the surfactant used in these vesicles, as well as 
the nature of the permeant
133
. 
1.5.3.3. Elastic liposomes in dermal delivery 
An extensive amount of research work has been conducted to study the in vitro skin 
delivery of various drugs from elastic liposomes. Some of the research findings of in 
vitro skin delivery of elastic liposomes are summarized in Table 1.1. 
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Table 1.1: Application of elastic liposomes in dermal delivery 
Drug or marker 
utilized/therapeutic 
use 




ER in terms of permeation 






SPC: S. Chol (86:14%), 
SPC:S80 (86.7:13.3%), 
SPC:T80 (84.5:15.5%); 
hydrated with 7% v/v 













Application condition: non-occluded; 
Donor: 20µL; Receptor: aqueous 
sodium azide for first 12 h, 50% v/v 









acid (4:1:0.25); hydrated 








Application condition: occluded; 
Donor:1mL; Receptor: citrate-




SPC: S. Chol (84:16%); 







Application condition: non-occluded; 





ic diseases and actinic 
keratoses 
SPC: S. Chol (44:15%); 








Application condition: not mentioned; 





lesions and pruritus 
SPC: S. Chol (1:0.28); 




After 8 h of administration, 
elastic liposomes transported 
1.16±0.26 µg/cm
2
 of cyclosporin 
A and amounted to 1.88 ±0.06 
µg 24 h later. Conventional 
liposomes failed to transfer 
cyclosporin A after 24 h. 
Application condition: Non-occluded; 
Donor: 20µL; Receptor: 20% ethanol 







EPC:T20 (6:1); hydrated 
with NTE buffer (pH 7.0, 
145mM NaCl, 10mM TES 
(N-Tris(hydroxymethyl)-
2-aminoethane sulfonic 










Drug suspension showed no skin 
permeation 
Application condition: non-occluded; 
Donor: 300µL; Receptor: Phosphate 





ute or chronic 
dermatitis 
PC:KG (2:1) PC:KG (4:1) 
PC:KG (8:1) HPC:KG 
(2:1) HPC:KG (4:1) 
HPC:KG (8:1) 
Full-thickness 
pig ear skin 
Flux was negligible, below 
detection limit 
Application condition: non-occluded; 
Donor: 100µg; Receptor: 0.002% w/v 
























Application condition: non-occluded; 
Donor: 500µL; PBS containing 0.1% 
sodium azide 





SPC:S 80 (86:14% (w/w)) 
hydrated with phosphate 
buffer (pH 6.5) 
Human cadaver 
skin 
robust systemic and mucosal 
antibody response 
Application condition: not mentioned; 





PC:KG (2:1), PC:KG 
(4:1), HPC:KG (2:1), 
HPC:KG (4:1) Phosphate 
buffer (pH 7.4) 
Full-thickness 











Application condition: non-occluded; 








SPC:SD. Chol (86:14%) 







Application condition: not mentioned; 





SPC: T80 (84.5:15.5%) 






Application condition: non-occluded; 
Donor: 150 µL; Receptor: pH 7.4 
isotonic phosphate buffer containing 







hydrated with  pH 5.0 
(0.05 M citrate buffer), pH 
6.0 or pH 7.0 (0.1 M 
phosphate buffers) 
respectively 
Non-occlusive co-treatment: 2 fold better permeation from elastic vesicles compared to 
buffer; non-occlusive pre-treatment with empty vesicles: no enhancement; Occlusion reduced 
the action of elastic vesicles, but could increase the drug transport since water is a good 
penetration enhancer for this particular drug. The highest pergolide skin permeation was 
obtained from an occluded saturated buffer solution, steady-state flux of 137.9 ng/h cm
−2
. 
Volume of application had no effect on drug transport. 
 
CH: Cholesterol, DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane, EPC: egg phosphatidylcholine, ER: enhancement ratio, HPC: 
hydrogenated phosphatidylcholine, KG:  Dipotassium glycyrrhizinate, SPC: soya-phosphatidylcholine, S. Chol: sodium cholate, S80: Span 80, 
SD. Chol: sodium deoxycholate, T80: Tween 80, T20: Tween 20 
 
A 
: relative to drug solution or suspension 
B
: Relative to conventional liposome
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1.5.4. Preparation of liposomes 
1.5.4.1. Phase transition temperature and bilayer fluidity  
Lipids have a characteristic phase transition temperature (Tc) and they exist in different 
physical states above and below this temperature. The most consistently observed phase 
transition occurs above the Tc, in which the membrane passes from a tightly ordered 
“gel” or “solid” phase to a liquid-crystal “fluid” phase where the freedom of molecular 
movement is higher
151
. The most widely used method to determine Tc is 
microcalorimetry.  
Phase transitions and fluidity of phospholipid membrane has been found to be very 
important both in the manufacture and exploitation of liposomes
60
. If liposomes are 
prepared below or above the Tc of the lipid, they will form gel state or liquid state 
vesicles respectively. It is very important to prepare liposomes above their Tc. Liquid 
state vesicles play predominant role in percutaneous penetration enhancement. They act 
not only in the superficial stratum corneum layers, but also induce lipid perturbations in 
the deeper layers of the stratum corneum where they can modify the intercellular lipid 
lamellae, whereas gel state vesicles only interact with the outermost layers of the 
stratum corneum. There they get fused which in turn might provide an additional 
permeation barrier
3
. The mechanism of action of fluid-state vesicles for skin interactions 
lies in the fact that they are more effective in enhancing drug transport into and across 
the skin
114
. However the membrane fluidity can be influenced by hydrocarbon chain 
length and unsaturation of different phospholipids
151
. On the whole, liposomal phase 
behaviour which affects bilayer fluidity determines liposomes‟ permeability, fusion, 
aggregation, and protein binding, which again markedly affect the stability of liposomes 




Ethanol, a key component of elastic vesicles was reported to exert a biphasic effect on 
the main Tc of fully hydrated PC
152
. In the absence of ethanol, the Tc value of the fully 
hydrated dipalmitoyl-PC bilayer is 41.6°C which decreased linearly with increasing 
ethanol concentration. At ethanol concentration of 50 mg/mL, maximum decrease in Tc 
 
29 
was about 2°C. Above this threshold limit the Tc increases with increasing ethanol 
content. This effect of ethanol on Tc could be due to the transformation of the partially 
interdigitated gel phase into the fully interdigitated gel phase of DPPC bilayer
153
. 
Recently it has been shown that above the threshold concentrations of ethanol, short-
chain primary and secondary alcohols up to 1-heptanol can induce chain interdigitation 




1.5.4.2. Method of preparation of liposomes 
Numerous methods for preparation of both conventional and elastic liposomes are 
described in the literature
81
. Among them, the thin film hydration technique is most 
commonly used and was chosen in this project to prepare all vesicles. Therefore it will 
be discussed in detail; the other preparation methods will be discussed in brief.   
1.5.4.2.1. Thin film hydration method 
Lipid film hydration method also called mechanical dispersion is the most commonly 
followed technique to prepare both conventional and elastic liposomes originated by 
Bangham et al
58
. In brief, phospholipid with or without cholesterol (in case of 
conventional liposome) and surfactant (in case of elastic liposome) and lipophilic drugs 
are dissolved in organic solvent(s) such as chloroform, methylene chloride, methanol, 
ethanol, ether alone or mixtures of these solvents
60
 in a 250 mL round bottom flask. This 
is then dried to form a lipid film onto the side of the flask by slowly evaporating the 
organic solvent using a rotary evaporator. Complete removal of organic solvent is 
assured by keeping the flask under vacuum overnight
76
.  
Next, the lipid film is hydrated by addition of an aqueous medium followed by rotation 
using rotary evaporator until the film has been completely dispersed. For hydrophilic 
drug loading, aqueous drug solution is added as hydration medium. In case of elastic 
liposome preparation, 3-10% ethanol can be added along with hydration medium. Upon 
hydration lipid bilayers are formed. It is believed that even before exposure to the 
hydration medium, the lipids in the film are oriented in such a manner as to separate 
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hydrophilic and hydrophobic regions from each other which resembles their 
conformation in the finished membrane preparation
76
. On hydration the lipids swell and 
peel off the support in sheets, generally to form MLVs
60
. The final milky white 
suspension is left to stand for 2 h at room temperature for complete swelling. 
By this method, liposome preparation is easy and quick and vesicles are relatively stable 
on storage. This method has many drawbacks. For example, the volume enclosed within 
liposome membrane is usually only about 5-10% of total volume used, therefore 
rendering the method very wasteful for hydrophilic compounds
81
. Furthermore solute 
distribution may be uneven in liposomes, which should be considered carefully when 
preparing liposomes for commercial use. Size distribution is heterogeneous, liposomal 
particle size as large as 30µ and as small as 0.05µ can exist
156
. Finally this method is 
difficult for industrial scale up. For instance, film thickness is determined by the size of 
the round bottomed flask. The thickness will affect the efficiency of the hydration 
process. For a large batch size, it is not feasible to build a large flask to make the film 
with a proper thickness
60
. 
The other commonly used methods of liposome preparation include pro-liposomes, 
reverse phase evaporation (REV) and solvent injection method. Pro-liposomes (approx. 
0.1µm in diameter) are dry, free-flowing product, which on addition of water, disperses 
to form an isotonic MLVs
76
. The process of pro-liposome involves casting a  solution of 
lipid and material to be entrapped onto sorbitol which is readily soluble in water and 
poorly soluble in organic solvent
60
. REV method was first developed by Szoka and 
Papahadjopoulos in 1978
77
 where lipid components are dried down onto a round bottom 
flask and the film is re-dissolved in diethyl ether
157
. Next, water soluble drug aqueous 
solution is added to it and the system is maintained under inert gas continuously
158
. Bath 
sonication of this system produces inverted micelles, which is placed in a rotary 
evaporator to remove the solvent under reduced pressure at room temperature with ~200 
rpm. This causes the phospholipid-coated droplets of water to coalesce and produces a 
sticky viscous gel
159
 which at a certain time collapses and forms an aqueous suspension 
(LUVs) within 5-10 min. This method has gained widespread application in producing 
 
31 
high encapsulation (up to 65%
159
) of water soluble drugs
77, 160
. However in this method, 
the compound to be entrapped is exposed to organic solvents. Enzymes, protein 
pharmaceuticals, RNA may undergo conformational changes; protein denaturation and 
breakage of DNA strands is possible due to the utilization of harsh solvents
81, 158
. 
Solvent injection method can be sub-divided into ether and ethanol injection method. 
The former was developed by Deamer and Bangham
161
 where a lipid solution dissolved 
in diethyl ether is slowly injected into warm aqueous solution of the compound to be 
entrapped at 55-65ºC or under reduced pressure. Ether vaporization leads to the 
formation of single layer vesicles
81
 (diameter ranging from 50-200 nm). This method is 
simple, easy to be scaled up and applicable for a wide variety of lipid mixtures and 
aqueous solution. However organic solvent used may be harmful for few compounds, 
rendering it not a useful method for protein incorporation
158
. Ethanol injection was first 
described by Batzri and Korn
162
. Briefly, lipid solution in ethanol is rapidly injected into 
an excess of buffer which leads to instantaneous formation of SUVs. This is a simple 
and rapid method which avoids sonication and exposure to high pressure, thus process is 
gentle. But removal of residual ethanol from the preparation may be problematic as the 
partial vapor pressure of ethanol at low concentration is smaller compared to that of 
water
158
. Moreover ethanol forms azeotrope with water and is difficult to remove under 




1.5.4.3. Particle size reduction 
MLVs are usually processed to reduce their size using a method which imparts high 
energy to lipid suspension.  This can be achieved by sonication, high pressure 
homogenization or extrusion.  
1.5.4.3.1. Sonication 
Sonication is an effective method for reducing particle size for small batches. On the 
basis of sonicator type, there are two types of sonication techniques: probe and bath 
sonication. However difficulty in uniformly sonicating large batches of preparation, 
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generation of personal hazard and production of the limited size vesicles are 
shortcomings of the sonication method
76
. 
Probe sonication is conducted by immersing a metal probe below the liquid surface. 
Owing to high energy input of this method, the particle size of the MLV can be reduced 
rapidly and reproducibly
163
. Moreover, small and homogenously distributed SUV 
liposomes can be produced by this method. However there is a risk of lipid degradation 
by probe sonication due to high input of energy generation if sonicated for long time. 
Thus the sonicator vessel must be cooled efficiently during sonication
158
. However for 
large batch size, this method is of little value.  
Bath sonication has the advantage of avoiding direct contact of the formulation with the 
probe, thus it is much mild and has less risk of lipid degradation
158
. Large volume can be 
sonicated and reproducible sizing is possible when the flask is placed in the same 





This method is very gentle in reducing size of MLVs by passing them through a series 
of membrane filter of defined pore size with much lower pressure (<100 p.s.i). Breakage 
and re-sealing of membrane occurs during the process. After repeated extrusion through 
100 nm filter; liposome suspension gets progressively unilamellar with a size 
distribution around the pore size of the membrane
164
. Therefore size can be controlled 
by selecting the pore size of membrane
76
. 
The rate at which suspension will pass through the membrane depends on the original 
size and lipid concentration of liposomes since liposomes with less fluid membrane are 
difficult to break down
76
. This process can be applied to all liquid crystalline bilayer 
lipids. Size distribution is homogenous and the method is relatively gentle, fast and 
reproducible. But relatively low lipid concentration (<50mg/mL) is employed and long 






1.5.5. Characterization of conventional and elastic liposomes 
Liposomes produced by different techniques have different physicochemical 
characteristics which have an impact on their behaviour in-vitro and performance in-
vivo (disposition)
165
. The characterization of liposomes is important not only for 
formulation design but also for evaluation and quality control purposes. Characterization 
parameters for the purpose of evaluation of liposomes in skin delivery system can be 
classified into two broad categories, physical and chemical characterization.  
Physical characterization evaluates various parameters, including size, shape, surface 
potential, entrapment efficiency (EE), lamellarity, phase behaviour and in vitro drug 
release profile
165, 166
. Liposome size has possibly the largest influence on physical 
properties and appearance of the formulation. Various techniques are available to 
measure particle size, most commonly used is the Dynamic Light Scattering technique. 
The number of lamellae in liposomes is an important parameter to be monitored because 
it influences the entrapment of lipophilic drugs into liposomal bilayers. The average size 
and number of lamellae can give theoretical estimation of the total volume of enclosed 
aqueous space within the liposomal core
60
. Though knowledge of size distribution and 
preparation method of liposomes may give some idea on the presence of number of 
lamellae, it is preferable to follow an established technique which gives direct 
determination of the number. The most regularly applied technique is the electron-
scanning microscopy. 
To determine the EE of liposomes, it is required to separate the free drug from 
liposomes by applying methods mentioned in Table 1.2. Determination can be 
performed by analyzing the free drug and liposomal pellets; for the latter, lipid 
solubilizers (Triton X-100) are used to destroy the liposomes. Among the routinely used 
techniques, dialysis and ultrafiltration offers membranes with a molecular weight cutoff 
between those of drugs and lowest expected liposome fraction. However in 
ultracentrifugation, liposomes are pelleted to separate the free drug. Drawback of this 
method includes the risk of vesicle rupture and presence of small liposomes in the 
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supernatant. However the entrapment of hydrophilic drug is dependent on the volume of 
aqueous core. For the incorporation of an ionizable drug, entrapment will depend on the 
partition coefficient of the drug between the aqueous phase and bilayers, more 
specifically on the distribution coefficient. 
The only difference in the characterization of conventional and elastic liposomes is the 
determination of bilayer elasticity for the latter. Measurement of vesicle membrane 
elasticity is accomplished by an extrusion method through small pore sized filters 
applying a fixed pressure. The elasticity value is expressed as deformability index.  
The purity and potency of various liposomal constituents is studied under chemical 
characterization
167
. Table 1.2 shows various techniques to characterize physical and 
chemical parameters of liposomes. 






Mean vesicle size and size 
distribution 
Dynamic Light Scattering, Size exclusion/molecular 
sieve chromatography, Electron microscopy, 
Ultracentrifugation, Ultrafiltration 
Vesicle shape and surface 
morphology 
Transmission electron microscopy, Freeze-fracture 
electron microscopy 
Number of lamellae 




Surface charge Micro-electrophoresis, Zeta potential 
Encapsulation volume Encapsulation of water soluble markers 
Entrapment efficiency 
Size exclusion/molecular sieve chromatography, 
Ultrafiltration, Ultracentrifugation/Dialysis 
Bilayer Fluidity 
Fluorescent probes, Spin label EPR, NMR probes, 
Calorimetry 
Phase behavior 
Freeze-fracture electron microscopy, Differential 
scanning colorimetery 
Drug release Diffusion cell/ dialysis 
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Elasticity measurement Extrusion 
Chemical Characterization 
Phospholipid concentration Barlett assay, stewart assay, HPLC 
Cholesterol concentration Cholesterol oxidase assay and HPLC 
Phopholipid peroxidation UV absorbance, Iodometric  and GLC 
Phospholipid hydrolysis, 
Cholesterol auto-oxidation. 
HPLC and TLC 
Osmolarity Osmometer 
 
Physical and chemical characterizations are very important for meaningful comparison 
of different liposomes for different batches. One should ensure that no major changes 
occur on liposome storage so that well characterized product is supplied with optimal 
and reproducible clinical effects.  
1.5.6. Stability of liposome 
Storage instability is the most common problem in liposomes. On storage the physical 
characteristics of liposomes change, which should be regularly monitored by using 
appropriate techniques. However the chemical stability of the phospholipid and other 
components incorporated into liposomes is also an important parameter
60
. Chemical 
degradation of lipid affects the physical stability of liposomes. Lipid degradation is most 
commonly attributed to hydrolysis and oxidation; the lat ter may be prevented by adding 
anti-oxidants in the liposomal formulation. However hydrolysis is the most dangerous 
cause of lipid degradation, which significantly alters the physical stability leading to 
liposome aggregation, fusion and breakage. 
The vesicle size distribution is the most important parameter to be monitored on a time 
basis because it affects liposomal efficacy and biodistribution. Generally liposomes 
consisting of only PC are prone to aggregate upon storage. Therefore small amount of 
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charged lipids are added to formulation
170
. Moreover change in particle size also alters 
the number of lamellae present in liposomes and the EE.  
1.6. Compounds of interest 
1.6.1. Ibuprofen 
A number of products (including creams, gels and more complex transdermal systems) 
have been designed to deliver non steroidal anti inflammatory drugs (NSAID) to the 
skin surface for local activity
171
. Ibuprofen [2-(4-isobutylphenyl)-propionic acid] (IBU); 
chemical formula: (CH3)2CHCH2C6H4CH(CH3)COOH) is a NSAID belonging to the 
group of arylpropionic acid derivatives and shares its pharmacodynamic properties with 
the rest of the NSAIDs.  
 
Figure 1.9: Chemical structure of Ibuprofen (IBU) 
IBU is a small molecule (MW 206.29) with a log (octanol–water partition coefficient 
(P)) of around  3.72, and pKa 4.45
172
  .  




pH 2.2 2.3 4.0 5.0 6.0 7.0 9.0 9.2 
Solubility 
(mg/mL) 
0.024 0.027 0.029 0.096 0.52 3.70 7.83 14.8 
 
IBU is used in the management of mild to moderate pain, fever, and inflammation which 
are promoted by the release of prostaglandins in the body. IBU blocks the enzyme that 
produces prostaglandins (cyclo-oxygenase) which results in lower levels of 
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prostaglandins. As a result, inflammation, pain and fever are reduced. Therefore IBU is 
used topically to treat local inflammation (i.e. acne) and it works clearly beneath the 
transport-limiting barriers of the skin
174
. With pronounced analgesic properties, IBU is 
used in the long-term treatment of rheumatoid arthritis, osteoarthritis and ankylosing 
spondylitis
175, 176
. The systemic treatment of such diseases with NSAID has proven to be 
efficient; however like other drugs of this class, IBU has dose-dependent side effects, 
especially GI irritation, bleeding, ulceration or perforation after oral administration. 
Considering the fact that IBU is often used for a long-term period, it is therefore 
considered a good candidate for skin delivery which will minimize the adverse effects 
arising from oral administration
177, 178
 by dispensing sub-cutaneous therapeutic doses 
through tissue penetration
179
, at the same time will provide relatively consistent drug 
levels at the application site for prolonged periods
180, 181
.  
IBU delivery via passive diffusion is dose-dependent; better therapeutic effect will be 
achieved when the drug will permeate the skin better
174
. An effective permeation of 
IBU, however, is difficult to achieve due to its extremely poor skin permeability, even 
though IBU is relatively good compared to other NSAIDs in common use
182
. The 




.  In order to 
enhance permeation of IBU supersaturated solutions, eutectic systems, mucoadhesive 
patches, and vehicle containing non-ionic surfactants or fatty acid have been explored
183-
187
. Elastic liposomes were found to show enhanced skin penetration for a range of drugs 
loaded (Table 1.1). Therefore development and evaluation of elastic liposomes with IBU 
could be a promising delivery vehicle of this drug. Thus IBU was chosen as a model 
drug in this study. However liposomal incorporation of poorly water soluble compounds 
is not only dependent on the physicochemical properties of the drug, factors including 








1.6.2. Sodium fluorescein 
Sodium fluorescein (NaFl) is an orange–red fine powder that is hygroscopic and is 
freely soluble in water (≥100 mg/mL), soluble in alcohol but practically insoluble in 
hexane and methylene chloride. The chemical formula and molecular weight of NaFl are 
C20H10Na2O5 and 376.3 respectively. In water it has an absorption maximum at 494 nm 
(blue) and emission maximum of 513 nm (green–yellow). NaFl is sensitive to pH, 
fluorescing maximally in the range of 8–9
189
. A solution of it is strongly fluorescent, 
even in extreme dilution. The fluorescence disappears when the solution is made acidic, 
and reappears when the solution is again made alkaline because in acidic condition, 
fluorescence is in equilibrium with spironolactone form. 
 
Figure 1.10: Chemical structure of sodium fluorescein (NaFl) 
NaFl is the only fluorophore routinely used in experimental dermatology for in vivo 
study of skin. Increasingly wider application has been found in epidermal labeling, 
intradermal injection to investigate skin conditions in vivo when using non-invasive 
devices such as confocal scanning laser microscopy
189
. NaFl can be used to visualize 
and selectively stain subtle structures in the skin at the subcellular levels such as nuclei 
and lipids
190
. Moreover it has been used as an intravenous bolus injection for decades 
for the examination of the vasculature of the ocular fundus (fluorescein angiography) 
and as eye drops for the diagnosis of corneal erosions
189
. In this study, NaFl was chosen 
as a model molecule because of its water solubility, ease of analysis, availability and 
low cost. Also it has been incorporated into vesicular carriers as a marker for 
fluorescence microscopy to study the distribution of liposomes after skin penetration.  
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1.7. Objective of current study 
The primary objective of current study was to design and evaluate elastic liposomes, in 
comparison to free drug solution and conventional liposomes, in topical delivery of IBU 
across human epidermis. The scope of the project included liposome development, 
investigation of influence of formulation variable on the physical characteristics 
(particle size, zeta potential, EE and bilayer elasticity) of liposomes and optimization 
based on their characteristics as well as determination of IBU penetration from 
conventional and elastic liposomes through human epidermis to establish the 







1. L-α-Phosphatidylcholine (PC) (Soybean, purity-95%); Physical state: Granules; 
MW: 758.07; Lot: SPC95-166; Avanti Polar Lipids, USA 
2. Ibuprofen (IBU), 98% ; MW: 206.29; Lot: 026H1368; Sigma-Aldrich, USA 
3. Cholesterol; MW: 386.66; Batch No.: C318; Allwest Scientific, Perth, WA 
4. Fluorescein sodium salt (NaFl); MW: 376.27; Batch No.: 84325; Labchem, Azax 
Chemicals, Australia  
5. Tween® 80; MW: 604.81; Batch No.: 064K0063; Sigma-Aldrich, USA 
6. Sodium cholate hydrate, 99%; MW: 430.6; Lot: 104K0090; Sigma-Aldrich, USA 
7. Sodium azide, not less than 99%; MW: 65.01; Batch No.:1001010; analytical 
grade; BDH Chemicals Ltd., England 
8. Sodium sulphide; MW: 240.18; Batch No.: 312802; Ramprie Laboratories, WA 
9. 0.2% w/w sulphuric acid, 98%; Batch No.: 04102038; Labscan Asia Co Ltd, 
Patumwan, Bangkok, Thailand 
10. 2N hydrochloric acid, 32%; Batch No.: 0806328; Labserv, Biolab (Aust) Ltd, 
Clayton, Victoria, Australia 
11. 30% Hydrogen peroxide; analytical grade; MW: 34.01; Batch No.: AF412330; 
Ajax Finechem, Australia 
12. Sodium hydroxide; analytical grade; MW: 40.0; Batch No.: 06110161; Lab-Scan 
Analytical Sciences, Thailand. 
13. Acetonitrile; HPLC grade; MW: 41.05; Lot: 096370; Fisher Scientific, Australia 
14. Boric acid 99.5%; analytical grade; MW: 61.83; Batch No.: F1L048; Univar, 
Asia Pacific Specialty Chemicals, Australia 
15. Potassium chloride; analytical grade; MW: 74.55; Batch No: 243524; Biolab 
(Aust) Ltd, Clayton, VIC 




17. Methanol, 99.9%; analytical grade; MW: 32.04; Lot No.: H43830; Mallinckrodt 
Chemicals, USA 
18. Chloroform, 99.97%; MW: 119.38; Lot No.: 38243; EM Science, USA 
19. Absolute alcohol; Batch No.: 201206; EX CSR Distilleries, Yarraville, VIC. 
20. Water (deionised): passed through a milli ‘Q’ apparatus (Millipore Corporation, 
Bedford, MASS, USA) with an internal specific conductivity of 18 MΩ cm at 
25°C  
 
2.2. Equipment and Instrumentation 
 
1. High Performance Liquid Chromatography (HPLC) 
An HPLC system (Shimadzu, USA) consisted of a pump (LC-20AT), auto 
sampler (SIL-20A), on line degasser (DGU-20A5), equipped with a UV-Vis dual 
wavelength spectrophotometric detector (SPD-20A). Separation was achieved on 
a stainless steel C18 column (Apollo C18 5 μm), 150 x 4.6 mm; Lot No.: 
0604000194; Grace Davison Discovery Sciences, NSW 
2. Zetasizer 3000HS; Malvern Instrument, UK 
3. Vacuum rotary evaporator; Buchi Rotavapor R-200, Buchi Labortechnik AG, 
Switzerland 
4. Fluorescent Spectrophotometer; Cary Eclipse, Varian Instruments; Walnut 
Creek, USA 
5. Franz-type diffusion cells, customer-made, University of Queensland  
6. Dermalab, Cortex Technology, Hadsund, Denmark. 
7. Centrifuge;  Eppendorf minispin AG 22331; Eppendorf, Germany 
8. Nanosep® 300K Omega; Centrifugal devices, Lot: 09551484, PALL Life 
Sciences, USA 
9. Dialysis tubing, high retention seamless cellulose tubing; MW 12000 cut off, 
average flat width 32 mm; Batch No.: 3110; Sigma-Aldrich, USA 
10. pH meter; Microprocessor pH/mV/°C Meter, Model-8417N; Hanna Instruments, 
Singapore 
11. Magnetic stirrer RW 20.n Ika labortechnik; Postfach, Staufen, Germany 
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12. An in-house purpose device for elasticity measurement; a sample holder made of 
10 mL plastic syringe attached with a pressure gauge of 2.5 bar  
13. Bath sonicator; Bransonic Ultrasonic cleaner 2510E-DTH; Branson Ultrasonic 
Corporation, USA 
14. Probe sonicator, MicrosonTM, ultrasonic cell disrupter, equipped with P-3 
microprobe (3/32
״
, 2.4 mm diameter), output power: 40W, output frequency: 0.5 
cycle, Farmingdale, New York, USA 
15. Vortex mixer; Laboro Vor-mix, Scientific Equipment Manufacturers Pty. Ltd, 
Australia 
16. Transmission Electron Microscope (TEM); JEOL 2100, equipped with an 11 
Mpix digital camera capable of recording both images and diffraction data, 
operated at 120 kV; LaB6 filament; images saved using Gatan Digital 
micrograph software.  
17. Field Emission Scanning Electron Microscope (FESEM); Leo Supra 55 Variable 
Pressure FESEM, Germany 
18. Leica DC 100; Leica Microscopy Systems Ltd., Switzerland. 
19. Oven (Memmert, Germany) 
20. 0.1 µm Supor® Membrane, 25 mm, sterile, non-pyrogenic; Lot: 375147; 
Acrodisc
®
 Syringe Filters; Pall Corporation, USA 
21. 0.2 µm Supor® Membrane, 25 mm, sterile, non-pyrogenic; Lot: 375371; 
Acrodisc
®
 Syringe Filters; Pall Corporation, USA 
22. Polycarbonate 0.05 µm, 25 mm membrane filters; Batch No.: 256274, GE Water 
& Process Technologies 
23. 0.02 µm, 10 mm, sterile,  membrane filters; Batch No.: 09036A, Whatman 








2.3.1. HPLC assay validation of Ibuprofen 
2.3.1.1. Chromatographic conditions 
IBU HPLC analysis method was adopted from a reported method with slight 
modification
191
. The drug elution was performed at ambient temperature at a flow rate of 
1.2 mL/min and detected at the UV wavelength of 222 nm. The mobile phase used was 
60% Acetonitrile and 40% phosphoric acid (50 mM, pH 3.0), which gave a retention 
time of 4.8 min for IBU and was run in an isocratic mode. The mobile phase was filtered 
through a 0.45 µm membrane filter prior to use. All samples were analyzed by HPLC 
using injection volumes of 20 μL. The HPLC assay of IBU was validated for selectivity, 
linearity, precision, recovery (accuracy), and sensitivity. 
 
2.3.1.2. Preparing standard solutions 
A stock solution of IBU was prepared by dissolving a known amount of IBU in 
methanol. Different concentrations of standard solution were prepared by proper 
dilutions of the stock with mobile phase (60% Acetonitrile, 40% phosphoric acid (50 
mM, pH 3.0). 
 
2.3.1.3. Selectivity 
A forced degradation (stress testing) study described below
192
 was performed to 
generate degradation products that were used to demonstrate specificity and selectivity 
of the method.  
 
2.3.1.3.1. Preparation of stressed samples 
Degradation products were generated by subjecting a standard solution of IBU (1 
mg/mL) to four different stress conditions such as light (laboratory light, approximate 
5660 flux), temperature (35±2ºC), acid hydrolysis (hydrochloric acid; 2M)  and 
oxidation (hydrogen peroxide; 30%) . A stock solution (1 mg/mL IBU) was prepared in 
methanol. For acid and oxidation stresses, 20 µg/mL IBU was prepared by diluting stock 
solution with 2M hydrochloric acid, and 30% hydrogen peroxide respectively. For 
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temperature and light stress, dilutions were done with mobile phase.  Samples were 
analyzed immediately after applying each stress to establish initial (t=0) level. Stressed 
samples were stored up to 3 weeks and were analyzed on suitable time interval. A 
standard solution (20µg/mL) of IBU and a blank were injected.  
 
2.3.1.4. Linearity 
The assay linearity was determined by using IBU standard solutions prepared from the 
mobile phase. Eight different standard concentrations of 0.5, 1, 2, 2.5, 5, 10, 15 and 20 
µg/mL covering the entire range of expected entrapment and release study of IBU were 
prepared by diluting the IBU standard stock solution (1 mg/mL) with mobile phase and 
were injected directly into HPLC under conditions described in section 2.3.1.1. The 
calibration curve was constructed by plotting peak areas against different concentration 
of IBU standard solutions. 
 
2.3.1.4.1. Linearity of Ibuprofen in release medium 
The effect of release medium (Phosphate buffer solution; PBS 50 mM, pH 7.4 
containing 0.05% sodium azide) on IBU detection in HPLC was performed by preparing 
a stock solution of IBU in release medium. Different standard concentrations were 




System precision was determined by analyzing six replicate injections of three different 
concentrations (0.5, 2.5 and 5.0 µg/mL) from the same standard solution.  
Method precision, which measures the closeness of analytical results following a 
particular method, was determined by analysis of five independent standard solutions of 
three different concentrations (0.5, 2.5 and 5 µg/mL). 
The variations in the results of both precisions were calculated in terms of percentage of 
relative standard deviation (% R.S.D.) of the determinations.  
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2.3.1.6. Intra- and inter-day repeatability 
Intra-and inter-day repeatability were assessed at three concentrations (5, 2.5 and 0.5 
µg/mL) covering specified range. All injections were carried out in triplicate. Intra-day 
repeatability was obtained by analyzing three sets of freshly prepared standards six 
times at different times in a day. The chromatographic peak areas were compared and 
the % R.S.D between measurements was estimated as a measure of intra-day 
repeatability. 
Inter-day repeatability was measured as % R.S.D between analysis of the same three 
standards six times (stated above) on three consecutive days. The intra- and interday 
repeatabilities were assessed by the level of % of R.S.D obtained. 
 
2.3.1.7. Recovery (Accuracy) 
For determination of assay recovery, eight concentrations ranging between 0.5 and 20 
µg/mL were analyzed by spiking an aliquot of empty liposome with a known amount of 
IBU. Spiked vesicles were disrupted with ethanol and all dilutions were done with 
mobile phase prior to HPLC analysis against a standard solution. The percentages of 
measured concentrations over added concentrations were calculated to determine the 
interference of liposome matrix on the IBU assay.  
2.3.1.8. Sensitivity 
Sensitivity of assay was determined by estimation of limit of detection (LOD) and limit 
of quantification (LOQ). A blank (methanol diluted with mobile phase) was injected 6 
times on HPLC. The noise level was determined. LOD and LOQ were calculated based 
on 3.3 times and 10 times of noise level respectively using the calibration curve of peak 






2.3.2. Sodium fluorescein assay 
2.3.2.1. Linearity 
NaFl was analyzed by using the fluorescent spectrophotometer with an excitation 
wavelength of 494 nm and an emission wavelength of 513 nm. Different NaFl standard 
solutions were prepared from a stock solution of NaFl in water (at 1mg/mL) and diluting 
5000 times with borate buffer pH 9. Linearity was performed by analysis of diluted 
standard solutions of NaFl. The calibration curve was constructed by plotting 
fluorescence intensity against concentration (ranging from 0.05 µg/mL to 0.30 µg/mL) 
of NaFl standard solutions. 
 
2.3.2.2. Effect of light on sodium fluorescein fluorescence intensity 
To determine the effect of light on NaFl fluorescence intensity, six different standard 
concentrations were left for a period of 24 h on bench top and fluorescence intensities 
were determined.  The purpose of this experiment was to determine the extent of effect 
of light on sodium fluorescein fluorescence intensity under normal experimental 
conditions with various sample concentrations.  The 24 hrs period covers the length of 
time used in release studies. 
 
2.3.3. Solubility study of Ibuprofen 
2.3.3.1 Determination of Ibuprofen solubility in water at room temperature 
10 mg of IBU was dissolved in 0.5 mL of ethanol and was diluted with water up to 10 
mL so that the final concentration of IBU in water is 1 mg/mL. As soon as water was 
added, IBU precipitated out and a milky white suspension formed, which was left for 
continuous stirring at room temperature overnight. This allowed most of the ethanol to 
evaporate from the system. After approximately 24 h, 1 mL of dispersion was taken out 
and was filtered through 0.45 µm filter and was diluted with mobile phase. This was 
injected into HPLC to determine the solubility of IBU in water. 
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2.3.3.2. Determination of Ibuprofen solubility in 50mM PBS pH 7.4 at room 
temperature 
IBU is not readily soluble in PBS. Stirring and temperature affects its solubility. Again 
the solubility depends on the molarity of PBS. The purpose of the mentioned work was 
to determine the solubility of IBU in PBS 50 mM pH 7.4 at room temperature at various 
time intervals. An excess amount of IBU was added to 10 mL of 50 mM PBS pH 7.4 
until the buffer was saturated. After shaking this IBU-PBS system manually for 5 min, 1 
mL of the dispersion was withdrawn and filtered through 0.45 µ filter. This was diluted 
with mobile phase prior to injection into HPLC. The IBU-PBS dispersion was left for 2 
days at room temperature with continuous stirring to favor further solubility and 1 mL 
was withdrawn after 0.1, 8, 24, and 48 h to determine the solubility of IBU in PBS pH 
7.4. The IBU-PBS dispersion was used as the system was saturated with excess amount 
of IBU to permit the solubility study. 
 
2.3.4. Stability of Ibuprofen and sodium fluorescein in release medium 
Stability of IBU and NaFl in release medium (50 mM PBS pH 7.4, containing 0.05% 
sodium azide) was determined by keeping a standard solution of IBU and NaFl (1 
mg/mL) in release medium for a period of 7 days at 35±2ºC. Triplicate samples of 10 
and 5µg/mL of IBU and 0.2 and 0.1µg/mL of NaFl were prepared by dilution with 
mobile phase and borate buffer pH 9 respectively and were analyzed immediately after 
preparation as well as on day 0, 3, and 7.  Analysis was performed according to 
conditions described under section 2.3.1.1 and 2.3.2.1. IBU potency was calculated as a 
percentage of IBU peak area over the total area of IBU and its related peaks. 
2.3.5. Liposome preparation  
2.3.5.1. Preparation of conventional liposomes 
2.3.5.1.1. Film formation 
Conventional liposomes were prepared by thin film hydration technique described by 
Bangham et al.
58
. In a typical procedure, the lipid phase consisting of PC (70-100 mg) 
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and cholesterol (0-30 mg) were dissolved in 10 mL of organic solvent (chloroform: 
methanol; 3:1v/v) and the mixture was introduced into a 250 mL of clean, dry, round 
bottom flask. The flask was then attached to a rotary evaporator and immersed in a 
temperature controlled water bath. The solvent was slowly removed with reduced 
pressure at above Tc of phospholipid (around 42ºC for 95% PC and 50-55ºC for 
cholesterol containing vesicles) with 100 rpm stirring speed. The drying process was 
continued for 10 min or more until the dry lipid film first appeared. The flask was then 
removed from the rotary evaporator and placed under vacuum in a vacuum oven 
overnight at ambient temperature to remove the final traces of organic solvent. 
2.3.5.1.2. Film hydration & drug loading  
Deposited lipid film was hydrated with 10 mL of aqueous hydration medium above Tc 
(around 42ºC for 95% PC and 50-55ºC for cholesterol containing vesicles) for 1 h with 
100 rpm stirring speed using the rotary evaporator. Vesicles produced by thin film 
hydration method are multilamellar as shown in the literature
58
. IBU or NaFl was loaded 
into the vesicles via two different hydration media: IBU was dissolved in PBS pH 7.4, 
while NaFl was dissolved in water and both were added to the lipid film as hydration 
medium. In all liposomal formulations, the final total concentration of lipid system 
(PC/cholesterol/surfactants) was 10 mg/mL and IBU or NaFl concentration was 
1mg/mL. All liposomes contained a total of 100 mg lipid or lipid phase 
(PC/cholesterol/surfactants; depending on the type of formulation) and 10 mg IBU or 
NaFl in 10 mL hydration medium. The resulting vesicles were swollen for 2 h at room 
temperature to get large MLVs, which were then sonicated using a bath sonicator for 30 
min below room temperature followed by probe sonication for 1 min at 4±2°C, with 
energy output 40W, and 0.4 cycles to produce smaller vesicles. Finally, obtained 
liposomes were extruded ten times through 200 and 100 nm Supor
®
 membrane filters 
(each). All samples were immediately flushed with nitrogen in a 10 mL glass vial and 




Figure 2.1: A representative diagram of liposome formation by Thin film 
hydration technique: 1: Formation of lipid film; 2: Addition of drug/probe solution 
as hydration medium; 3: Rotation using rotary evaporator; 4 MLVs which were 
downsized (Figure adapted from Lasic
193
) 
2.3.5.2. Preparation of elastic liposomes 
2.3.5.2.1. Film formation 
Elastic liposomes were prepared by thin film hydration technique described by Cevc et 
al.
194
. In brief, the lipid phase composed of PC (75-95 mg) and surfactant (5-25 mg) 
were dissolved in 10 mL of an organic solvent (chloroform: methanol; 3:1 v/v) in a 250 
mL of clean, dry, round bottom flask. The solvent was then removed by rotary 
evaporator at above Tc of lipid (43°C) with 100 rpm stirring speed until a thin lipid film 
formed at the flask. Complete removal of residual solvent from the resulting film was 
performed by removing the flask from the rotary evaporator and keeping under vacuum 
in a vacuum oven overnight at ambient temperature. 
2.3.5.2.2. Film hydration & drug loading 
Resultant lipid film was hydrated with 9.3 mL of IBU or NaFl solution in PBS or water 
respectively at above Tc (around 42ºC) for 1 h with 100 rpm stirring speed. The flask 
was then left to cool down to room temperature. 0.7 mL of absolute alcohol was added 
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separately and dropwise to the liposomal dispersion with continuous stirring and manual 
shaking for approximately 5 min. Thus a total 10 mL of hydration medium was added.  
The ultimate hydration medium for elastic liposomes was a hydroalcoholic mixture 
containing 7% ethanol. IBU or NaFl was loaded into the vesicles in two different ways: 
IBU was dissolved in PBS pH 7.4 (1.075 mg/mL), while NaFl was dissolved in water 
(1.075 mg/mL). The volume of 9.3 mL of each of these solutions was used as hydration 
medium.  For complete swelling, vesicles were left at room temperature for 2 h and 
were then sonicated with a bath sonicator for 30 min and probe sonicated for 1 min at 
4°C, 40W, and 0.4 Hz. Liposomes were then finally extruded ten times through 200 nm 
Supor
®
 membrane filters followed by ten times extrusion through 100 nm Supor
®
 
membrane filters.  
2.3.5.3. Preparation of empty vesicles 
Empty conventional and elastic liposomes were prepared and processed using the same 
method described above with hydration medium of water or PBS pH 7.4. All empty 
liposomes contained 10 mg/mL of lipid. 
 
2.3.6. Physicochemical characterization of conventional and elastic 
liposomes 
2.3.6.1. Determination of liposome size and size distribution 
Liposome size was measured by photon correlation spectroscopy using a Zetasizer 
3000HS.  Briefly, liposomal dispersion was suitably diluted with hydration medium at 
25±2°C, Samples were placed in quartz cells and were analyzed at 25±0.1°C and at a 
detection angle of 90°. Size of liposomes was expressed as average diameter (z-average) 
that was obtained by cumulative analysis performed by the Zetasizer 3000HS Software. 
The experiments were performed in triplicate and each sample was analyzed ten times to 
obtain mean diameter and polydispersity index
195
. For each formulation, the mean ±SD 
of three replicate determinations were used to express the result. 
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2.3.6.2. Determination of liposome zeta potential 
To determine the type of surface charge on liposomal particles, zeta potential of 
liposomes was measured using Zetasizer with a zeta mode based on the Laser Doppler 
Anemometry principle. Samples were diluted with hydration medium and measurements 
were performed in triplicate. For each sample, the mean± SD of three determinations 
was repeated. 
2.3.6.3. Liposome morphology 
Liposomes were visualized by using a Jeol 2100 TEM with an accelerating voltage of 
120 kV. Prior to TEM, a fine drop of liposome suspension was placed onto a carbon-
coated copper grid to form a thin film. The grid was left at room temperature to allow 
the evaporation of moisture.  The grids were then placed in the sample inlet chamber of 
TEM and observed. Crude and empty liposomes were also visualized. A series of 
micrographs were taken without the overlap of areas. 
Morphological evaluation of liposomes was also performed using FESEM and optical 
microscope. For FESEM, one drop of liposomes was mounted on a carbon coated stub. 
Excess sample was removed carefully. A Cressington sputter-coater (208HR) was used 
to coat the samples with chromium. Samples were then examined under FESEM at an 
accelerating voltage of 1 kV. For examination under optical microscope, 2/3 drops of 
liposomes were spread on a glass slide and was covered with a cover slip before 
observed under the microscope (Leica DC 100). 
2.3.6.4. Determination of entrapment efficiency  
The EE of liposome was measured indirectly by determining the amount of non-
entrapped IBU or NaFl in liposome dispersion by using centrifugation technique
196
. 
Briefly, an aliquot of liposomal dispersion, stored at 4±2°C, was placed in the upper 
chamber of a Nanosep
®
 (300K Omega) which was then centrifuged at 4000 rpm for 40 
min to separate the liquid (supernatant, which contains the un-entrapped IBU or NaFl). 
The liquid containing free NaFl or IBU was collected in the receptor chamber of the 
Nanosep
®
 and their concentration was then determined by using Fluorescent 
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Spectrophotometer and HPLC respectively.  EE was calculated from the equation 
below: 
       
 initial- free
 initial
    ……………………………(Equation1) 
Where, Winitial is the total amount of NaFl or IBU used in the formulation 
               Wfree is the amount of free NaFl or IBU found in the supernatant  
 
2.3.6.5. Determination of bilayer elasticity 
The elasticity of different formulations was measured by an in-house purpose built 
device, based on the description given in reports 
136,197
.  A schematic diagram of this 
device is presented in Figure 2.2 and a picture of device set-up is presented in Appendix 
1. All elastic formulations were placed in a 10 mL sample holder which was attached to 
a stainless steel case containing a 0.05µm membrane filter with 25 mm diameter. The 
filtration was performed with the application of an external pressure of 2.0 bar. The 
volume of vesicle suspension which was extruded within 5 min was measured and 
vesicle size was monitored before and after extrusion. The experiment was performed in 
triplicate for each sample and duplicate formulations were analyzed.  
According to van den Bergh et al, the elasticity of vesicles was expressed in terms of 





 ……………………………………………(Equation 2) 
Where, 
D= Deformability index 
J= volume of suspension (mL) which was extruded within 5 min 
rv= Size of vesicles (nm) (after extrusion) 















Figure 2.2: A typical diagram of the set up of extrusion device 
 
2.3.7. Stability of liposomes under different storage conditions 
The effect of storage condition on the size of NaFl loaded conventional liposomes was 
studied by keeping liposomes at three different temperature conditions i.e., 4±2°C 
(refrigerator), 25±2°C (room temperature), 35±2°C (hot room) for a period of 4 weeks. 
All liposomal suspensions were kept in sealed 10 mL vials after flushing with nitrogen. 
Samples were withdrawn periodically and the sizes were analyzed by Zetasizer. 
2.3.8. In vitro release study of liposomes 
Release study of liposomes was carried out using a dialysis method
199
. The details are 
described below. 
2.3.8.1. Treatment of dialysis membrane 
The dialysis membrane was first washed with running water for 3-4 h to remove the 
glycerin. This was then immersed in 0.3% w/v of sodium sulphide at 80°C for 1 minute 
to remove the sulphur. Sodium sulphide was then removed by washing the membranes 






(maximum 2.5 bar) 






The membranes were finally rinsed with hot water at 60°C to remove the acid and were 
stored in Milli ‘Q’ water at 4°C until used. The water was replaced with fresh water 
daily to minimize the risk of microbial growth. 
2.3.8.2. Separation of non-entrapped sodium fluorescein or Ibuprofen from 
liposomes 
In vitro release studies of NaFl and IBU liposomes were conducted by dialysis 
technique.  In the present study, the dialysis tube with average flat width of 32 mm and 
molecule weight cut-off of 12,000 Da was used. Three optimized formulations 
containing NaFl and IBU along with their respective controls were chosen for this study. 
The effect of cholesterol on IBU release from conventional liposomes was also 
investigated. Free drug in each formulation was removed prior to release study by an 
initial 80 min dialysis. To do this, 8 mL of liposome was placed in the dialysis bag, 
which was fully immersed in 1 L of PBS pH 7.4 and was dialyzed for 80 min at room 
temperature to remove non-entrapped drug. Samples were taken from the receiver 
compartment (50 mM PBS pH 7.4) at predetermined time intervals and were analyzed 
for their NaFl or IBU content. A control drug solution (1 mg/mL) was also dialyzed in 
the same manner to ensure that complete removal of free drug was at around 80 min. 
After 80 min, purified liposomes were taken out for release study. 
 
2.3.8.3. Determination of release rate of sodium fluorescein or Ibuprofen 
 
As soon as free NaFl or IBU was separated, purified liposome dispersions containing 
approximately 1 mg NaFl or IBU were then transferred to a separate dialysis bag and 
immersed in a 50 mL release medium (PBS pH 7.4 with 0.05% sodium azide) in a 100 
mL closed jar and was immediately transferred to 35±2ºC for release study as per set up 
in Figure 2.3. Sodium azide was added in the release medium to minimize the growth of 
microbes. Both ends of the dialysis membrane were tightly bound with threads. Control 
bags were prepared and tested along with the liposomal dispersions. Each control bag 
contained 1 mg/mL NaFl aqueous solution or 1 mg/mL IBU in PBS pH 7.4. The jar was 
kept on a magnetic stirrer with constant stirring speed. A solution of 1 mL was collected 
at 0.5, 1, 2, 3, 5, 7, 10, 12, 15, 20 and 24 h and replaced with fresh 1 mL release medium 
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to maintain sink condition. The release study was conducted in triplicate for each 
optimized formulation and controls. NaFl release was assayed spectrophotometrically at 
an excitation wavelength of 494 nm and an emission wavelength of 513 nm. IBU release 









Figure 2.3: A typical diagram showing the set up of in vitro release study by 
dialysis method 
 
2.3.9. In vitro permeation of Ibuprofen through human epidermis 
2.3.9.1. Treatment of skin 
Excised human skin from patients of Perth hospitals who had undergone abdominal 
plastic surgery was used under Curtin approved ethics protocol (No.HR 129/2008). 
Freshly obtained skin was wrapped in aluminum foil and stored in polyethylene bags at 
−20°C until use. This condition is sufficient for the skin to be stable for 3 months with 
regard to the penetration of drugs, as well as maintaining the thickness of the SC over a 




. The skin was carefully checked through a magnifying 
glass to ensure that samples were free from any surface irregularities such as tiny holes 





Dialysis bag (Containing liposome) 
Magnetic stirrer  
50 mL glass container with lid 
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2.3.9.2. Preparation of epidermis 
The human epidermis was prepared by a heat separation technique
203, 204
. Prior to 
penetration study, whole skin was thawed and cut into suitable pieces. Each skin piece 
was soaked in water at 60°C for 1 min followed by careful separation of the epidermis 
from dermis using a scalpel. The obtained epidermal pieces of tissues were wrapped 
individually in parafilm in an aluminum foil and stored at a temperature of -20ºC until 
used. For penetration experiments, thawed epidermis was cut into small disks, cleaned, 
and then transferred onto the Franz diffusion cells.  
2.3.9.3. Franz diffusion cell 
The Figure 2.4 describes the setup of the Franz diffusion cell.  The epidermal membrane 
was clamped between the donor and receptor compartments of the cell with nominal 
diffusion area of 1.13 cm
2
 and a receptor compartment of a 3 mL capacity. The receptor 
was filled with PBS (50 mM, pH 7.4) which was constantly stirred by magnetic stirrer at 
100 rpm. The epidermal side of the skin was exposed to ambient conditions while the 
dermal side was bathed by receiver. The receptor fluid was maintained at 35±1°C using 
a re-circulating water bath in order to ensure skin temperature. All bubbles were 
carefully removed between the underside of the skin and solution in the receiver 
compartment. To achieve higher reproducibility, the skin was pre-hydrated with PBS for 
45 min before it was used for penetration study. A minimum of four diffusion cells were 









2.3.9.4. Liposome dosage regime and sampling time 
A volume of 0.5 mL (at 1 mg/mL of IBU) of different liposomes (conventional, elastic 
liposomes) and plain drug solution containing IBU were applied non-occlusively to the 
epidermal surface of skin mounted in Franz type diffusion cells. Samples were 
withdrawn through the sampling port of the cell at predetermined time intervals over a 
period of 12 h and were analyzed. Receptor phase was immediately replenished with 
equal volume of fresh PBS. After 12 h, the experimental set up was dismantled and 
samples were removed from receptor compartments and analyzed by HPLC. The 
amount of IBU retained in the skin was determined by extraction of skin at the end of 
the experiment. 
2.3.9.5. Extraction of Ibuprofen from epidermis 
At the end of permeation experiment, the epidermal pieces were carefully removed. 
Each epidermal piece was washed three times with PBS pH 7.4 to remove any surface 
bound drug. 0.5 mL of methanol was added to each piece, which was vigorously 
vortexed for 2 min every 10 min over a period of 30 min. The epidermis was removed 
and another 0.5 mL of methanol was added to it. The same process was repeated. After 
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1 h, drug content in both methanol extractions were analyzed separately by suitable 
dilution with the mobile phase. However a 3
rd
 extraction was applied by adding 0.5 mL 
of mobile phase to each epidermal piece followed by vortexing for 2 min every 30 min 
over a period of 2 h to ensure complete extraction of IBU. The total drug content in 
epidermis was calculated from the three extractions. 
2.3.9.6. Calculation of permeation parameters 
The cumulative amount of drug permeated per unit area was plotted as a function of 
time. The steady-state permeation rate or the flux (Jss, µg/cm
2
/h) was calculated using 
the slope of the straight line portion of the curve i.e. cumulative amounts of the drug that 
permeated the membrane vs. time period of the experiment. Permeability Coefficient 
(K) and enhancement ratio (ER) were calculated from the following equations 
respectively.  
Permea ility Coefficient ( ) 
 lux of individual  ranz cell
Concentration of drug in donor
               
 R  
Transdermal flux from vesicular formulation
Transdermal flux from plain drug
               
 
2.3.10. Data analysis 
Statistical analysis was carried out employing the Student’s t-test using the software 
PRISM (Graph Pad). The mean of at least 3 experiments was taken together with the 
standard deviation (SD) for all data representation unless otherwise stated. In order to 
compare the skin penetration data in different samples, a linear mixed regression model 
was fitted. All data presented in skin penetration study were a mean± standard error 







RESULTS AND DISCUSSION 
 
3.1. Validation of analytical method 
3.1.1. HPLC assay validation of Ibuprofen 
IBU assay was performed from a stock solution of IBU in methanol and appropriate 
dilution with mobile phase to prepare a range of standard concentrations (0.5-20 
µg/mL) of IBU. 
3.1.1.1. Selectivity 
The purpose of doing specificity and selectivity of analytical assay is to ascertain 
that the analyte can be analyzed unequivocally in the presence of other expected 
components. Analytical method validation should be specific and selective, therefore 
be able to detect quantitative changes in drug substance over time. To achieve this, a 
forced degradation study was conducted to allow that IBU degraded under acid and 
oxidation stress. Typical HPLC chromatograms of IBU and its acid and oxidation 
degradation products are illustrated in Figure 3.1 showing a complete separation of 
IBU from its degradation products. The retention time of IBU, and its acid and 
oxidation degradation products were approximately 4.8 (Figure 3.1 (a)), 12.36 
(Figure 3.1 (c)) and 5.73 min (Figure (d)) respectively. No degradation products 
were found for light and temperature stressed samples within the specified time 
period. Typical chromatograms of temperature and light stressed samples are shown 
in Appendix 2A and 2B respectively.  For comparison purpose, a blank of empty 
liposome (PC: cholesterol 70:30) (Figure 3.1 (b)), 30% hydrogen peroxide in mobile 
phase (Appendix 2C) and 2M HCl in mobile phase (Appendix 2D) were injected 
separately into HPLC, where no detectable peak was found at the retention time of 
IBU. Additionally a known amount of IBU was spiked with empty liposome to 








Figure 3.1(a): A typical HPLC chromatogram of 10 µg/mL of IBU in 
methanol as a standard 
 
Figure 3.1 (b): A typical HPLC chromatogram of empty liposome (PC:   





Figure 3.1(c): A typical HPLC chromatogram of IBU (retention time 4.8 min) 
and its acid stressed degradation product (retention time 12.4 min)  
 
Figure 3.1(d): A typical HPLC chromatogram of IBU (retention time 4.9 min) 
and its oxidation stressed degradation product (retention time 5.7 min) 
Thus it can be concluded that the assay method for IBU detection was selective and 





Linearity study establishes the concentration range of analyte where the detector 
response was linearly proportional to analyte concentration. For 20 µl injection of 
IBU, the regression plot showed a good linear relationship over the concentration 
range of 0.5-20 µg/mL of IBU in mobile phase which covered the concentrations 
encountered in the analysis of IBU loading and release study. The correlation 
coefficient was 0.9999. The typical standard curve is shown in the Figure 3.2. 
Linearity (quoted as R
2
) was evaluated by linear regression analysis, which was 
calculated by the least square linear regression method. 
 
Figure 3.2: Standard curve for IBU in mobile phase, 20µL injection volume 
3.1.1.2.1. Linearity of Ibuprofen in release medium 
To investigate the retention time and area of IBU in release medium (50 mM PBS 
pH 7.4 containing 0.05% sodium azide) a stock solution of IBU was prepared in 
release medium. When different standard concentrations of IBU in PBS were 
injected into HPLC, data showed no significant difference in both peak area and 
retention time compared to those prepared in methanol and diluted with mobile 



























“The precision of an analytical method expresses the closeness of agreement (degree 
of scatter) between a series of measurements obtained from multiple sampling of the 
same sample under the prescribed conditions.”
206
. Precision validation was 
performed for both system and method precision. The results of system precisions of 
the assay method are shown in Table. 3.1. The R.S.D. values found for 6 injections 
of 5, 2.5 and 0.5 µg/mL of IBU in mobile phase are 1.09, 0.05 and 0.27% 
respectively. For method precision, the R.S.D. values obtained for 5 preparations of 
the same three concentrations were 1.77, 1.54 and 1.78% respectively (Table 3.1). In 
both cases, the R.S.D. values were below the nominal acceptable level of 2.0% 
which indicates that the HPLC analytical method for IBU is precise. Detailed data of 
system and method precision are given in Appendix 3A and 3B. 
Table 3.1: System precision and method precision of the HPLC method for 












5 1.09 1.77 
2.5 0.05 1.54 
0.5 0.27 1.78 
    
A
 six replicate injections of each sample, 
B
 five replicate injections of each sample 
3.1.1.4. Intra- and inter-day repeatability 
Intra-and inter-day repeatability is assessed as the degree of reproducibility of the 
method when samples are analyzed on the same day or over a period of time. The 
analyses of assay variation at intra-and inter-days are summarized in Table 3.2. The 
highest value of % of R.S.D. analysis was found to be 0.16 (0.5 µg/mL) for intra-day 
measurements, while it was found to be 1.14 (5 µg/mL) for inter-day measurements. 
Both the intra-day and inter-day R.S.D. of IBU were below 2.0%, within the nominal 
acceptable level which indicates a considerable degree of precision and 














5 0.13 1.14 
2.5 0.13 0.57 
0.5 0.16 0.28 
a
 n=3, at each concentration, triplicate samples were prepared and analyzed by HPLC 
b 
Analyses of samples were performed at 0, 3 and 6 h in the same day and all data 
were included in the calculation of R.S.D. 
c 
Analyses of samples were performed at 0, 1, and 2 day and all data were collected 
in the calculation of R.S.D. 
 
3.1.1.5.  Recovery (Accuracy) 
Recovery is a measure of the extent of analyte recovered from the test matrix so as to 
assess the errors or loss occurred in extraction or in analysis in the experiment
206
. In 
another words, it is the closeness between experimental and true value
207
. Recovery 
studies were performed by spiking the empty liposomes with a known amount of 
IBU and the extent recovered in analysis was translated to percent recovered. The 
data is shown in Table 3.3. The average recovery of known amount of IBU was 
99.33% with a R.S.D. of 1.25% over the concentration range of 0.5-20 µg/mL. The 
95% confidence interval (CI) of the slope ranged from -0.10257343 to 0.2215060. 
Results indicate that IBU can be considered fully recovered in the presence of 








Table 3.3: Recovery of IBU
a 






0.50 0.48 96.40 
1.00 0.99 98.95 
2.00 2.00 99.85 
2.50 2.51 100.40 
5.01 5.01 100.00 
10.02 9.97 99.50 
15.03 15.02 99.93 
20.05 19.98 99.65 





Correlation coefficient 0.1185 
95% CI Slope -0.10257343 to 0.2215060 
95% CI Y-intercept 97.3334 to 100.5023 





The sensitivity of HPLC method is determined by LOD and LOQ. LOD is the lowest 
concentration of the analyte the method can detect and LOQ is the lowest 
concentration that can be quantified by the method with accuracy and precision. For 
IBU, the LOD and LOQ determined in mobile phase were 2.7ng/mL and 8.2 ng/mL 





3.1.2. Linearity of sodium fluorescein 
Fluorescence analysis of NaFl was performed in fluorometer with an excitation and 
emission wavelength of 494 nm and 513 nm respectively
208
. A stock solution of 
NaFl was prepared in water; however different NaFl standard concentrations were 
prepared by dilution with water and borate buffer pH 9 respectively. The 
fluorescence profile of NaFl in water was found not reproducible and markedly 
smaller than that of in buffer (Figure 3.3(a) and (b)). For example, the average 
fluorescence intensities of NaFl at 0.25µg/mL in water and borate buffer pH 9 were 
155.58 and 834.96 respectively. This can be explained by the fact that the 
fluorescence of NaFl is highly pH dependent
209
; in aqueous solution NaFl can exist 
in 4 different monomeric forms over the pH range of 0-13. Each form has its own 
absorption values as the absorption spectrum of these aqueous solutions are pH 
dependent. The protonation of the molecule results in a reduction of efficacy of the 
mechanism by which absorbed energy is converted into fluorescence emission, i.e. a 
pH associated quenching. Therefore in an acidic pH, the fluorescence is expected to 
be lower
210
. Another research group, Zhu et al found that the higher the pH the 
higher was the fluorescence of NaFl and maximum fluorescence was observed when 
the pH was beyond 8.4
211
. They found that the fluorescence intensity of NaFl 
increased 1.25 times when the solution pH value increased from 6.9 to 8.4. 
Considering our data and supportive literature findings, in this study, a separate 
linearity was performed in borate buffer pH 9 (Figure 3.3(b)). A stock solution of 
NaFl (1mg/mL) was prepared in water and different standard concentrations were 
prepared by diluting with borate buffer. The fluorescence intensity of NaFl was 
linear over a narrow concentration range (0.05µg/mL-0.30µg/mL). Concentration 




Figure 3.3(a): Fluorescence profile exhibited by NaFl standards (dilution with 
water; pH approx. 5.4), data represents as mean ±SD, n=3 
 
 
Figure 3.3(b): Linear fluorescence profile exhibited by NaFl standards (dilution 
with borate buffer pH 9), data represents as mean ±SD, n=3 
 
3.1.2.1. Effect of light on sodium fluorescein fluorescence intensity 
NaFl is not stable under light and may undergo photoquenching. A clear reduction in 
fluorescence intensity was observed when different standard solutions of NaFl were 
stored on bench top for a period of 24 h. Table 3.4 shows the % of decrease in 
fluorescence intensity of NaFl solutions stored on bench top without protection from 
light. 




















































Table 3.4: % of decrease in fluorescence intensity of NaFl on bench top without 




intensity: Day 0 
Fluorescence 
intensity: Day 1 
% Decrease in 
Fluorescence 
intensity 
0.3 965.66 823.91 14.67 
0.2 682.13 632.76 14.47 
0.1 342.65 277.57 18.99 
 
Therefore in this study, all NaFl samples were covered with foil to protect them from 
photoquenching.  
3.2. Determination of solubility (saturation concentration) of 
Ibuprofen 
3.2.1.  Determination of solubility of Ibuprofen in water at room 
temperature 
A saturated solution of IBU in water was prepared at room temperature described 
under section 2.3.3.1. After 24 h, the solubility was determined and found to be 56.0 




3.2.2.  Determination of solubility of Ibuprofen in 50 mM PBS pH 7.4 
at room temperature 
The saturated solution of IBU was prepared at 25°C by dissolving an excess amount 
of drug in 50 mM PBS pH 7.4. This solution was kept at continuous stirring for a 
period of 48 h and an aliquot was withdrawn at 0, 8, 24 and 48 h, filtered and 
analyzed for drug content by HPLC. The solubility of IBU in PBS pH 7.4 at 0.1, 8, 
24 and 48 h were found to be 2.58, 4.37, 4.41 and 4.45 mg/mL respectively. Al-
Saidan reported the solubility of 10.4±0.9 mg/mL for IBU in disodium hydrogen 
phosphate solution (100 mM) under the similar condition. He also showed that with 
the increase in molarity of disodium hydrogen phosphate solution, the solubility 





Therefore it can be concluded that the solubility of IBU (4.45mg/mL) determined in 
current study with 50mM PBS pH 7.4 was reasonable and expected. 
 
Solubility of IBU in both water and PBS were determined to know its solubility 
profile in respective hydration medium and also to maintain a sink condition in the 
in-vitro drug release study. 
3.3. Stability of Ibuprofen and sodium fluorescein in release 
medium 
IBU stability in the release medium was evaluated at 35±2ºC using HPLC method 
described under section 2.3.1.1. Neither any degradation product nor any significant 
change in area was found for two different IBU standard concentrations (10 and 
5µg/mL) after 7 days storage at 35±2ºC.  
Different standard solutions of NaFl (0.2 and 0.1µg/mL) in release medium stored at 
35±2ºC for a period of 7 days did not show any change or decrease in fluorescence 
intensity (Table 3.5) provided that they were stored in amber glass containers. 




Concentration (µg/mL) Concentration(µg/mL) 
 10 5 0.2 0.1 
0 100.0 100.0 100.0 100.0 
3 100.0 99.80 99.81 99.79 
7 99.89 99.30 99.85 99.69 
 
These data suggest that both IBU and NaFl should maintain their stability over the 
period of our release and skin penetration study. Because of the light sensitivity issue 
with NaFl, all samples containing NaFl were handled either in the dark or with 





3.4. Preparation and characterization of liposomes  
The purpose of this study was to develop and optimize different conventional and 
elastic liposomes on the basis of vesicle shape, size, zeta potential, EE and elasticity 
for dermal delivery using a water soluble dye NaFl and a model lipophilic drug, IBU. 
Formulation variables such as PC, cholesterol and type and concentration of 
surfactant; Tween 80 and sodium cholate were studied to identify and assess their 
influence on the size, charge, EE, bilayer elasticity, and in-vitro drug release of 
various liposomes. All other formulation and process variables such as lipid 
concentration, hydration time, speed of rotation and amount of drug used were kept 
invariant throughout the study to examine the influence of formulation variable on 
characterization, in vitro drug release and skin penetration study of liposomes. 
3.4.1. Selection of process variable 
3.4.1.1. Preparation technique, method of drug loading and type of lipid 
Several methods are available for liposome preparation; among them the thin film 
hydration technique is the simplest and commonly used in the laboratory scale 
preparation. Thus this method was chosen in this project to prepare both 
conventional and elastic liposomes.  
 
Efficient liposomal encapsulation of therapeutic agents can be achieved using 
passive and active loading procedures, depending on the nature of the drug
214
. In 
passive loading technique, which was selected in current project for liposome 
preparation, the therapeutic moiety is added during vesicle formation, while in active 
loading, the drug can be added to preformed liposomes by applying pH gradient 
technique. The mechanism of passive loading of hydrophilic compounds is based on 
the capture of the aqueous solution in the liposomal core, which is related to drug 
solubility in the aqueous solution, drug‟s ability to cross the lipid bilayer, the type of 
additive present in the formulation as well as to the molecular weight of the 
therapeutic compound
215
. Amphipathic and hydrophobic drugs can be associated 
with the lipid bilayer components and therefore their passive incorporation can be 




The purity of lipid is very important in developing a quality liposomal formulation. 
Impure lipids for example, oxidized/hydrolyzed or lipid suspended in oil or 
triglycerides tend to destabilize the liposome
84
. Therefore PC, with purity 95% was 
chosen in the current project as the common ingredient for the development of all 
liposomes. 
 
3.4.1.2. Selection of a solvent system 
The selection of organic solvent to dissolve lipid and lipophilic components in 
liposomes is crucial in the formation of a thin, homogenous and clear film which 
again affects the uniform distribution of lipids in bilayer and particle size of 
vesicles
81
. It is known that high drug entrapment can be obtained by hydrating lipid 
film which is thin
216
. A thin film eventually produces vesicles with relatively 
homogenous size distribution.  
Chloroform: methanol is a suitable solvent system for developing a fine and 
homogeneous film. They are mostly used by investigators. However because of the 
toxicity of chloroform, it should be avoidable. Therefore liposomes were developed 
initially using ethanol, ether, dichloromethane, methanol, and isopropyl alcohol 
alone. Among them utilization of dichloromethane left a badly solidified lipid at the 
bottom of the flask, therefore it was found not suitable for liposome preparation. 
However ethanol, methanol and isopropyl alcohol respectively formed film which 
was not homogenous and was thick (Table 3.6). Ethanol could be used to improve 
the safety, but it is not easy to remove it from the final product. In the current study 
though ethanol was used in hydration medium to prepare elastic liposomes, the 
development of traditional liposomes must be devoid of ethanol. Therefore after 
doing the above mentioned trials with various organic solvents (Table 3.6), an 
appropriate ratio (3:1) of chloroform: methanol was found to be the solvent mixture 
that can consistently produce satisfactory film, and was therefore chosen to prepare 
all liposome formulations. 
Solvent residue must be kept well below the toxic level because the contaminant in 
chloroform is carbon tetrachloride, which is a known carcinogenic product. However 
there are no set maximum acceptable limits of solvents like chloroform
81
. To avoid 
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the concentration of impurities during evaporation high purity chloroform was used. 
Solvent evaporation under vacuum for overnight or at least 12 h was performed in all 
formulations to ensure maximum removal of organic solvents. Residual solvent 
traces in formulations were not determined in the present study due to shortage of 
time. However the use of a smaller batch size (10 mL in current study) is expected to 
produce less chloroform residue in phospholipid film in each batch. 
Table 3.6: Effect of solvent system on the formation of lipid film 
Type of Solvent Observation 
Ethanol 
Thick and non-homogeneous 
film formed 
Dichloromethane 
No film formation, lipid badly 
solidified 
Methanol 
Thick and non-homogeneous 
film formed 
Isopropyl alcohol (IPA) 
Slow solubilization of the 
lipid in IPA, and formation of 
non-homogeneous film 
Chloroform: methanol (3:1) 
Clear, thin and homogeneous 
film formed 
                        
3.4.1.3. Effect of hydration medium 
 
To study the effect of hydration medium on vesicular size distribution and zeta 
potential, empty pure PC liposomes were prepared and only bath sonicated before 












Table 3.7: Effect of hydration media on particle size distribution, zeta potential 











Water 309.9±16.1 0.54±0.01 -5.9±0.6 
Stable 
suspension 
PBS pH 7.4 344.1±13.0 0.50±0.01 8.4±1.7 
Stable 
suspension 
Phosphate buffer saline 
pH 7.4 (200 mM NaCl)
A
 
873.2±11.2 0.55±0.21 2.9±0.5 
Complete phase 
separation 
Phosphate buffer saline 
pH 7.4 (100 mM NaCl)
B
 
850.4±8.1 0.67±0.41 4.8±0.7 
Complete phase 
separation 





which were done twice 
 
Liposomal stability is dependent upon physical characteristics of both the suspended 
liposomes and the suspension medium. Empty PC liposomes hydrated with water 
and PBS were quite stable upon refrigeration and also produced smaller particles 
compared to those of phosphate buffer saline hydrated liposomes. However 
phosphate buffer saline was found not suitable for formation of a stable liposome 
product because of rapid settlement of particles. On refrigeration, a clear phase 
separation was observed. 
 
Liposomes hydrated with water produced particles of lowest size (309.9±16.1 nm) 
whereas PBS yielded slightly bigger particles, which however was not statistically 
significant (P>0.1). The bigger particles formed from phosphate buffer saline could 
be due to the ionic interactions that might have increased the bilayer thickess, and 
consequently caused an expansion within liposome particles. Polydispersity index is 
a measure of the size distribution of particles in a tested sample. The polydispersity 
index of all empty PC liposomes were more than 0.3 which means particle size 
distribution was not homogenous. This may be because vesicles were only bath 
sonicated which could be affected by the position of the sample inside the flask
76
. 
However the zeta potential found in PC liposomes hydrated with water was negative 
whereas in vesicles hydrated with PBS and phosphate buffer saline were positive. 
Mohammed et al also reported a similar zeta potential (-5.9±0.6) of empty PC 
74 
 
liposomes (PC= 12.16 mg/mL) hydrated with water and prepared by film hydration 
technique
212
. However zeta potential of PBS hydrated liposomes was more positive 
than that of phosphate buffer saline hydrated liposomes which potentially could 
contribute to the better stability of liposomes.  
 
The zeta potential of particles is the overall charge that the particles acquire in a 
particular medium. It is not an actual measurement of the individual particle surface 
charge; rather, it is a measurement of the electric double layer produced by the 
surrounding ions in solution including adsorbed counter ions
217
. These counter ions 
play a major role in the zeta potential measurement. According to the electric double 
layer theory, zero electrophoretic mobility was expected for neutral liposomes. 
However it has been reported that liposomes composed of neutral phospholipids (i.e. 
PC) acquire a negative surface charge in water. Makino et al found that neutral 
liposomes exhibited a negative zeta potential in solution of low ionic strength and 
higher ionic strength caused the zeta potential of neutral liposomes to reverse sign
218
. 
At low ionic strength, the phosphatidyl groups (negatively charged) are located at the 
outer portion of the head group. Makino et al proposed that this reversal of zeta 
potential is triggered by changes in the direction of the choline group (positive) 
which at higher ionic strength approaches the outer region of the bilayer while the 
phosphatidyl group hides behind the PC bilayer
218
. As water has no ionic strength, 
and PBS and phosphate buffer saline have higher ionic strength, a negative zeta 
potential in water hydrated liposome and positive zeta potential in PBS and 
phosphate buffer saline hydrated liposomes could be explained by Makino‟s theory. 
However zeta potential in phosphate buffer saline hydrated liposomes were less 
positive compared to that of PBS hydrated liposomes (Table 3.7). This could be due 
to the presence of anion (Cl
-
) in the saline which might have adsorbed on PC 
molecule resulting in a less positive charge of liposomes. 
 
The aggregation and particle settlement is expected in case of liposomes hydrated 
with phosphate buffer saline. In theory, agglomeration state varies significantly, 
depending upon a variety of factors. One possible factor is the influence of ionic 




 ions. Increasing the 
ionic strength of the hydration medium may lead to an agglomeration state likely 
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through charge shielding and condensation of the charge at the electric double 
layer
219, 220
. Therefore liposomes hydrated with PBS containing NaCl showed phase 
separation on refrigeration. This can be further supported by another study where 





Particle size is one of the most important factors in percutaneous penetration. 
Smaller vesicles were reported to show better transdermal flux than that of larger 
ones
63, 222
. Both water and PBS hydrated liposomes produced stable liposome 
suspension and size difference in between the two was not significant. Liposome 
charge has been reported to exert an effect on skin penetration. Ogiso et al found that 
in vitro penetration of Melatonin entrapped in negatively charged liposomes was 
higher than that of positively charged ones (P<0.05)
223
. This was further supported 
by Yu and Liao who reported a significant increase in in-vitro permeability of 
triamcinolone acetonide through rat skin by negatively charged SUVs
108
. Therefore 
based on charge, PBS was not considered as preferred hydration medium. After 
considering all the above mentioned factors on particle size and zeta potential, water 
was finally chosen as the hydration medium to prepare all liposomes.  
 
3.4.1.4. Effect of method of size reduction 
Producing MLVs by thin film hydration technique usually yields particles with 
heterogeneous size distribution which then need to be controlled by downsizing. Size 
reduction can be done by sonication, extrusion and homogenization.  
In the present study, both bath and probe sonication were applied to reduce particle 
size. It was found that only bath sonication was not enough to reduce size 
considerably; additional one minute probe sonication effectively reduced particle 
size. Finally additional ten times extrusion through 200 and 100 nm polycarbonate 
filters (each) were performed which was found to be efficient in producing well-




Although in theory the application of high frequency in probe sonication can lead to 
the production of smaller SUVs, in practice the probe sonicator, which was used can 
only generate a maximum 1 Hz frequency and its prolonged application resulted in 
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the destabilization of liposomes. Extrusion process is important for producing 
homogenous size of liposomes although its sole in downsizing liposomes is limited. 
To avoid the contact of liposomes with probe sonicator for long time/ with high 
frequency, extrusion was chosen, which improved polydispersity index.  Extrusion is 
not expected to have negative effect on the amount of SUV obtained especially when 
elastic liposomes are extruded. The latter can squeeze and pass through filters 
irrespective of their size. 
 
Table 3.8 shows the effect of combined downsizing techniques on particle size and 
polydispersity index of empty pure PC liposomes. It is clear from the table that 
vesicle size after downsizing reduced considerably compared to that of crude 
(1559.0± 29.2 nm) liposomes and those that were bath sonicated (309.9±16.1 nm). 
One minute probe sonication and ten times extrusion through a series of filters 
reduced particle size most efficiently. Effect of sonication and extrusion on 
polydispersity index of liposomes was quite clear. As expected, vesicle size 
distribution was heterogeneous (with very high polydispersity index) when they 
were characterized before downsizing. Sonication reduced particle size, creating 
relatively more homogenous particle distribution. Repeated extrusion through a fixed 
pore size membranes produced highly reproducible and most homogenous size 
distribution.  
 
Table 3.8: Effect of downsizing technique on particle size distribution of empty 






No downsizing (Crude) 1559.0±29.2 1.0±0.00 
Bath sonication (30 min) 309.9±16.1 0.540±0.01 
Probe sonication (one min at 40 W, 0.5 cycle) 188.6±7.8 0.44±0.02 
Extrusion (10 times through 200 and 100 nm 
filters) 
153.0±2.9 0.351±0.00 
  Each downsizing technique was used in combination with the previous one.  Data 
represented as mean± SD (n=3) 
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Particle size has been reported to play a crucial role in dermal penetration. Large 
vesicles with a size >600 nm are not able to deliver their contents into the deeper 
layers of the skin and these liposomes stay in/on the top of the stratum corneum. 
Liposomes with size <300 nm delivered their contents to some extent into deeper 
layers of the skin
222
. Verma et al showed enhanced penetration of carboxyfluorescein 
containing liposomes with diameter of 120 nm compared to that of larger ones 
(greater than 300 nm) in human abdominal skin model concluding that smaller 
particles better penetrated the skin
222
. In order to achieve efficient downsizing of a 
reasonable size batch, all three techniques of size reduction were combined to 
produce small and relatively homogeneous vesicles. 
 
3.4.1.5. Hydration time and speed of rotation  
 
Hydration time and speed of rotation are also important factors to be considered in 
designing liposome formulation. The time allowed for the hydration of the lipid layer 
with the aqueous phase/drug solution determines the amount of drug entrapment 
which again influences the size of MLVs. Drug entrapment with similar lipid 
composition was enhanced by slower rate of hydration
164
. The hydration time of 1 h 
and rotation speed of 100 rpm was chosen because these are the conditions mostly 




3.4.2. Characterization of empty conventional and elastic liposomes 
hydrated with water 
Unloaded or empty liposomes were prepared with water as hydration medium 
according to the method described under section 2.3.5.3. Formulations with different 
composition were prepared with a view to characterize them based on particle size 
and zeta potential and eventually to be used for comparing with that of NaFl loaded 






Table 3.9: Characterization of empty conventional and elastic liposomes 
hydrated with water 
Formulation ratio 
(% w/w) 
Size (nm) Zeta potential (mV) 
Pure PC 153.1±2.9 -5.9±0.6 
PC:CH 70:30 131.3±3.7 -27.2±0.7 
PC:T80 85:15 90.9±5.8 -6.7±0.4 
PC:S. Chol 85:15 69.3±0.8 -15.2±3.3 
CH: Cholesterol; PC: Phosphatidylcholine; S. Chol: sodium cholate;  
T80: Tween 80. Characterization of liposomes was done after ten times 
extrusion through 200 and 100 nm Supor
®
 membrane filters. Data 
represented as mean± SD (n=3) 
 
Table 3.9 shows that empty pure PC liposome had the biggest particle size compared 
to that of other formulations. Cholesterol incorporation in PC bilayer reduced size to 
131.3±3.7 nm. However a significant drop in vesicle size was observed when 
surfactants were included to PC liposome. Addition of Tween 80 and sodium cholate 
produced elastic liposomes with an average size of 90.9±5.8 nm and 69.3±0.8 nm 
respectively. The effect of cholesterol and surfactant on particle size of liposomes is 
discussed in detail in section 3.4.3.1 and 3.4.4.1 respectively.  
 
The effect of formulation variables on zeta potential of empty liposomes was 
prominent. Pure PC liposomes showed a negative zeta potential in water whereas 
addition of cholesterol in vesicle bilayer increased the negative charge on PC 
molecule. When 15% w/w of Tween 80 and sodium cholate were added to PC 
liposomes, the zeta potential obtained were negative; more negative than pure PC 
liposome and less negative than cholesterol containing liposomes. Neutral PC is 
reported to produce a net negative charge in presence of low ionic strength (such as 
water) medium
212
.  The increase in negative charge of cholesterol containing 
liposome is probably because the polar head of cholesterol contains hydroxyl groups, 
which may easily combine with choline in the polar region of PC to produce a type 




However the reason for the more negative zeta potential of elastic liposomes 
compared with that of empty pure PC liposomes could be due to the partial 
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hydrolysis of Tween 80
226
. Another study reported that Tween 80 may cause more 
negative zeta potential due to the shift in the shear plane of the particle
227
. The 
inclusion of sodium cholate in liposomes induced a negative surface charge due to 
the adsorption of cholate anion on PC molecule. Essa et al found that estradiol 
loaded ultradeformable liposomes had higher negative zeta potential (−29 ±2.4 mV) 
due to the adsorption of cholate anion, compared to the conventional estradiol 
liposomes
228
. However the zeta potential in Tween 80 containing elastic liposomes 
was less negative than that of sodium cholate due to the fact that sodium cholate is 
anionic (Figure 3.4 (a) and 3.4 (b)). The latter might have adsorbed on PC to increase 
the negative charge of liposomes.  
 
 
        (a)                                                             (b) 
 
Figure 3.4: Structure of sodium cholate (a) and Tween 80 (b) 
 
3.4.3. Characterization of conventional liposomes loaded with sodium 
fluorescein 
Conventional liposomes can be prepared from phospholipid with or without 
cholesterol. The beneficial role of cholesterol within liposomal drug  carriers is well 
recognized. Because of its flat and rigid fused ring structure
229
 cholesterol generates 
more rigid vesicles. Thus in current study conventional liposomes were prepared and 
characterized with a view to show the effect of cholesterol content on liposome size, 
zeta potential and EE of NaFl. Because the analysis of NaFl is simple and less time 
consuming, it was chosen to prepare various traditional and elastic liposomes. 
Moreover NaFl is a small molecular weight compound and freely soluble in water, 
therefore it can be used as a model hydrophilic compound. According to passive 
loading theory, it is entrapped in the aqueous core of liposomes. Four different 
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conventional liposomes loaded with 1mg/mL of NaFl were prepared with a range of 
PC (70-100 mg) and cholesterol (0-30 mg). They were coded as NaFl CON 0 (NaFl 
loaded liposome containing no cholesterol i.e. pure PC), NaFl CON 10, 20 and 30 
denote NaFl loaded conventional liposome prepared from PC: cholesterol ratio of 
90:10, 80:20, and 70:30 respectively. 
 
Methods of characterization of liposomes immediately after preparation and upon 
storage are required for adequate quality control of the product. The methods have to 
be reproducible, precise and rapid in the context of their use in industrial and even in 
laboratory setting. Therefore all liposomes were characterized within a day of their 
preparation. 
 
3.4.3.1. Vesicle size distribution 
As soon as NaFl loaded SUVs were formed, they were characterized for particle size 
distribution, zeta potential and EE. However vesicle sizes were determined both 
before and after extrusion (ten times through a series of 200 and 100 nm Supor
® 
membrane filters). The mean diameters of all different vesicles are shown in Table 
3.10. Sonicated vesicles which contained no cholesterol, i.e. pure PC vesicles had 
relatively bigger particle size (401.1±10.1 nm) compared to other cholesterol 
containing vesicles. Compared to NaFl CON 0, addition of 10% w/w cholesterol in 
the formulation, particle size reduced significantly (187.4±6.4 nm, P<0.005). Further 
addition of cholesterol reduced particle size more, with the lowest size achieved 
upon addition of 30% w/w cholesterol (153.1±6.6, P<0.005). All extruded vesicles 
reduced in size after extrusion; however NaFl CON 0 showed the maximum size 
reduction upon extrusion (60.01%). Extruded conventional liposomes also showed a 
similar pattern of size reduction upon addition of cholesterol. NaFl CON 30 showed 
the smallest size (133.46±7.01 nm, P<0.005) after extrusion compared to that of pure 
PC (160.7±3.4 nm) (Table 3.10).  
 
Liposomal size reduction induced by cholesterol can be explained by the 
condensation effect of cholesterol on the bilayer. Surface pressure measurements on 
monolayers of nonionic surfactant/ cholesterol mixtures demonstrated a condensing 
effect of cholesterol showing a decrease in the effective area per molecule as the 
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cholesterol content of the monolayer increased
230
. Similar effect was also observed 
by Semple et al when they found cholesterol inclusion within liposomal bilayers 
resulted in an increased packing densities of phospholipids molecules
231
 which is 
thought to result from the accommodation of cholesterol in the molecular cavities 
formed by surfactant monomers assembled into vesicles
232
. This condensation effect 
clearly contributed to the effect of cholesterol on size reduction of bilayer vesicles.  
 
The polydispersity index of less than 0.1 indicates a narrow size distribution and 
greater than 0.3 indicates wider size distribution
233
. However polydispersity indices 
of various NaFl loaded conventional vesicles were found to be ≤ 0.3, which is 
reasonably narrow size distribution. After extrusion polydispersity index of all 
liposomes reduced slightly. Ideally mechanical dispersion method yields MLVs with 
a wider size distribution
1
. Sonication and extrusion steps should result in the 
formation of vesicles with a narrow size range, although standardizing sonication 




3.4.3.2. Zeta potential 
Knowledge of zeta potential of a liposome preparation can help to understand 
dispersion and aggregation processes
234
 and to predict the fate of the liposomes in 
vivo. Zeta potential has often been used for characterizing colloidal drug delivery 
systems
235
 to determine the type of interaction between the active substance and the 
carrier; i.e. whether the drug is encapsulated within the body of the particle or simply 
adsorbed on the surface.  In this study zeta potential was found to be highly negative 
in all NaFl loaded conventional liposomes compared to that of empty pure PC (Table 
3.9) and cholesterol containing liposomes (Table 3.10). Drug loading showed an 
effect on the zeta potential of liposomes which suggest that there was a drug-
liposome interaction. The highly negative zeta potential of NaFl loaded conventional 
liposomes could be a result of the carboxylate (from NaFl) anion adsorption on 
surface of liposomes. Carboxylic acid functional groups of NaFl are almost fully 
ionized in aqueous solutions above pH 9. pKa of fluorescein is 6.4. The pH of all 
NaFl loaded liposomes was found to be 7.3 to 7.4; at this pH NaFl is expected to be 
highly ionized (>50%). Because of the ionization it is likely that the ionized 
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carboxylate functional group of NaFl was absorbed at the surface of PC molecules 
creating a highly negative zeta potential. 
 
3.4.3.3. Entrapment efficiency  
The EE of liposomes is governed by the ability of the formulation to retain drug 
molecules in the aqueous core or in the bilayer membrane of the vesicles. 
Purification process such as ultracentrifugation has been reported to be responsible 
for losing a large quantity of entrapped molecule probably due to the increased 
leakage of lipid membranes because of the high speed used in such method
196
. In this 
study a moderate speed centrifugation method in conjunction with the use of an 
ultrafiltration device (Nanosep
®
) was applied for a relatively short time to separate 
unentrapped NaFl molecule from the trapped one. Nanosep
®
s having a filter 
membrane can easily separate the liquid even at a low speed leaving the liposomal 
pellet on top of the filter. 
Table 3.10 shows the EE of NaFl loaded various conventional liposomes, which was 
found to be dependent on the amount of cholesterol present in their structure. 
Vesicles with no cholesterol had an EE of 13.8±0.2%. A similar EE was found by 
Coderch et al. who reported 15.9% EE from pure PC liposomes containing 10 
mg/mL lipid and 1 mg/mL of NaFl from REV vesicles
208
. However EE was found to 
increase with each inclusion of cholesterol in the formulation. 30% w/w inclusion of 



















100:0 401.9±10.0 160.7±3.9 0.26±0.09 0.25±0.11 -32.7±1.0 13.8±0.2 
NaFl 
CON 10 
90:10 187.4±6.4 140.0±1.9 0.30±0.06 0.29±0.06 -39.3±0.1 20.7±1.0 
NaFl 
CON 20 
80:20 151.8±10.2 141.7±4.3 0.29±0.04 0.28±0.04 -42.2±2.5 22.3±2.0 
NaFl 
CON 30 
70:30 153.1±6.6 133.4±7.0 0.25±0.06 0.23±0.05 -46.6±1.4 24.8±0.5 
NaFl 
CON 40 
60:40 Characterization was not done because liposomes were not formed 
CH: cholesterol; PC: Phosphatidylcholine; NaFl CON 0: sodium fluorescein (NaFl) loaded conventional liposome 
with no cholesterol, NaFl CON 10, 20 and 30 denote NaFl loaded conventional liposome prepared from PC: CH 
ratio of 90:10, 80:20, and 70:30 respectively. 
Size-1, P.I.-1 = Size and polydispersity index of vesicles determined after sonication but before extrusion 
Size-2, P.I.-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 nm 
Supor
®
 membrane filters 
EE= Entrapment efficiency  




The increase in EE of hydrophilic NaFl with inclusion of cholesterol may be due to 
the increased stability of the liposomal membrane due to increased membrane 
rigidity.  Gregoriadis and Davis demonstrated that inclusion of 50% mol/mol 
cholesterol within a liposome  formulation increased stability and reduced 
permeability of liposomal bilayers
236
. It was thought that cholesterol took place in 
the cavities formed by lipid molecules and filled up the empty spaces. This space 
filling action combined with the interaction of cholesterol with phospholipid 
significantly reduced the permeability of small hydrophilic solutes and ions
237,238
. 
Moreover above the Tc (50-55ºC) cholesterol makes the membrane more ordered and 
inhibits the gel from transition into the liquid phase, hence it effectively prevented 
leakage of drug
239, 240
. Water soluble NaFl is initially effectively entrapped inside the 
aqueous core of liposomes. Addition of cholesterol reduced the leakage of entrapped 
NaFl and as a result increased EE. 
When 40% w/w cholesterol was added to PC liposomes, a hard film developed at the 
bottom of the flask which was very difficult to hydrate. At the end of 1 h hydration, 
most of the film left on the flask and some formed into hard lipid flakes. No 
satisfactory vesicles were formed. Such phenomena may be due to the crystallization 
of cholesterol at high concentration. It has been reported that above a certain mole 
fraction, cholesterol shows crystallinity, even in the presence of bilayer 
membranes
229
.  The conditions required for this behaviour is strongly dependent on 
the type of phospholipid with which cholesterol is bound
94
. 
3.4.3.4. Bilayer elasticity  
Vesicular elasticity, expressed as deformability index, is a term which is used to 
measure the elasticity of elastic liposomes to differentiate them from conventional 
liposomes. The former can squeeze and penetrate through the very tiny pores of SC 
whereas the latter cannot because of their rigid structure. Among the various NaFl 
loaded conventional liposomes, CON 0 and CON 30 were the most different in terms 
of their characteristics and composition. Therefore they were selected for elasticity 
measurement. NaFl CON 30 showed poor elasticity of about 3.61 which was less 
deformable than that of NaFl CON 0 (6.72±0.7) (Table 3.11).  Conventional 
liposomes lack the propensity for highly curved structures, therefore generating 
greater resistance against particle deformation. Inclusion of cholesterol in liposome 
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bilayer is known to further restrict the flexibility of the lipid hydrocarbon chains, 
making it more rigid
241
. Thus pure PC liposome, showed better deformability than 
cholesterol containing liposome. More discussion on elastic liposome and their 
elasticity measurement will be done later in this chapter.  












J (mL) D 
NaFl 
CON 0 
100:0 101.9±2.3 0.21±0.10 1.6±0.1 6.72±0.7 
NaFl 
CON 30 
70:30 98.3±2.8 0.23±0.03 0.9±0.1 3.61±0.7 
CH: cholesterol, PC: phosphatidylcholine, NaFl CON 0 and 30 denote sodium 
fluorescein (NaFl) loaded conventional liposome with no CH and 30% w/w of CH. 
a
size and polydispersity index were determined after extrusion through 50 nm 
polycarbonate membrane filters 
J= Volume of suspension passed through filter within 5 min 
D= Degree of deformability (Deformability index)  
Data represented as mean± SD (n=3) 
Optimization of liposome composition is the first step in developing a liposomal 
formulation with desired properties for the delivery of bioactive agents. The primary 
properties that should be considered for evaluation of liposomes include size, zeta 
potential, EE and elasticity, all of which are affected by the amount and structure of 
the membrane constituents used
160
. Therefore, a proper understanding of the 
physicochemical properties of liposomes as a function of the liposomal membrane 
composition will guide us to understand how to modulate liposome properties to 
improve their in vivo performance. Though NaFl CON 30 showed less deformation 
than that of NaFl CON 0, applying the criteria of small particle size and high EE, 
NaFl CON 30 was considered to be the best conventional liposome here in this 
context. Smaller particles are expected to lead to deliver an increased amount of drug 
into the deeper skin strata
63, 222
. Consequently vesicles with high EE would carry 
more drug into the skin.  
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3.4.4. Characterization of elastic liposomes loaded with sodium 
fluorescein 
NaFl loaded elastic vesicles were prepared by the procedure described in section 
2.3.5.2. The basic composition of elastic liposomes comprised of PC (the stabilizing 
agent), surfactant (the destabilizing agent) and 7% ethanol in order to impart 
elasticity to vesicle membrane. In the preparation steps, ethanol was added 
separately to vesicles after 1 h hydration. This is because at around 40ºC, ethanol 
might evaporate or even cause breakage of liposomes.  
In the current study two surfactants were used: sodium cholate and Tween 80 with 
varying ratios for optimization of formulation. Tween 80 and sodium cholate are 
good excipients for skin drug delivery because of their low toxicity and low 
irritation. Tween 80 is pharmaceutically acceptable and biocompatible. 
Characteristics of various elastic liposomes prepared from Tween 80 and sodium 
cholate are presented in Table 3.12 and 3.13. To simplify the names, vesicles were 
coded by the name of the compound entrapped and the type and weight percentage 
of surfactant. For example, NaFl T80 5 and NaFl S. Chol 5 denoted NaFl loaded 
elastic liposome where 5% w/w Tween 80 and 5% w/w sodium cholate were used in 
conjunction with PC respectively.  
3.4.4.1. Vesicle size distribution 
The particle sizes of both types of elastic liposomes loaded with NaFl were measured 
both before and after extrusion. Before extrusion, there was a marked decrease in 
size with increase in level of surfactant (Table 3.12 and 3.13). For instance, NaFl 
T80 5 had an average vesicle size of 158.3±4.3 nm. When 15% w/w Tween 80 was 
used, size reduced significantly (132.9±3.3 nm, P<0.02). Similarly NaFl S. Chol 5 
had an average diameter of 129.7±2.5 nm whereas inclusion of 15% w/w sodium 
cholate reduced size considerably (115.7±1.5 nm, P<0.03). The effect of Tween 80 
on liposome size may be considered due to a steric repulsion occurring between the 
Tween molecules, which are exposed from the outer and inner leaflet of the 
liposomal bilayer
225
. The Tween surfactants exposed from the outer leaflet would 
tend to increase the liposome particle curvature, whereas the Tween surfactants 
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exposed to the inner leaflet may do the opposite. Hence, it is thought that addition of 
Tween surfactants reduced the initial liposomal size since there were more Tween 
surfactants in the outer leaflet than that in the inner leaflet of the bilayer
225
.  
After extrusion, however a further marginal size reduction was noticed with both 
Tween 80 and sodium cholate containing elastic liposomal formulations when 
surfactant increased from 5% w/w to 15% w/w (Table 3.12 and Table 3.13). These 
results are expected because of the elasticity phenomena of elastic vesicles which 
can be pushed through fixed pore size filters. Upon extrusion elastic vesicles 
eventually produce similar sized particles, which is close to the pore size of the filter 
membrane. However a very significant drop of vesicle size was observed for both 
types of elastic liposomes when surfactant concentrations were increased above 15% 
w/w. This may be due to the formation of micelles, which are relatively smaller in 
size. This can be suggested from the data reported for the lecithin/sodium cholate 
systems where vesicles and mixed micelles were found to coexist at 20% sodium 
cholate, only mixed micelles being found at 30% 
94
. 
For all elastic liposomes, the polydispersity index reduced after extrusion which 
suggests that particles with narrow size distribution were produced. However when 
25% w/w surfactant was used, although smaller particles were formed, a relatively 
large polydispersity index (0.63±0.04 in 25% w/w Tween 80 and 0.71±0.03 in 25% 
w/w sodium cholate) was observed (Table 3.12 and 3.13) with both elastic liposomes 




Table 3.12: Characterization of NaFl loaded elastic liposomes prepared using PC and Tween 80 










EE (%)  Size-3 (nm) P.I.-3 J (mL) D 
NaFl 
T80 5 
95:5 158.3±4.3 136.1±2.8 0.52±0.02 0.35±0.06 -12.0±1.4 15.6±1.1  118.1±2.4 0.22±0.01 3.5±0 19.7±1.0 
NaFl 
T80 10 
90:10 134.4±3.4 124.3±0.6 0.44±0.01 0.36±0.01 -12.8±0.1 13.3±1.0  112.9±2.4 0.21±0.04 4.3±0.1 22.2±1.7 
NaFl 
T80 15 
85:15 132.1±3.3 128.4±2.0 0.46±0.01 0.35±0.02 -14.7±0.5 14.4±1.5  109.8±2.6 0.22±0.05 7.6±0.1 35.8±0.6 
NaFl 
T80 20 
80:20 112.4±1.0 104.5±3.4 0.43±0.03 0.37±0.01 -13.6±1.1 6.4±0.5  88.0±2.3 0.17±0.03 3.3±0.2 10.4±1.2 
NaFl 
T80 25 
75:25 104.3±3.5 93.7±1.4 0.63±0.04 0.27±0.01 -11.6±0.0 6.7±1.0  86.4±3.1 0.23±0.02 2.7±0.1 8.0±0.2 
PC: Phosphatidylcholine, T80: Tween 80, NaFl T80 5, 10, 15, 20 and 25 denote sodium fluorescein (NaFl) loaded elastic liposome containing 5, 
10, 15, 20 and 25% w/w T80 respectively in conjunction with PC.  
Size-1, P.I.-1 = Size and polydispersity index of vesicles determined after sonication but before extrusion 
Size-2, P.I.-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 nm Supor
®
 membrane filters 
Size-3, P.I.-3 = Size and polydispersity index of vesicles determined after extrusion through 50 nm polycarbonate membrane filters 
EE= Entrapment Efficiency 
J= Vol of suspension extruded within 5 min, D= Degree of deformability (Deformability index) 
Data represented as mean± SD (n=5) except the elasticity measurements which were done thrice 
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Table 3.13: Characterization of NaFl loaded elastic liposomes prepared using PC and sodium cholate 









EE (%)  Size-3 (nm) P.I.-3 J (mL) D 
NaFl S. 
Chol 5 
95:5 129.7±2.5 122.3±2.8 0.44±0.01 0.38±0.01 -18.6±1.1 20.0±0.6  110.7±1.7 0.22±0.03 2.9±0.1 14.2±0.2 
NaFl S. 
Chol 10 
90:10 118.6±2.6 113.4±4.3 0.43±0.01 0.40±0.06 -19.7±3.1 17.8±2.4  106.4±2.5 0.20±0.00 3.6±0.2 16.5±1.7 
NaFl S. 
Chol 15 
85:15 115.7±1.5 109.4±1.6 0.46±0.05 0.37±0.06 -20.8±0.5 17.7±2.9  104.0±1.1 0.21±0.04 7.0±0.1 30.3±0 
NaFl S. 
Chol 20 
80:20 106.4±1.9 98.6±7.5 0.48±0.07 0.39±0.04 -20.1±2.2 9.5±0.7  74.1±1.5 0.24±0.00 3.0±0.3 6.6±1.0 
NaFl S. 
Chol 25 
75:25 91.4±1.5 74.8±2.1 0.71±0.03 0.43±0.02 -15.8±1.3 6.0±0.9  70.6±0.8 0.16±0.03 2.9±0.2 5.8±0.4 
PC: Phosphatidylcholine, S. Chol: sodium cholate, NaFl S. Chol 5, 10, 15, 20 and 25 denote sodium fluorescein (NaFl) loaded elastic liposome 
containing 5, 10, 15, 20 and 25% w/w S. Chol respectively in conjunction with PC.  
Size-1, P.I.-1 = Size and polydispersity index of vesicles determined after sonication but before extrusion 
Size-2, P.I.-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 nm Supor
®
 membrane filters 
Size-3, P.I.-3 = Size and polydispersity index of vesicles determined after extrusion through 50 nm polycarbonate membrane filters 
EE= Entrapment Efficiency, J= Vol of suspension extruded during 5 min 
D= Degree of deformability (Deformability index) 
Data represents as mean ±SD of n=5 except the elasticity measurement which were done thrice 
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3.4.4.2. Zeta potential 
The mean values of zeta potential of all NaFl loaded elastic liposomes were found to be 
negative (Table 3.12 and 3.13) and the addition of surfactant at various ratios mostly did 
not affect the zeta potential significantly which is consistent with previous literature 
reports
242, 243,244
. Compared with empty elastic liposomes (Table 3.9), the zeta potential 
found in NaFl loaded elastic liposomes were more negative. This is likely due to the 
adsorption of carboxylate ion from NaFl on PC molecule.  
3.4.4.3. Entrapment efficiency 
The effect of surfactant concentration on the EE of elastic liposomes containing NaFl 
(Table 3.12 and 3.13) clearly shows that EE decreased with an increase in concentration 
of surfactant. The maximum EE found in Tween 80 and sodium cholate elastic 
liposomes were around 15.6% and 20.1% respectively, which was at 5% w/w inclusion 
of surfactant. The possible reason of decrease in EE up to 15% w/w surfactant content 
could be due to the property of surfactants which make the vesicle bilayers soft and 
more leaky, subsequently increase the tendency of trapped molecule to be leaked 
through the bilayers. As expected above 15% w/w of surfactant, EE reduced 
significantly in both types of elastic liposomes. 20% w/w surfactant dropped EE to 6.4% 
(in Tween 80) and 9.5% (in sodium cholate). This is due to the possible coexistence of 
mixed micelles and vesicles at higher concentrations of surfactant leading to lower drug 
entrapment in elastic formulations
245,246
. Lasch et al
247
 and Lopez O et al
248
 studied the 
formation of mixed micelles due to the solubilisation of phospholipid in liposomes by 
non-ionic surfactants such as Triton X-100, octyl glycoside by a variety of techniques. 
They reported that transformation of liposomes to mixed micelles was a concentration-
dependent process. Vesicle to micelles transformation was mainly governed by the 






3.4.4.4. Bilayer elasticity 
Bilayer elasticity is the critical feature of all elastic liposomes. It is the stress dependent 
adaptability of elastic vesicles which differentiates them from traditional liposomes and 
other types of lipid suspensions. The surfactant present in the formulations causes 
fluidization of bilayer that is responsible for increase in elasticity of vesicle 
membrane
233
. This in turn permits elastic liposomes to squeeze themselves through 
pores that are much smaller than their own diameter
112
. This is achieved by combining 
at least two amphiphilic components (phospholipid and surfactant) with sufficiently 
different packing characteristics into a single bilayer. The high ultradeformability 
permits elastic liposomes to penetrate the skin spontaneously and minimizes the risk of 
complete vesicle rupture in the skin.  
Ethanol is not an essential component in the development of our elastic liposomes as its 
concentration was kept low. Surfactants were essential. In ethosomes and niosomes 
(containing 30% ethanol), ethanol, however may interact with the polar head group 
region of the phospholipid/surfactant molecules resulting in the reduction of melting 
point, thereby increasing the fluidity of the vesicles. In present study, 7% ethanol was 
used. In case of elastic liposomes, ethanol is expected to impart some bilayer elasticity 
on vesicle membrane, which, however may be small. It should be pointed out that the 
difference in elasticity of various elastic liposomes observed in this study was due to the 
presence of different amount of surfactants, as ethanol concentration was kept constant 
in all formulations. Thus the effect of surfactants on bilayer elasticity was 
explained.Comparative measurement of elasticity of the bilayer of different elastic 
liposomes was carried out by extrusion measurement using 50 nm membrane filters 
(Table 3.12 and 3.13). The results indicate that elasticity of vesicles depend on 
surfactant concentration. With an increase in Tween 80 concentration from 5% to 15% 
w/w membrane elasticity (D) increased from 19.7±0.7 to 35.8±0.6 whereas for sodium 
cholate vesicles deformability increased from 14.2 to 30.3.  
A dramatic drop of elasticity however was observed when the surfactant content was 
increased more than 15% w/w with minimum elasticity obtained at the surfactant 
concentration of 25% w/w (from 35.8±0.6 to 8.0±0.2 for Tween 80 vesicles and from 
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30.3 to 5.8±0.4 for sodium cholate vesicles). This is because when the critical micelle 
concentration (CMC) of surfactant is reached lipid vesicles and mixed micelles coexist. 
The resultant mixtures are reported to be less deformable in nature with less skin 
permeability in comparison to elastic liposomes 
22, 247, 248
. 
Elastic liposomes are reported to pass through narrow pores of skin irrespective of their 
size
22
, which means they are able to deform. Therefore no vesicle leakage is expected. 
To support this phenomenon, NaFl loaded elastic liposomes were extruded through 50 
nm membrane filters and were then centrifuged to separate the free dye by using 
Nanosep
®
. The concentration of NaFl in the supernatant was found to remain the same 
which indicates that elastic liposomes are able to hold their structural integrity when 
squeezing through the narrow pores. This further suggests that the entrapped drug (i.e. 
inside elastic elastic liposomes) will be able to penetrate through the small pores of the 
stratum corneum to reach the region in the skin where drug molecules normally cannot 
reach by themselves. To confirm that the extrusion process not interrupted by free dye 
adsorption on the filter, 1mg/mL of NaFl solution was extruded through 50 nm filter and 
no change in the dye concentration was found after extrusion.  
In order to cross the intact stratum corneum, elastic liposomes should be capable of 
passing through pores of diameter less than 50 nm under influence of suitable 
transdermal gradient
194
. Only properly optimized and moderately loaded carriers can 
pass through pores smaller than their own diameter. Our study showed that increasing 
the concentration of surfactant beyond a certain level brings no advantages in terms of 
elasticity of liposomes which ultimately will not help in deep skin transportation 
efficiency. Only optimum ratio of lipid and surfactant can lead to maximum flexibility. 
This is why it is crucial in optimizing the elastic liposomal formulation of the bilayer 
membrane
245
. In our case the maximum elasticity was found with 15% w/w surfactant. 
Although 85:15 PC: surfactant did not show highest entrapment, considering that higher 
elasticity would lead to better penetration, elastic liposomes composed of 15% w/w 
surfactant were chosen for further studies. 
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3.4.4.5. Morphology of sodium fluorescein loaded liposomes 
NaFl loaded conventional and elastic liposomes with different composition were 
examined under TEM. Their micrographs are shown in Figure 3.5(a)-3.5(d). Vesicles 
were appeared as homogenous, regular, and spherical shape in conventional and elastic 
liposomes (containing 15% w/w surfactant). Elastic liposomes prepared using 20 and 
25% w/w surfactants were also visualized under TEM, where no spherical structures 
were found. A typical TEM micrograph of NaFl T8025 is shown in Appendix 4. The 
absence of spherical structure demonstrates that these liposomes formed structures other 
than vesicles; however from TEM micrograph it was difficult to define them as 
micelles. Such a phenomenon observed with elastic liposomes prepared from 20% and 
25% w/w surfactant suggests structures other than vesicles because of the possible 
coexistence of mixed micelles and micelles. This was supported by the report on lecithin 
surfactant system where the investigators showed vesicles and mixed micelles formed at 
20% and micelles formed at 30% w/w of sodium cholate
249
. A typical micrograph of 
extruded (through 50nm membrane filter) NaFl T80 15 is shown in Figure 3.5 (e). No 






Figure 3.5 (a): TEM micrograph of sonicated NaFl T80 15 (NaFl loaded elastic 
liposome containing 15% w/w of Tween 80) (scale 0.5µm). The tiny white spots on 
the vesicle are because of incompletely dried material. TEM imaging using a strong 
beam led to vesicle disruption and damage. 
 
Figure 3.5 (b): TEM micrograph of sonicated NaFl S. Chol 15 (NaFl loaded elastic 
liposome containing 15% w/w of sodium cholate)  
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Figure 3.5 (c): TEM micrograph of sonicated NaFl CON 0 (NaFl loaded 
conventional liposome containing no cholesterol. i.e. Pure PC)  
 
Figure 3.5 (d): TEM micrograph of sonicated NaFl CON30 (NaFl loaded 
conventional liposome containing 30% w/w of cholesterol). The tiny white marks on 
vesicles at the copper grid are due to incompletely dried material. TEM imaging using a 
strong beam led to vesicle disruption and damage.  
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Figure 3.5 (e): TEM micrograph of NaFl T80 15 (NaFl loaded elastic liposome), 
extruded through 50 nm membrane filter 
Micrograph shows no vesicle rupture after extrusion through 50 nm filter, which 
indicates that elastic liposomes are able to deform or change their shape while passing 
through small sized pores of the stratum corneum.  
 
3.4.5. Effect of cholesterol on storage stability of sodium fluorescein 
loaded conventional liposomes 
Average particle size of liposomes determined after their preparation changes upon 
storage. This is largely due to aggregation, fusion, or rupture of liposomes and occurs 
virtually in all liposome dispersions. Thus the ability of the system to maintain its 
original size distribution gives an indication of physical stability of liposome system. 
From a pharmaceutical point of view, it is important to formulate liposomes that can be 
stored for a long period of time. Degradation processes particularly oxidation and 
hydrolysis can lead to an increase in particle size of liposomes
250
. In this study, the 
stability of conventional liposomes loaded with NaFl was investigated by particle size 
analysis for a period of 4 weeks at 4±2°C, 25±2°C and 35±2°C. The results are 
presented in Table 3.14. 
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Effect of storage condition on the stability of liposomes showed that all vesicles had 
tendency to increase in size upon storage with an exception of that at 4±2ºC where no 
significant size increase was detected. At 35±2ºC, the maximum increase in size 
(42.9%) was found with NaFl CON 0, which had no cholesterol in the bilayer. It was 
observed that the presence of cholesterol in the lipid mixture reduced the tendency of 
liposome to grow in size. The stabilization effect of cholesterol on size was much more 
pronounced when liposomes were stored at 35±2ºC. 10, 20 and 30% w/w cholesterol in 
bilayer showed significant stability of liposomes compared to that of no cholesterol. 
Lowest increase (14.4%) in size was found with NaFl CON 30. At room temperature, 
vesicular instability was less pronounced than that of at 35±2ºC but more than that of at 
4±2ºC (Table 3.14). Table 3.15 shows the % of increase in diameter of various NaFl 
conventional liposomes stored at different temperatures at the end of 4 weeks.  
 
Table 3.14: Effect of storage condition on size of NaFl loaded conventional 
liposomes 
 




T=0 week T=1 week T= 2 week T= 4 week 
CON 0 100:0 160.7±3.9 161.0±3.0 161.7±5.4 165.7±6.2 
CON 10 90:10 140.0±1.9 140.5±2.3 141.9±2.0 142.9±0.8 
CON 20 80:20 141.7±4.3 143.2±3.7 144.3±4.1 145.3±4.5 
CON 30 70:30 133.4±7.0 134.7±6.1 135.2±7.9 135.9±8.6 
Physical stability study at 25±2ºC; Particle size (nm) 
CON 0 100:0 160.7±3.9 162.2±4.2 170.5±1.0 174.3±1.8 
CON 10 90:10 140.0±1.9 141.5±1.5 144.1±1.3 145.8±2.7 
CON 20 80:20 141.7±4.3 143.2±5.0 145.1±5.6 148.4±4.2 




Physical stability study at 35±2ºC; Particle size (nm) 
CON 0 100:0 160.7±3.9 174.9±6.8 196.8±4.7 229.7±0.6 
CON 10 90:10 140.0±1.9 147.6±2.6 157.2±2.8 177.3±3.1 
CON 20 80:20 141.7±4.3 149.0±3.8 153.8±2.4 167.4±3.2 
CON 30 70:30 133.4±7.0 142.3±7.1 148.2±4.6 152.7±3.5 
 
CH: cholesterol, PC: Phosphatidylcholine, CON0, 10, 20 and 30 denote sodium 
fluorescein (NaFl) loaded conventional liposome prepared from PC: CH ratio of 
90:10, 80:20, and 70:30 respectively. To avoid repeatation, NaFl is removed from 




Figure 3.6: Effect of cholesterol on particle size of various NaFl loaded 






























Table 3.15: % of increase in particle size of various NaFl loaded conventional 
liposomes stored at three different storage conditions at the end of 4 weeks 
% of increase in particle size at the end of 4 weeks  
Code 4±2ºC 25±2ºC 35±2ºC 
NaFl CON 0 3.09 8.47 42.94 
NaFl CON 10 2.06 4.11 26.59 
NaFl CON 20 2.54 5.92 18.13 
NaFl CON 30 1.80 5.42 14.41 
CON0, 10, 20 and 30 denote sodium fluorescein (NaFl) loaded conventional 
liposome with 0, 10, 20 and 30% w/w of cholesterol. 
 
It is known that changes in average particle size of liposome dispersions are strongly 
affected by lipid composition. From Table 3.14 it is clear that cholesterol produced 
better stability in PC vesicles in all storage conditions. In presence of cholesterol in 
phospholipid bilayers, the amount of hydroperoxides produced by ionizing radiation is 
dramatically reduced. This decreased production of hydroperoxides can be explained by 
the protective effect by cholesterol, which is due to a steric hindrance to the radical 
chain propagation reaction through the unsaturated lipids. This effect can be explained 
by the property of cholesterol which modifies the physical state of bilayer from the 
solid-ordered phase to liquid-ordered phase
251
. Because of the presence of cholesterol 
between two adjacent unsaturated acyl chains of phospholipid, the order of bilayers in 
the liquid-crystalline phase is increased by promoting a tighter packing of the bilayer. 
This results in increased resistance to liposome oxidative degradation
252
. Water has been 
shown to play a major role in radiation-induced oxidative damage, with the aqueous 
phase being a source of reactive oxygen species 
253-255
. Cholesterol reduces the content 
of water at the hydrophobic–hydrophilic interface of the bilayer, influences resistance of 
liposomes to oxidative damage and increases their stability
256
. Therefore cholesterol has 





In an aqueous medium, liposomal phospholipids can hydrolyze to free fatty acids and 
lysophospholipids. Formation of free hydrolytic products might limit the shelf life of 
liposome. Elevated content of lysophospholipids tend to destabilize the bilayer and the 
membrane becomes more sensitive to vesicle fusion
250
. The stabilizing function of 
cholesterol was reported by Samuni et al 
260
 who measured the Laurdan‟s GP 
(Generalized Polarization) values for various egg PC- cholesterol liposomes (The 
increase in GP values reflects a decrease in bilayer hydration) and confirmed in their 
study that the presence of cholesterol in lipid bilayers decreased the hydration of the 
bilayer. This effect can again be explained by the phenomena that cholesterol increases 
bilayer packing in the head group and acyl chain regions, thereby decreasing the rate of 
diffusion of water into the bilayer
261-264
. Furthermore, decrease in water content and 
consequently protons and hydroxide ions results in a decrease of direct hydrolytic 
degradation caused to the membrane lipids. Altogether cholesterol reduces particle 
fusion and promotes better stability.  
 
From Table 3.15, we can see that instability increased when the system temperature 
increased. Thus it is evident that the instability is mostly dependent on temperature. The 
increase in temperature is responsible for frequent collision between liposomes, which 
enhances thermal motion of liposomal bilayer, and accelerates the speed of liposome 
fusion
265
. Therefore NaFl CON 0 which showed marked particle aggregation at 35±2ºC, 
showed slight increase in size (3.09%) in refrigerated condition, whereas CON 30 that 
was most stable in all storage conditions showed lowest size increase (1.80%) at 4±2ºC. 
It is therefore highly recommended that all liposomes should be stored in refrigerated 
condition. 
3.4.6. Development of Ibuprofen loaded liposome 
IBU loaded conventional liposomes were prepared by following the thin film hydration 
technique as described under section 2.3.5.1. Initially all liposomes were prepared by 
dissolving IBU (1 mg/mL) with the lipid phase in the organic solvent followed by film 
hydration with 10 mL of water. In current study because water was used as a hydration 
medium for NaFl liposomes, for comparison purpose water was also chosen as the 
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hydration medium to prepare IBU liposomes initially. However we encountered the 
problem of IBU crystallization in water which resulted in an artificially high EE. This 
led to the decision made on choosing PBS pH 7.4 as hydration medium instead of water. 
Initially IBU loaded pure PC liposome prepared using water as hydration medium 
showed a very high EE (around 98%) which was unexpected for a compound like IBU 
and was very different to that reported by Mohammed et al. Mohammed et al reported 
an EE of 29.5±0.6% of IBU loaded pure PC liposome (PC=12.41 mg/mL PC and 
IBU=0.625 mg/mL) when liposomes were hydrated with water
212
. Therefore after taking 
into consideration that IBU has a very poor water solubility (60µg/mL
212
), the following 
investigation was conducted to reveal the true EE of IBU loaded liposomes. 
A known amount of IBU was dissolved in approximately 0.5mL of ethanol. Sufficient 
amount of water was added to obtain a final drug concentration of 1 mg/mL. As soon as 
water was added the solution started to turn turbid due to the formation of IBU crystals. 
This dispersion (dispersion-1) was left on a stirrer overnight to allow the ethanol 
evaporates. Next day an aliquot of this dispersion was observed under light microscope 
to visualize the appearance of the drug crystals that originated from a solvent-water 
system. Another saturated solution of drug in pure water (dispersion-2) was prepared 
where drug crystals were visible by naked eye. This dispersion was prepared to compare 
with the crystals of dispersion-1. 
   
Figure 3.7: (a): Drug crystals found in dispersion-1 (at 40 X magnification) (b): 
Drug crystals found in dispersion-2 (at 40 X magnification) 
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The second investigation was to prepare IBU loaded pure PC liposome and to leave on 
bench top without downsizing for a period of 2 h. Large vesicles were supposed to settle 
down by this time along with the undissolved drug. An aliquot of the bottom layer of 
liposome suspension was sampled and observed under the light microscope.  
 
Figure 3.7(c): Bottom layer of Ibuprofen (IBU) loaded liposome showing drug 
crystal (at 40X magnification) 
The presence of IBU crystal in liposomal suspension (Figure 3.7 (c)) confirmed our 
suspicion that the high entrapment of IBU was a result of poor solubility of IBU in 
water.  
Based on the above finding, a washing protocol was developed to determine the true EE 
of IBU loaded pure PC liposome. Briefly liposomal vesicles were centrifuged using 
Nanosep
®
. The supernatant was removed completely from liposomal pellet and the 
pellet was washed twice with 50 mM PBS pH 7.4 by applying centrifugation speed of 
4000 rpm for 20 min each. The two washes were collected and analyzed separately for 
drug content. A third wash of liposomal pellet using PBS was performed where no 
detectable drug was analyzed by HPLC. Drug contents in three supernatants (including 
two washes) were pooled to calculate the cumulative drug content. The EE was 
calculated from the equation stated in section 2.3.6.4, and was found to be around 
25.3%. Therefore it was evident that the previous EE of 98% was incorrect. The 
artificially high EE was a result of a large amount of drug being insoluble in water, 
which upon centrifugation was unable to pass through the Nanosep
®
. Consequently drug 
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content “appeared” very high in liposomal system but in reality, only a very small 
quantity of drug was truly entrapped inside or associated with the liposomes.  
Although IBU loaded liposomes could be prepared by hydration with water and the EE 
could be determined by using washing protocol, but an ideal liposome formulation 
should not contain undissolved drug in the system. Therefore a dialysis method was 
applied to separate the free IBU from liposomes. An exhaustive dialysis of 80 min (40 
min in PBS and 40 min in water) was found enough to remove the free drug.  
The second problem we encountered arose when cholesterol was added to the 
formulation. Vesicles composed of 10% w/w cholesterol formed with no difficulty but 
inclusion of 20% and 30% w/w cholesterol in IBU loaded PC liposomes resulted in the 
formation of very hard films which were not possible to be hydrated with water at 55ºC 
for 1 h. The hydration time was prolonged and beads were used to aid in hydration and 
swelling of films. Unfortunately this did not improve hydration. Even hydration with 
bath sonication above Tc
266
 was attempted which produced hard small lipid flakes. No 
vesicles formed.  
As water was found to be not suitable hydration medium for IBU conventional 
liposomes, PBS pH 7.4 was selected. IBU at pH 7.4 is highly ionized; therefore there 
was no solubility problem. Many potential penetrants are weak acids or weak bases and 
therefore ionization is possible. For such compounds it may be better to use buffer to 
prepare the liposome so that the solubility is maximized. On the other hand, drug in free 
acid or free base form (i.e. unionized) is better for skin permeation. At higher pH, IBU 
ionization is high, flux is high but permeability is low. In other words, high pH would 
ionize IBU and improve solubility
173
 but skin permeability may be compromised as a 
result
171
. However the effect of drug ionization may not affect its skin permeability if it 
is trapped inside the liposomes because liposomes have its own mechanism of skin 
penetration. Ionisation effect would be only applicable while studying the penetration 
profile of ionized and unionized free drug solution. To ensure all IBU in soluble form 
and the maximum amount can be incorporated into liposomes, PBS pH 7.4 was 
eventually chosen as the hydration medium for IBU loaded liposome preparation. 
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3.4.7. Comparison of empty liposomes hydrated with PBS to that of 
hydrated with water 
Empty liposomes were prepared in the same way as described in section 2.3.5.3 and 
were hydrated with PBS. Table 3.16 shows the size and zeta potential of various empty 
liposomes hydrated with PBS.  
Table 3.16: Comparison of empty liposomes hydrated with PBS to that of hydrated 
with water  
Formulation ratio 
(% w/w) 
Size (nm) Zeta potential (mV) 
PBS water PBS water 
Pure PC 204.9±8.2 153.1±2.9 8.4±1.7 -5.9±0.6 
PC/CH 70:30 138.7±3.0 131.3±3.7 -10.8±0.9 -27.2±0.7 
85/15 PC/T80 123.6±6.6 90.9±5.8 3.6±0.3 -6.7±0.4 
85/15 PC/S. Chol 127.7±3.2 69.3±0.8 -1.1±0.6 -15.2±3.3 
CH: Cholesterol, PC: Phosphatidylcholine, S. Chol: sodium cholate, T80: Tween 
80. Characterization of liposomes was done after ten times extrusion through 200 
and 100 nm Supor
®
 membrane filters. Data represented as mean± SD (n=3) 
 
Hydration medium was found to show pronounced influence on size and zeta potential 
of various empty conventional and elastic liposomes. All empty liposomes hydrated 
with water produced smaller sized vesicles compared to that of hydrated with PBS. The 
zeta potential of different liposomes was also found to be dependent on hydration 
medium. All PBS hydrated empty liposomes had less negative zeta potential compared 
to that of water hydrated liposomes. The possible reason of bigger particle size in PBS 
hydrated liposomes could be due to the ionic interaction that might have expanded the 
bilayer thickness, resulting in an increase in particle size. It is reported that in presence 
of higher ionic strength medium (such as PBS pH 7.4), the positively charged choline 
head group of PC approaches to outer bilayer region, which causes to put a net positive 
charge on particles (section 3.4.1.3). 
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 The size and zeta potential of various empty liposomes, however was found to be 
influenced by cholesterol and surfactants. Both cholesterol and surfactant containing 
liposomes produced smaller particle size compared to that of pure PC liposomes. 
Inclusion of cholesterol in liposomes caused a negative zeta potential on the particle. 
This could be due to the reason that the presence of cholesterol on bilayer increases the 
adsorption of negative ions on PC molecule from buffer. However compared to pure PC 
liposome, Tween 80 and sodium cholate containing elastic liposomes had more negative 
zeta potential which could be because of the hydrolysis of Tween 80 and adsorption of 
cholate ion (sodium cholate) on PC molecule. 
3.4.8. Characterization of Ibuprofen loaded conventional liposome 
 
The effect of cholesterol content on size distribution, zeta potential and EE of various 
IBU loaded conventional liposomes was investigated. Vesicles were prepared from a 
range of PC (70-100 mg) and cholesterol (0-30 mg). They were coded as IBU CON 0 
(pure PC, containing no cholesterol), and IBU CON 10, 20 and 30 (containing 10, 20 
and 30% w/w cholesterol respectively).  
 
3.4.8.1. Vesicle size distribution 
The effect of cholesterol content on IBU loaded liposome size, zeta potential and EE 
was investigated. Table 3.17 shows various characteristics of IBU conventional 
liposomes. Before extrusion all vesicles reduced in particle size with subsequent 
addition of cholesterol. The maximum vesicular diameter found was with IBU CON 0 
(298.6±11.3 nm) whereas IBU CON 30 showed the lowest particle size of 182.7±6.7 
nm. Before extrusion, all formulations showed large polydispersity index indicating 
wider size distribution. After extrusion, the size of all liposomes dropped considerably. 
The biggest size reduction was observed in pure PC liposome. However the particle size 
of IBU CON 10 was higher than that of CON 0, but reduced in liposomes containing 
20% and 30% w/w cholesterol. The cholesterol-induced size reduction of various 
conventional IBU liposomes can be explained by the condensation effect of cholesterol 
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in bilayer, a decrease in effective area per molecule
230
 due to an increased packing 
density, leading to decreased particle size. 
The polydispersity index of all IBU liposomes reduced considerably when vesicles were 
extruded. Upon extrusion the particle size usually becomes smaller and produces more 
uniformly shaped particles due to extrusion through a fixed pore sized filters repeatedly.  
 
3.4.8.2. Zeta potential 
Almost all particles in contact with a liquid acquire an electric charge on their surface. 
Compared with the zeta potential of empty pure PC and 30% w/w cholesterol containing 
liposome, the zeta potential of IBU loaded liposomes were more negative. This could be 
due to the reason that IBU is highly ionized at pH 7.4 (pKa=4.6). Being a carboxylate 
anion its adsorption on liposome forms part of an electrical double layer on liposome 





Table 3.17 shows that the zeta potential of various IBU loaded conventional liposomes 
were cholesterol dependent which is supported by the study of Minghui et al in which 
they showed the zeta potential of salidroside nanoliposomes gradually increased in 
magnitude with the increasing cholesterol content
268
. In the current study, pure PC 
liposome had a positive charge (1.8±0.4). 10% w/w addition of cholesterol caused a 
weak negative charge (-0.8±0.3) on particle. However 20 and 30% w/w cholesterol 
produced more negative charge. Such elevation in the negative zeta potential was also in 
agreement with the data reported by Liu et al who found progressively higher negative 
zeta potential due to subsequent addition of cholesterol to egg PC liposomes. This could 
be explained by the phenomena that incorporation of cholesterol into the bilayer reduces 








3.4.8.3. Entrapment efficiency  
The influence of cholesterol inclusion within the lipid composition on IBU EE was 
determined by varying cholesterol content from 0 to 30% w/w. The result of drug EE of 
various IBU loaded conventional liposomes indicated that as the concentration of PC 
decreased, EE decreased. The highest EE found was with CON 0, which was around 
33.8%. However EE reduced when 10 % w/w cholesterol was added to the system. The 
lowest EE found was with CON 30, around 21.0% (Table 3.17). 
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100:0 298.5±11.3 143.0±3.7 0.85±0.11 0.33±0.02 1.8±0.4 33.8±2.0 
IBU 
CON 10 
90:10 252.6±3.3 157.8±3.6 0.72±0.10 0.34±0.03 -0.8±0.3 27.2±1.6 
IBU 
CON 20 
80:20 235.1±6.2 154.7±4.2 0.55±0.08 0.34±0.04 -4.8±1.0 22.7±2.2 
IBU 
CON 30 
70:30 182.7±6.7 147.5±3.8 0.52±0.05 0.37±0.02 -12.2±0.5 21.0±1.8 
CH: Cholesterol; PC: Phosphatidylcholine; IBU CON 0: Ibuprofen (IBU) loaded conventional liposome 
with no cholesterol, IBU CON 10, 20 and 30 denote IBU loaded conventional liposome prepared from 
PC: CH ratio of 90:10, 80:20, and 70:30 respectively. 
Size-1, P.I-1 = Size and polydispersity index of vesicles determined after sonication but before extrusion 
Size-2, P.I-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 
nm Supor
®
 membrane filters 
EE= Entrapment efficiency 
Data represented as mean± SD (n=5) 
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At pH 7.4, ionization of IBU is more than 50%. Ionized species tend to be strongly 
associated with the liposomal lipid membrane by means of electrostatic interactions with 
the zwitterionic phospholipid of liposomes
270
. Drug-liposome membrane interaction can 




 mem for the 
liposome water system where P
N
mem= Partition coefficient of neutral species in 
liposomal membrane; P
I
 mem= Partition coefficient of ionized species in liposomal 
membrane
172
. The larger the δmem value, the smaller the affinity of ionized species for 
the liposome phase, relative to that of the neutral phase partitioning. The δmem value of 
IBU is shown in Table 3.18. However the partitioning of ionized drugs to lipid 
membrane is influenced by the acidity and basicity of drugs. The charged forms of 
amphiphilic (anionic) acids have less affinity for PC-based membranes than charged 
forms of amphiphilic (cationic) bases compared to uncharged species respectively
172
. 
Generally when ionized species move toward the aqueous exterior the first charge it 
experiences are those of the negatively charged phosphates. Further movement would let 
the ionized drug come closer to the vicinity of positively charged trimethylammonium 
groups (from choline). In case of ionized weak acids, for example IBU, this movement 
may lead to weakened membrane binding because of less affinity of ionized IBU for the 
liposomal membrane (Table 3.18).  
Table 3.18: IBU-liposomal membrane water system
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mem  3.80±0.03 
logP
I
mem  1.81±0.05 
δmem  1.99 
 
In current study, EE of IBU loaded liposomes decreased with an increase in cholesterol 
content. Maximum entrapment was obtained from pure PC IBU liposome. This could be 
explained by the binding of ionized IBU with liposomal membrane which would allow 
anionic head group of IBU to be associated with the positively charged choline of PC 
and more of the hydrophobic portion of IBU would insert into the lipid membrane in a 
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configuration similar to that of cholesterol. This is further supported by Yang et al. IBU 
is an amphipathic molecule with an ionizable carboxylic acid at PBS pH 7.4. Yang et al 
from the proton NMR spectroscopy suggested that the negatively charged carboxyl 
group of IBU may interact with the positively charged trimethyl head group of PC, 
while the phenyl and isobutyl groups of the IBU may take part in the Vander Waals 
interaction with the acyl regions of the lipids 
243
. Therefore it is assumed that binding of 
ionized IBU with the liposomal membrane would be due to drug partitioning and ionic 
interaction; while this binding may be comparatively smaller than its non-ionized form, 
yet considerably interfered with the EE of IBU loaded liposomes.  
The decrease in entrapment of IBU in liposomes with each addition of cholesterol could 
be explained by the membrane binding affinity of IBU. Cholesterol prefers to align in 
the hydrophobic region of the membrane and provides a limited space available for the 
ionized IBU by lowering the partitioning of drug molecules to the bilayer membrane. 
Therefore the higher amounts of cholesterol might have competed with IBU for the 
packing space within the bilayer excluding the drug  as the amphiphiles assemble into 
liposomes
212
. Moreover as cholesterol increases, the negative charge increased (Table 
3.17); this would tend to repel negatively charged IBU from the bilayer further, resulting 
in reduced EE. 
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Figure 3.8: A typical diagram of passive drug loading: possible location of trapped 
molecule (figure adapted from Jaafar-Maalej et al 
241
 and modified) 
 
3.4.8.4. Bilayer elasticity 
To determine elasticity of IBU loaded conventional liposomes, two most different 
formulations were chosen; IBU CON 0 and IBU CON 30. Their deformability indexes 
were found to be 8.4±1.3 and 4.8±0.8 respectively. As expected conventional liposomes 
showed poor elasticity. However the higher elasticity found with pure PC liposome is 
due to the absence of cholesterol in the formulation. Cholesterol is reported to restrict 















J (mL) D 
IBU 
CON 0 
100:0 115.2±5.5 0.23±0.01 1.6±0.2 8.4±0.3 
IBU 
CON 30 
70:30 112.7±2.7 0.25±0.02 0.9±0.2 4.8±0.8 
CH: Cholesterol; PC: Phosphatidylcholine; IBU CON 0 and IBU CON 30 denote 
Ibuprofen (IBU) loaded conventional liposomes with no CH and 30% w/w CH 
respectively. 
Size and polydispersity index of vesicles determined after extrusion through 50 nm 
polycarbonate membrane filter 
J= Vol of suspension extruded within 5 min 
D= Degree of deformability  
Data represented as mean± SD (n=2) 
 
Optimization of IBU loaded conventional liposomes was based on particle size and EE. 
IBU CON 0 was chosen as the best formulation because of its smaller vesicular diameter 
and highest EE. Furthermore the elasticity of pure PC IBU liposome was better than that 
of IBU CON 30. As not much deformability is expected in conventional liposomes, the 
relatively better elasticity was considered as an additional selection criterion.  
3.4.9. Characterization of elastic liposomes loaded with Ibuprofen 
Tween 80 and sodium cholate were utilized to develop IBU loaded elastic liposomes. 
Table 3.20 and Table 3.21 show various characteristics of IBU elastic liposomes. To 
simplify the names, they were coded by the name of the drug incorporated and the type 
and weight of surfactant added to formulation. For example, IBU T80 5 and IBU S. 
Chol 5 represent IBU loaded elastic liposome which contained 5% w/w of Tween 80 




3.4.9.1. Particle size distribution 
All IBU loaded elastic liposomes were characterized for particle size both before and 
after extrusion (Table 3.20 and Table 3.21). The more surfactant was added to bilayer, 
the smaller was the particle size which is consistent with the finding obtained from NaFl 
loaded elastic liposomes in which all surfactant containing liposomes had sizes much 
smaller than those without surfactant (Table 3.16). Table 3.20 shows that the highest 
vesicular diameter was found with elastic liposome containing Tween 80 at 5% w/w 
(171.83±6.20 nm), which reduced to 146.8±2.69 nm when 15% w/w Tween 80 was 
added. Similar size reduction pattern was observed with sodium cholate, where IBU S. 
Chol 5 had the largest particle size of about 181.23 nm; 15% w/w sodium cholate 
reduced size to 148.2±3.05 nm (Table 3.21). This result resembled that of PEG-grafted 
liposomes; a finding by Yoshida et al
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 where decreased particle size was reported with 
increased surfactant. However a significant drop in size was observed when surfactant in 
the system above was above 15% w/w; 110.4±1.13 nm and 113.75±6.85 nm for 25% 
w/w Tween 80 and sodium cholate respectively. This could be due to the presence of 
micellar structure at higher concentration of surfactant. After extrusion, the particle size 
of various elastic liposomes did not reduce significantly, but polydispersity index 
became smaller indicating relatively narrower particle size distribution. In both types of 
elastic liposomes size reduction occured significantly in 25% surfactant containing 
elastic liposomes (P<0.05 and <0.03 for Tween 80 and sodium cholate respectively) 
compared to that of 5% surfactant. 
3.4.9.2. Zeta potential 
The zeta potential found in Tween 80 containing elastic liposomes were slightly less 
positive and that in sodium cholate containing elastic vesicles were slightly more 
negative compared to that of empty elastic liposomes (Table 3.20, 3.21 and 3.16). The 






3.4.9.3. Entrapment efficiency 
The EE in all elastic liposomes reduced when the surfactant content was increased 
(Table 3.20 and 3.21). Maximum drug encapsulation was found in vesicles with 5% w/w 
of surfactant (30.7±1.4% and 26.7±2.4% for Tween 80 and sodium cholate 
respectively). Up to 15% addition of surfactant, the reduction in EE was not significant 
(P>0.05). A significant drop in EE was observed only when more than 15% edge 
activator was added. This could be due to the presence of vesicles and mixed micelles at 




Table 3.20: Characteristics of IBU loaded elastic liposomes prepared using PC and Tween 80 








EE (%)  Size-3 (nm) P.I.-3 J (mL) D 
IBU 
T80 5 
95:5 171.8±6.2 150.6±2.6 0.46±0.06 0.34±0.01 2.2±0.7 30.7±1.4  115.3±3.0 0.21±0.02 2.6±0.1 13.8±1.2 
IBU 
T80 10 
90:10 152.3±3.2 141.6±2.7 0.43±0.05 0.35±0.04 2.1±0.5 27.5±1.7  114.8±0.6 0.22±0.05 3.4±0.1 17.9±0.6 
IBU 
T80 15 
85:15 146.8±2.7 136.0±2.7 0.43±0.05 0.33±0.01 2.1±0.2 24.4±1.9  106.8±1.3 0.19±0.10 6.8±0.0 31.1±1.5 
IBU 
T80 20 
80:20 119.8±2.3 114.7±2.3 0.45±0.01 0.34±0.02 2.4±0.2 19.4±3.3  96.4±2.3 0.26±0.11 1.8±0.1 6.7±1.3 
IBU 
T80 25 
75:25 110.4±1.1 105.3±1.2 0.45±0.03 0.33±0.02 2.1±0.2 16.9±2.2  96.8±0.8 0.24±0.00 1.1±0.2 4.1±0.4 
PC: Phosphatidylcholine; T80: Tween 80, IBU T80 5, 10, 15, 20 and 25% denote Ibuprofen (IBU) loaded elastic liposome containing 
5, 10, 15, 20 and 25% w/w T80 
Size-1, P.I-1 = Size and polydispersity index of vesicles determined after sonication but before extrusion 
Size-2, P.I-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 nm Supor
®
 membrane filters 
Size-3, P.I-3 = Size and polydispersity index of vesicles determined after extrusion through 50 nm polycarbonate membrane filters 
EE= Entrapment Efficiency 
J= Vol of suspension extruded within 5 min 
D= Degree of deformability 
Data represents as mean ±SD (n=5) except the elasticity measurements which were done twice 
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Table 3.21: Characteristics of IBU loaded elastic liposomes prepared using PC and sodium cholate 









EE (%)  
Size-3 
(nm) 
P.I.-3 J (mL) D 
IBU S. 
Chol 5 
95:5 181.2±5.4 155.0±5.4 0.58±0.03 0.32±0.02 -2.9±0.1 26.7±2.4  118.6±3.0 0.24±0.03 2.1±0.1 11.8±1.5 
IBU S. 
Chol 10 
90:10 162.0±7.0 145.2±4.5 0.51±0.01 0.33±0.02 -2.2±0.4 25.2±0.7  115.8±1.1 0.21±0.10 2.9±0.2 15.5±0.4 
IBU S. 
Chol 15 
85:15 148.2±3.0 142.2±2.0 0.45±0.03 0.39±0.01 -2.5±1.1 23.0±0.7  111.4±2.6 0.22±0.12 5.8±0.2 28.8±2.1 
IBU S. 
Chol 20 
80:20 125.1±3.9 117.8±2.0 0.45±0.02 0.33±0.02 -2.8±0.1 17.8±1.1  104.4±4.6 0.21±0.10 1.2±0.1 5.2±1.3 
IBU S. 
Chol 25 
75:25 113.7±6.8 109.5±0.8 0.58±0.01 0.36±0.01 -3.5±0.1 14.9±0.7  92.3±2.1 0.25±0.3 1.0±0.1 3.4±1.0 
PC: Phosphatidylcholine; S. Chol: sodium cholate, IBU S. Chol 5, 10, 15, 20 and 25% denote Ibuprofen (IBU) loaded elastic liposome 
containing 5, 10, 15, 20 and 25% w/w S. Chol.  
Size-1, P.I-1 = Size and polydispersity index of vesicles determined after sonication 
Size-2, P.I-2 = Size and polydispersity index of vesicles determined after extrusion through 200 and 100 nm Supor
®
 membrane filters 
Size-3, P.I-3 = Size and polydispersity index of vesicles determined after extrusion through 50 nm polycarbonate membrane filters 
EE= Entrapment Efficiency 
J= Vol of suspension extruded during 5 min 
D= Degree of deformability 
Data represents as mean ±SD (n=5) except the elasticity measurements which were done twice 
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3.4.9.4. Bilayer elasticity 
 
The deformability of various IBU loaded elastic liposomes was found to be 
surfactant concentration dependent (Table 3.20 and 3.21). The relationship was non-
linear, more in a bell shape. Interestingly maximum elasticity was obtained when 
both Tween 80 and sodium cholate were at 15% w/w surfactant. Above this, a 
significant drop of elasticity was noticed in both types of elastic vesicles (Table 3.20 
and 3.21). It is known that only an optimum concentration of surfactant can provide 
maximum bilayer elasticity that results in better skin permeability
246
. Increasing this 
surfactant content above a certain level does not bring any benefit in skin penetration 
due to bilayer solubilization by surfactants
245
 and formation of micelles whose 
aggregate tend to block the pores of membrane therefore producing apparently low 
degree of deformation. 
 
3.4.9.5. Morphology of Ibuprofen loaded liposomes 
IBU loaded various conventional and elastic liposomes were observed under TEM 
and SEM where they appeared as spherical structures (Figure 3.9 (a) to Figure 3.9 
(d)). A typical SEM micrograph of IBU CON 0 is shown in Appendix 6 and a TEM 
micrograph of 1 month old IBU S. Chol 15 stored at 4±2ºC is shown in Appendix 7. 
 
Figure 3.9 (a): TEM micrograph of crude IBU S. Chol 15 (Ibuprofen loaded 
elastic liposome containing 15% w/w of sodium cholate) 
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Figure 3.9 (b): TEM micrograph of sonicated IBU T80 15 (Ibuprofen loaded 
elastic liposome containing 15% w/w of Tween 80). The white features inside 
vesicles could be inner dried liposomal components which were visible on a narrow 
focus. 
 
Figure 3.9 (c): TEM micrograph of sonicated (through 100nm filter) IBU 







Figure 3.9 (d): TEM micrograph of extruded IBU CON 30 (Ibuprofen loaded 
conventional liposome containing 30% w/w cholesterol) 
 
3.5. In vitro release study 
The in vitro release profile of the entrapped drug may not predict exactly how a 
delivery system would behave in vivo but it will allow us to compare the release 
characteristics of different formulations. In the current study, a dialysis method, 
described under section 2.3.8.3 was used to investigate the release rate of NaFl and 
IBU from various liposomes using 50 mL PBS (50mM, pH 7.4 containing 0.05% 
sodium azide) as receptor. Drug release by dialysis has the advantage of separating 
free drug from liposomes without the application of centrifugal force which 
potentially can destroy liposomal structure. The release study was conducted using 
various optimized formulations and respective controls.  
The drug release or diffusion from liposomes is governed by the transfer of the 
molecules from the liposome system to the external aqueous phase and diffusion of 
molecule through the dialysis membrane from the external phase to the receptor 
fluid
233
. A fixed surface area of dialysis membrane, fixed quantity of drug inside the 
dialysis bag and fixed volume of final formulation should be employed to eliminate 
variation within identical formulations. Any defects could lead to huge variations in 
the release profile of same liposomes and would generate untrue or unmeaningful 
data for formulations. Moreover if sufficient agitation is not employed, a stagnant 
120 
layer may form, which will represent an opposing force to drug release from the 
formulation through the dialysis membrane, leading to a faulty and unsatisfactory 
release profile. In this study all these factors were controlled to ensure the generation 
of meaningful data. 
 
3.5.1. In vitro release of sodium fluorescein from liposomes 
Evaluation of in vitro drug release from various NaFl encapsulated liposomes was 
conducted 35±2ºC by the dialysis method. The in vitro release behaviour of the free 
NaFl (i.e. Control), a conventional liposome (NaFl CON 30) and two elastic 
liposomes (NaFl T80 15 and NaFl S. Chol 15) is profiled by plotting cumulative 
percentage of NaFl released over time (h) and the results are presented in Figure 
3.10. To maintain the sink condition drug concentration in the release medium 
should be kept below 10% of saturation
199
. As NaFl is freely soluble in water, 
maintaining a sink condition in buffer was not a issue.  
 
To study the effect of liposome formulation on the release of NaFl, a control sample 
containing only the drug solution was used to generate data on drug diffusion 
throughout the dialysis membrane. Drug release from liposome dispersions was 
found to be a function of the formulation variables. Significant prolonged NaFl 
release was achieved with the liposome formulations in comparison with that of free 
drug solution (control; 96.46% after 90 min). NaFl release from 30% w/w 
cholesterol containing liposome was the slowest, 43.82±3.52% over 24 h while 
elastic liposomes provided relatively faster release (62.10±1.23% with Tween 80 and 
57.84±1.45% with sodium cholate) over the same period of time. From the release 
profile it appears that drug release from liposomes was a biphasic process consisting 
of an initial faster release for the first 2 h, followed by a relatively slow release, 
lasting over the next 22 h. The initial burst effect of drug release varies with the 
liposome type and lipid composition. For example, in NaFl CON 30, during the first 
2 h 28.15±4.24% of NaFl released whereas Tween 80 and sodium cholate containing 





Figure 3.10: Cumulative percentage of sodium fluorescein (NaFl) release as a 
function of time across dialysis membrane from different liposomes and control 
in water over 24 h. Control represents 1mg/mL NaFl solution in water, NaFl CON 
30 represents NaFl loaded conventional liposome composed of 70% w/w 
phosphatidylcholine (PC) and 30% w/w cholesterol, NaFl T80 15 and NaFl S. Chol 
15 represent NaFl loaded elastic liposomes containing 15% w/w Tween 80 and 
sodium cholate in conjunction with PC respectively. Data represents as mean ±SD 
(n=3). 
 
The slow release from cholesterol containing liposome can be explained by the 
stabilizing effect of cholesterol in the bilayers. At above the Tc (55ºC for cholesterol 
containing liposome), cholesterol modulates membrane fluidity by restricting the 
movement of the relatively mobile hydrocarbon chains, reducing bilayer 
permeability
273
 and decreasing the efflux of the encapsulated drug, which results in 
prolonged drug retention
274
. On the contrary, the faster drug release from elastic 
liposomes compared to that of conventional liposome was due to the high fluidity 
provided by the incorporation of edge activator
233
. The significantly lower release of 
NaFl from both conventional and elastic liposomal formulations as compared to the 
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So far no published literature on the release profile of NaFl from liposome was found 
which employed the same conditions that were used in present study. However 
Henriksen et al
275
 showed around 15% of carboxyfluorescein (100 mM 
carboxyfluorescein solution in 60 mM Tris Buffer pH 8) released from liposome 
containing 50 mg/mL PC after 5h following a fractional dialysis method. Compared 
with Henriksen‟s report, the release of NaFl observed from different liposomes in 
current study was faster in the same period of time, about 39.5% and 52-56% from 
conventional and elastic liposomes respectively. This is expected as the lipid 
concentration in current study is 10 mg/mL, much lower than that of Henriksen‟s 
study. In addition, NaFl is more water soluble than carboxyfluorescein and a 
relatively low dose of NaFl was used in our study (37.6 mg/mL carboxyfluorescein 
in Henriksen‟s, report whereas in current study, 1mg/mL). Higher lipid concentration 
eventually lead to slow release of entrapped drug and higher drug concentration will 
probably take time to diffuse through the dialysis membrane. 
 
For an ideal topical delivery, improved skin permeation as well as sustained release 
of drug is desirable. Though drug release was slower from cholesterol containing 
liposomes than that of elastic liposomes, traditional liposomes are not able to 
penetrate deeper into the skin which may not help ultimately. Considering the 
permeability through skin, elastic liposomes are advantageous which allow for drug 
delivery into the skin.  
 
3.5.2. In vitro release of Ibuprofen from liposomes 
3.5.2.1. Effect of cholesterol  
The same dialysis method was applied to investigate the effect of cholesterol on IBU 
release from various conventional liposomes. Results of the in vitro release study are 
shown in Figure 3.11. The release profile was found to be apparently biphasic in 
nature; initial rapid drug leakage was observed where about 39-48% of the entrapped 
drug was released from different IBU conventional liposomes in the first 2 h of 
incubation. However during the following 22 h, a slow release occurred in which a 
maximum of 26% of IBU was leached from different conventional liposomes. The 
initial burst release of IBU could be because highly ordered lipid particles cannot 
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accommodate large amounts of drug. A significant amount of IBU was associated 
with or adsorbed to the surface of liposomes, which released quickly after being 
exposed to large volume of buffer
276
. The slow release in next 22 h could be 
attributed to the release of IBU which was trapped deep inside bilayer of liposomes. 
 
Figure 3.11: Cumulative percentage of Ibuprofen (IBU) release as a function of 
time across dialysis membrane from different conventional liposomes over 24 h. 
IBU CON 0, IBU CON 10, IBU CON 20, IBU CON 30 represent IBU loaded 
conventional liposomes containing Phosphatidylcholine (PC) with 0, 10, 20 and 30% 
w/w cholesterol. Data represents as mean ±SD (n=3). 
 
From Figure 3.11, it is observed that cholesterol free IBU conventional liposome 
showed slightly higher release (approximately 69.8%) after 24 h compared to those 
containing 10% cholesterol (IBU CON 10) in the system where 63.87% of IBU 
released. Significant slower drug release was observed from IBU CON 20 releasing 
approximately 54.7% of drug over 24 h compared to that of pure PC liposomes 
(P<0.002). However further increase in cholesterol content (up to 30%) in the lipid 
bilayer showed a faster release (67.78%) compared with that of IBU CON 20. IBU 
release from IBU CON 30 not very significantly different from that of pure PC 













































The faster release profile of IBU from pure PC liposomes could be explained by the 
absence cholesterol in the structure. It is generally accepted that cholesterol 
decreases the leakage and permeability of entrapped drug from liposomal bilayer. 
Cocera et al 
277
 reported that cholesterol produced an optimum hydrophobicity which 
decreased the formation of transient hydrophilic holes, by decreasing membrane 
fluidity, producing a more ordered structure, responsible for drug release through 
liposomal layers
158
. However it is reported that higher amount of cholesterol in 
liposome beyond a certain concentration may disrupt the regular linear structure of 
vesicular membrane and increase drug release consequently
76
.  
The release of IBU from various cholesterol containing conventional liposomes was 
investigated by Mohammed et al
212
 who reported approximately 30% of IBU release 
from 16:4 µmol of PC: cholesterol liposome (equivalent to 12.16 mg/mL PC and 
1.546 mg/mL cholesterol) over a period of 5 h. In our study, higher drug release 
from 10% w/w cholesterol containing liposome was obtained. This difference in 
release rate could be due to several reasons. First of all, Mohammed et al 
investigated drug release from MLVs whereas SUVs were prepared in current study. 
Bilayer lamellarity is an important parameter that affects the drug release. It is 
generally accepted that drug release from MLVs is slower than that of SUVs due to 
having more concentric lamellae in case of the former, which acts as a drug diffusion 
barrier. Moreover Mohammed et al formulated all IBU liposomes from water, 
whereas PBS was used as hydration medium in present study. The effect of 
solubility and ionization on drug release might have an influence here. 
3.5.2.2. Effect of Surfactants  
An in vitro release study was performed on IBU loaded optimized elastic liposomes 
(IBU T80 15 and IBU S. Chol 15) with free IBU as control. For comparison purpose, 
cumulative release rate of IBU CON 0 was also included in the plot. The release 
profile is shown in Figure 3.12. The release of IBU from formulations was found to 
be biphasic in nature. Initial rapid release was observed which lasted during the first 
3 h when maximum 66% of drug was released. Then it was followed by a steady 
release during the next 21 h. Drug release from free drug was found to be highest 
than that of formulations; 95% IBU was released into the receptor from control 
125 
within 1 h, whereas the average release from liposomes was around 28.6%. 
Therefore all IBU loaded liposomes showed sustained release.  
As expected drug release from elastic liposomes was higher than that of conventional 
liposome. At the end of 24 h, 69.8, 74.06 and 81.89% of IBU released from pure PC, 
Tween 80 and sodium cholate containing liposomes respectively. This is due to the 
presence of bilayer softening agent in elastic liposomes which tend to make the 
liposomes more leaky, thus provides faster drug release. 
 
Figure 3.12: Cumulative percentage of Ibuprofen (IBU) release across dialysis 
membrane from different liposomes and control in PBS pH 7.4 over 24 h. IBU 
CON 0 represents IBU loaded conventional liposomes containing no cholesterol, 
IBU T80 15 and IBU S. Chol 15 represent IBU loaded elastic liposomes containing 
15% w/w Tween 80 and sodium cholate respectively in conjunction with 
phosphatidylcholine (PC). Control: 1mg/mL of IBU solution in PBS pH 7.4. Data 
represents as mean ±SD (n=3). 
 
Compared with the release rate of NaFl, IBU liposomes showed relatively faster 
drug release. This could be due to the relatively stronger electrostatic repulsion 
between negatively charged ionized carboxyl groups of IBU and phosphate groups in 
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Weinstein et al. (1981) have provide 
3.6. In vitro permeation of Ibuprofen through human epidermis 
The non-occlusive in vitro skin penetration study, using Franz type diffusion cells 
mounted with excised human abdominal epidermis, was conducted with two elastic 
and one conventional liposome formulations, and IBU solution as the control. For 
comparison purpose, the amount of IBU in all formulations and control was kept 
constant (0.5 mg). The results, plotted as cumulative amount of IBU permeated per 
unit area as a function of time are presented in Figure 3.13, cumulative percentage of 
IBU permeated per unit area as a function of time in Figure 3.14. Various 
transdermal permeation parameters were calculated and are summarized in Table 
3.22.  
 
In this penetration study, a pre-hydration time of 45 min was selected. A volume of 
0.5 mL of formulations and control were applied as donor to cells. Samples were 
withdrawn from the receptor containing 50 mM PBS pH 7.4 at predetermined time 
intervals over 12 h. Fresh buffer was added each time. Withdrawn samples were 
analysed for their drug content at each time point. To confirm skin integrity, skin 
resistance test or conductivity test was carried out on the skin both before starting the 
experiment and at the end of the experiment. The conductivity values obtained are 
tabulated in Appendix 8. As the data suggest, the skin integrity was intact before and 
after the penetration experiment, therefore, the experimental data generated can be 
considered as the valid data for skin penetration study. 
 
Results of in vitro skin penetration study (Figure 3.13) showed that IBU permeation 
from the control (free IBU solution in PBS pH 7.4) was lowest (8.5±0.9 µg/cm
2
), 





5.34 folds of that of the control. In comparison, IBU permeation from conventional 
liposome (12.7±0.5 µg/cm
2
) was not statistically significant different from that of the 
control (P>0.3). Furthermore, the cumulative amount of drug penetration from both 
Tween 80 and sodium cholate containing elastic liposomes were significantly 
different from that of the conventional liposome and control. However, no 
significant difference was found between the two elastic liposomes although elastic 
liposomes of Tween 80 appear to be slightly better than that of sodium cholate 
(Figure 3.13).  
127 
 
Figure 3.13: Cumulative amount of Ibuprofen (IBU) permeated across human 
epidermis from different liposomes and control in PBS pH 7.4 over 12 h. IBU 
T80 15 and IBU S. Chol 15 represent IBU loaded elastic liposomes containing 15% 
w/w of Tween 80 and sodium cholate in conjunction with Phosphatidylcholine (PC) 
respectively. IBU CON 0 represents IBU loaded conventional liposome with no 
cholesterol. Control: 1mg/mL of IBU solution in PBS pH 7.4. Data represents as 



















































Figure 3.14: Cumulative percentage of Ibuprofen (IBU) permeated across 
human epidermis from different liposomes and control in PBS pH 7.4 over 12 h. 
IBU T80 15 and IBU S. Chol 15 represent IBU loaded elastic liposomes containing 
15% w/w of Tween 80 and sodium cholate respectively in conjunction with 
Phosphatidylcholine (PC). IBU CON 0 represents IBU loaded conventional 
liposome with no cholesterol. Control: 1mg/mL of IBU solution in PBS pH 7.4. Data 
represents as mean ±S.E.M (n=4-8) 
 
The values of steady-state transepidermal flux from various IBU loaded liposomes 
were found to be formulation dependent; IBU T80 15 and IBU S. Chol 15 had flux 
values of 3.0±0.90 µg/cm
2
/h and 2.74±1.01 µg/cm
2
/h. The flux values obtained from 
Tween 80 and sodium cholate elastic liposomes were 5.0 and 4.5 fold higher than 
that of control respectively (0.64±0.04 µg/cm
2
/h) and 3.0 and 2.7 fold higher than 
that of conventional liposome (1.0±0.03 µg/cm
2
/h) respectively (Table 3.22). 
Boinpally et al
145
 studied the epidermal penetration of diclofenac (weak acid; pKa 
4.0) from elastic liposomes (containing sodium cholate and 10% ethanol) and 
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) De (µg) ER
A
 
IBU CON 0 1.00±0.03 0.97±0.04 3.01±0.51 1.6 
IBU T80 15 3.00±0.90 2.90±0.90 13.24±4.02 5.0 
IBU S. 
Chol 15 
2.74±1.01 2.70±1.00 14.12±8.11 4.5 
Control 0.64±0.04 0.65±0.04 5.82±4.03 - 
Jss: steady-state flux; K: permeability coefficient; De: drug deposited in the 
epidermis; ER
A
: Enhancement ratio compared to control 
 
The possible reasons for better transepidermal flux, better enhancement and 
improved skin deposition of drug from elastic liposomes can be explained by the 
effect of non-occlusion, surfactants and ethanol. 
The osmotic force by which vesicles may enter the skin is defined as xerophobia, or 
a non-occluded condition, which is of utmost importance in topical/transdermal drug 
delivery. When phospholipid vesicles are applied on the skin non-occlusively, due to 
their tendency to avoid dry surrounding to remain in swollen state, they tend to drive 
themselves towards the hydrated viable tissue by following the transdermal 
hydration gradient
112
. Elastic liposomes work most effectively under non-occluded 
condition. Surfactants, the key component of elastic vesicles introduce elasticity to 
liposomal membrane
246
. Under non-occluded condition, when elastic liposomes are 
applied on the skin, they can squeeze and drive themselves through the stratum 
corneum because of the high curvature produced by surfactant molecules. Therefore 
Tween 80 and sodium cholate had played vital role in the enhanced penetration of 
IBU from elastic liposomes. Moreover under non-occluded condition, drug partition 
coefficient may be improved due to the partition of phospholipids in the stratum 
corneum and epidermis, which is the result of increased diffusion of drug within the 
stratum corneum
134
. Moreover surfactants not only exert deformability to liposome 
membrane but also bind with stratum corneum and may extract lipids from it, which 
finally disrupts the lipid bilayer packing
130
, thus increase the pore size of it, hence 
enhance permeation. Anionic surfactants for example sodium cholate causes 
alteration in stratum corneum barrier function by strongly interacting with the 
negatively charged components of the stratum corneum. They probably enhance 





Another reason of improved transdermal flux from elastic liposomes could be due to 
the effect of ethanol which generally acts by affecting the intercellular regions of the 
stratum corneum 
120, 121
. Ethanol generally acts by the „push-pull‟ mechanism. Elastic 
liposomes containing ethanol, when applied on the skin, two factors may play roles: 
firstly, ethanol may permeate though the skin, carrying the drug molecules dissolved 
in it. This can improve drug partitioning into the stratum corneum. Secondly ethanol 
evaporated from the system, causing an increase in drug concentration in donor, 
which changed the thermodynamic activity of drug, and enhanced permeation.  
The poor permeation of IBU from conventional liposome was due to less 
deformability of bilayer membrane. Conventional liposomes when applied on the 
skin non-occluded, to avoid dry surroundings, they tend to squeeze though the 
narrow pores of stratum corneum but due to the lack of elasticity, these vesicles 
cannot squeeze and only remain in the upper layers on the stratum corneum.  
From skin extraction data, it was found that the highest IBU deposition in the 
stratum corneum was from elastic liposomes. As elastic liposomes showed better 
transepidermal flux, more drug was expected to be found in the stratum corneum due 
to the penetration enhancing ability of elastic vesicles. These vesicles might have 
carried the drug into the stratum corneum or travelled through the stratum corneum 
as intact. Higher drug deposition showed that elastic liposomes may have depot 
forming ability that could be beneficial to localize IBU to diseased tissue. There was 
no significant difference found in the level accumulated in the stratum corneum from 
the control and the conventional liposomes, though marginal better flux was found 
from conventional liposomes. 
 
Delivery of IBU by passive diffusion and its consequent pharmacological effect are 
dose dependent; the better is the permeation, the greater the therapeutic effect. 
Therefore formulation plays a vital role in topical drug delivery as the vehicle 
composition influences drug partitioning and/or the diffusivity and absolute amount 
delivered. The results of our in vitro release study demonstrated greater effectiveness 
of dermally applied IBU elastic liposomal formulation in comparison to the 
conventional liposome and free drug solution. Therefore an optimized elastic 
131 
liposomal formulation of IBU may offer a promising means for the non-invasive 
treatment of local pain and inflammation by topical application. Furthermore, this 
study also highlighted the potential of elastic liposomes as topical carriers for other 
therapeutic molecules to improve their skin permeation and local therapeutic 



























GENERAL DISCUSSION AND 
CONCLUSION 
4.1. General discussion 
Due to the unwanted reactions arising from the systemic administration of IBU, a 
considerable interest has grown in the potential usefulness of the topical application 
of this drug. However the problem associated with topical application of IBU is its 
poor permeability
177
. Therefore the primary objective of this project was to develop 
elastic liposomes of IBU and to evaluate its skin permeability in comparison to that 
of conventional liposome and free drug solution when applied topically. 
Conventional and elastic liposomes were developed and characterized in terms of 
their physicochemical properties, such as particle size distribution, vesicular shape, 
zeta potential and EE. Two different compounds were chosen for drug loading into 
liposomes; NaFl, a model hydrophilic compound, and IBU, a poorly water-soluble 
drug. NaFl was chosen because of its simple and rapid analysis and also to show the 
difference between physicochemical properties of liposomes loaded with hydrophilic 
and hydrophobic compound.  
 
4.1.1.  Preparation and characterization of liposomes 
In this project, all liposomes were prepared by the thin film hydration technique as 
this technique is very simple and easy for laboratory scale-up procedures. To prepare 
a stable liposomal suspension, few process variables were investigated for example a 
suitable solvent system for lipid film formation, hydration medium to hydrate the 
film and method of size reduction of liposomal particles. After careful evaluation, 
chloroform-methanol (3:1) was found to be the best solvent system to form a 
homogeneous and thin film. To minimize the level of chloroform residue, a 12 h or 
overnight drying of lipid film was conducted with each preparation under vacuum to 
ensure maximum removal of chloroform.  
 
The selection of a suitable hydration medium was achieved by evaluating three types 
of hydration media (water, PBS and phosphate buffer saline). The effect of hydration 
medium on particle size, zeta potential and physical appearance of pure PC liposome 
was investigated. Results showed that both water and PBS produced stable 
133 
suspensions whereas phosphate buffer saline caused a clear phase separation due to 
the influence of electrolytes on particle aggregation, therefore the latter was found 
not suitable as hydration medium. The zeta potential of water hydrated liposome was 
negative, whereas that of PBS was positive. This effect could be explained by the 
change in the direction of the positive choline head group of PC which orientates to 
the outer region of bilayer while in PBS, resulting in an overall positive charge
218
. 
As smaller size and negatively charged liposomes are expected to have better skin 
penetration, water was selected as the hydration medium to develop all liposomes. 
Thin film hydration technique produces MLVs which are larger in size. SUVs are 
advantageous for skin permeation, as has been previously demonstrated: 120 nm 
vesicles showed better transdermal flux of carboxyfluorescein compared to that of 
larger ones (>300 nm)
222
. Hence MLVs were downsized to smaller sized particles. 
The combination of a 30 min bath and a 1 min probe sonication followed by 
extrusion through 200 and 100 nm filters effectively reduced particle size to 
approximately 153 nm and data were found to be reproducible. Therefore in a 
standard formulation process all three techniques were combined to obtain small and 
constant liposome size.  
 
Evaluation of formulation variables (phospholipid, cholesterol and surfactant and 
type of therapeutic molecule incorporated) in terms of their effect on 
physicochemical properties of liposomes allow us to better understand factors that 
influence the properties and eventually the performance of liposomes in vivo. 
Therefore once the process variables were optimized, a set of NaFl loaded 
conventional and elastic liposomes were prepared by passive loading technique using 
cholesterol and surfactants by varying their ratios. Incorporation of cholesterol into 
conventional liposome reduced the particle size of NaFl loaded liposomes. This 
effect was in agreement with the published literature
230
 and can be explained by the 
condensation effect of cholesterol on bilayer showing a decrease in effective area per 
molecule as cholesterol content increases. The zeta potential of cholesterol 
containing liposomes was more negative than that of cholesterol free liposomes 
possibly because of the binding of hydroxyl groups of cholesterol with the choline in 
PC, creating a dipole tropism which increased the surface negative charge
225
. 
Compared to cholesterol, surfactants (Tween 80 and sodium cholate) had similar 
effect on particle size and zeta potential of elastic liposomes. Liposomal size was 
134 
found to reduce with each inclusion of surfactant; maximum size reduction was 
observed with the formulation containing 25% w/w surfactant. This effect is in close 
agreement with published report where it was shown that the higher concentration of 
surfactants produced micellar structures which are much smaller in size
247
.  The zeta 
potential of elastic liposomes was dependent on the type of surfactant. Tween 80 
containing elastic liposomes had less negative surface charge compared to that of 
sodium cholate containing elastic liposomes. This effect may be attributed to the 
partial hydrolysis of Tween 80 and the adsorption of cholate anion on PC molecule 
respectively
226, 228
. The EE however was found to increase in presence of cholesterol 
containing liposomes whereas decreased in elastic liposomes because cholesterol is a 
stabilizing agent which causes the bilayer more rigid
236
 and surfactants are 
destabilizing agent, make bilayer flexible and soft. When 40% w/w cholesterol was 
included in bilayer no liposomes were formed because of the crystallization of 
cholesterol at high concentration
229
 which suggests that cholesterol provides stability 
only up to a certain concentration. 
 
Bilayer elasticity was determined in all NaFl loaded elastic liposomes and maximum 
elasticity was found when 15% w/w surfactant was used. Surfactant concentration 
above this significantly reduced elasticity due to the formation of micelles which are 
much less deformable in nature
247, 248
. For comparison, the elasticity of two 
conventional liposomes (containing 30% w/w of cholesterol and pure PC) was 
determined which as expected, showed very poor elasticity compared to that of 15% 
w/w surfactant containing elastic liposomes, due to the absence of membrane 
softening agent „surfactant‟ in the former, thereby reducing the probability of 
squeezing upon extrusion through the 50 nm pores of the filter. It is reported that 
elastic liposomes, irrespective of their size, can penetrate through very tiny pores of 
the skin. To support this phenomenon, NaFl level in elastic liposomes was 
determined after extrusion through 50 nm membrane filters and was found to remain 
the same indicating that elastic liposomes maintained their structural integrity when 
squeezing through the narrow pores. This finding is significant as it suggests that 
drug loaded inside the elastic liposomes will be able to penetrate through small pores 
to reach the region in the skin where the drug molecule normally cannot reach by 
itself. Along with cholesterol and surfactant, the type of drug to be incorporated has 
also influence on the characteristics of liposomes. Thus various empty liposomes 
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were prepared by hydrating with water and were characterized. The size and zeta 
potential of NaFl loaded liposomes (both conventional and elastic) were more 
negative compared to those of the empty liposomes, possibly due to the probe 
entrapment and the carboxylate anion (from NaFl) adsorption on PC molecule 
respectively. 
 
Above findings suggest that formulation variables have pronounced influence on the 
characteristics of liposomes, which should be carefully considered in optimizing 
liposomal delivery systems. In optimization of conventional liposomes, particle size 





 particles showed better skin penetration. Therefore, 
NaFl CON 30 (NaFl loaded liposomes containing 30% w/w of cholesterol) was 
chosen as optimized conventional liposome. In optimization of elastic liposomes, 
bilayer elasticity is the only selection criteria as it indicates vesicular deformability, a 
factor directly related to enhanced dermal penetration. Considering the data of 
deformability index, 15% w/w surfactant containing elastic liposomes were selected 
as optimized. 
 
Physical stability of liposomes is a very important parameter which should be 
regularly monitored. Upon storage, vesicles tend to undergo aggregation, fusion and 
even rupture. Therefore NaFl loaded conventional liposomes were stored for a period 
of 4 weeks at three different storage conditions and particle sizes were measured. 
Data obtained in the study showed that cholesterol induced better stability; 
maximum stability was achieved from NaFl CON 30, which promoted more 
resistance against particle aggregation and fusion at all storage conditions. Thus 
cholesterol was evaluated as stabilizing molecule for liposomes. 
 
On completion of characterization of NaFl loaded liposomes, IBU was loaded into 
both conventional and elastic liposomes with a view to evaluate elastic liposomes in 
topical delivery of IBU. As water was chosen as suitable hydration medium, pure PC 
IBU liposomes were prepared with water which showed a very high EE of around 
98%. This is not realistic for a compound like IBU. Therefore investigations were 
carried out and found that IBU crystals were present in liposome, and an EE of 
25.3% was achieved after washing pellets with PBS pH 7.4 twice. As it became 
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evident that IBU was in insoluble form in the formulation, dialysis technique (40 
min in PBS pH 7.4 and 40 min in water) was applied to purify IBU liposomes by 
removing the non-entrapped IBU. However, later it was found that inclusion of 20 
and 30% w/w cholesterol in the bilayer required the use of PBS pH 7.4 as hydration 
medium to form IBU loaded liposomes as water could not fully hydrate the above 
lipid films. Moreover at pH 7.4, IBU is almost fully ionized so solubility problem in 
liposomal vehicle was solved. Therefore, PBS was selected as the hydration medium 
to prepare all IBU loaded liposomes. 
IBU loaded conventional and elastic liposomes were prepared and characterized as 
done in the case of NaFl loaded liposomes. Similar to findings in NaFl loaded 
liposomes, cholesterol and surfactants showed to reduce the particle size and 
increase the negative charge on IBU loaded liposomes. The zeta potential of 
liposomes was found to be dependent on cholesterol, surfactant and drug as well. 
Maximum size reduction of IBU loaded elastic liposomes was found in 25% w/w 
surfactant, possibly due to the formation of micellar structures. Compared to the zeta 
potential of empty pure PC and 30% w/w cholesterol containing liposome in buffer, 
IBU loaded liposomes had less positive and more negative charge respectively due to 
the adsorption of anionic IBU on the surface of PC molecule 
267
. With each inclusion 
of additional cholesterol, the zeta potential of IBU conventional liposomes tended to 
become more negative which could be explained by the reduction in surface binding 
affinity of cations from PBS on PC molecule in presence of cholesterol
269
. In 
contrast to NaFl loaded conventional liposomes, cholesterol had a negative effect on 
the entrapment of IBU loaded liposomes. At PBS pH 7.4, IBU is almost fully ionized 
and these ionized species tend to be associated with the lipid membrane by an ionic 
interaction. The higher EE found in pure PC liposomes could be explained by the 
ionic interaction between the PC and IBU molecule; the anionic portion (carboxylate 
ion) of IBU associated with the positively charged choline head of PC and the 
hydrophobic portion of IBU inserted into the acyl regions of PC tails
243
. With each 
inclusion of cholesterol in liposomal bilayer, the EE reduced, which was possibly 
due to the competition between IBU and cholesterol to take place in the hydrophobic 
region of PC, providing a limited space available for IBU
212
. Comparing to the EE of 
NaFl loaded liposomes, which is freely soluble in water, when loaded into 
liposomes, readily resides in the aqueous zone. Therefore incorporation of 
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cholesterol in bilayer had no competition with NaFl, rather it increased bilayer 
stability, leading to reduced permeation of entrapped NaFl through the bilayer to 
aqueous exterior. EE in all IBU loaded elastic liposomes reduced when surfactants 
were included. Maximum reduction in EE was noticed in 25% w/w surfactants 
containing liposomes, due to the formation of micelles. 
Vesicular elasticity was determined in all IBU loaded elastic liposomes and in two 
selected conventional liposomes. Maximum elasticity was found with 15% w/w 
surfactant, which dropped when more surfactant was added. Conventional liposomes 
had overall less deformation compared to elastic liposomes. Cholesterol is reported 
to reduce the freedom of molecular movement of PC molecule, causing poor 
elasticity. Results of characteristics of IBU loaded liposomes provided some 
knowledge on the influence of formulation variables on IBU loaded liposome 
optimization. Analyzing characterization data, IBU CON 0 was selected as most 
suitable because of their lowest size and highest EE whereas IBU T80 15 and IBU S. 
Chol 15 were selected for their highest elasticity. Only optimized liposomes were 
selected for the in vitro drug release study and the in vitro epidermal penetration 
study.  
4.1.2. In vitro drug release study 
All optimized liposomes were chosen for the in vitro drug release study. Drug 
release from liposomes was found to be dependent on formulation variables and 
showed a biphasic release pattern. Irrespective of the type of compound entrapped, 
significant prolongation of release was found from formulations compared to the 
control (free NaFl or IBU solution). NaFl loaded elastic liposomes showed faster 
release than that of the conventional liposome because of the presence of surfactant 
in their structure respectively. Surfactants are destabilizing molecule, causing bilayer 
soft and flexible for the entrapped drug to diffuse fast. The effect of cholesterol on 
the release of IBU was studied using different conventional liposomes, which 
showed a gradual reduction in release up to inclusion of 20% w/w cholesterol. When 
30% w/w of cholesterol was incorporated, faster release was observed compared to 
that of 20% w/w of cholesterol containing liposome suggesting that high 
concentration of cholesterol might have disrupted the bilayer structure
76
.  IBU 
releases from elastic liposomes were only slightly faster than that of conventional 
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liposome. Compared to NaFl release, IBU release was faster which could be due to 
the location of trapped molecule inside liposome. NaFl, being located in the core, is 
expected to show slow release as it has to cross the bilayer first to diffuse out 
whereas IBU, being partitioned in the bilayer is close to the vicinity of large 
receptor.  
4.1.3. In vitro skin penetration study 
An in vitro penetration study of IBU loaded optimized liposomes across human 
epidermis was conducted non-occlusively. The study revealed that the 
transepidermal flux of IBU from Tween 80 and sodium cholate containing elastic 
liposomes were 5.0 and 4.5 fold higher than that of control (0.64±0.04 µg/cm
2
/h) 
respectively and 3.0 and 2.7 fold higher than that of conventional liposome 
(1.00±0.03 µg/cm
2
/h) respectively. Penetration enhancing property of liposomes was 
dependent on formulation variable. Surfactants were found to be the key components 
in enhancing epidermal penetration which exert high deformability on liposome 
structure. Along with surfactants, another component which is thought to play role in 
improving transepidermal flux of IBU was ethanol, which might have improved drug 
partitioning into the stratum corneum. Elastic liposomes showed better drug 
deposition in the stratum corneum compared to that of conventional liposome and 
control suggesting that elastic liposomes may show depot forming ability to exert the 
local therapeutic effect of IBU. No significant difference in transepidermal flux was 
observed in between the two elastic liposomes. Conventional liposomes were found 
not suitable delivery system for topical application of IBU because they failed to 
show better IBU permeation compared to that of control. Result of epidermal 
permeation study shows that elastic liposomes have potential to be considered as 




In this study elastic liposomes were prepared to evaluate the topical delivery of  plain 
drug solution and conventional liposomes in delivering  IBU  as a model NSAID. 
Both conventional and elastic liposomes were developed and characterized with a 
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view to evaluate formulation variables in terms of their effect on the 
physicochemical properties of liposomes.  
 
Inclusion of both cholesterol and surfactant into liposomal bilayer was found to 
reduce particle size and increase the negative charge of liposomes compared to that 
of liposome without cholesterol and surfactant. The influence of cholesterol on EE of 
liposomes was found to be dependent on the type of compound entrapped. 
Cholesterol increased the EE of NaFl loaded liposomes while reduced the same in 
IBU loaded liposomes suggesting that the design of conventional liposomes should 
pay careful consideration on the influence of cholesterol on liposomal 
physicochemical properties. The hydration medium was found to show marked 
influence on size and zeta potential as well; all liposomes hydrated with water had 
smaller particle size and more negative zeta potential than those hydrated with PBS 
pH 7.4. Bilayer elasticity of elastic liposomes was found to be highly dependent on 
the  ratio of PC and surfactant. All elastic liposomes showed maximum 
deformability at the surfactant content of 15% w/w regardless of the type of 
surfactant used. Above this content, elasticity was found to drop dramatically 
suggesting that elastic liposomes that show maximum deformation at 15% surfactant 
inclusion may be expected to  enhance skin penetration . Results of physical stability 
of liposomes showed that cholesterol incorporation into bilayer has potential 
stabilization of liposome against particle aggregation and fusion upon long term 
storage. Vesicular stability improved under refrigeration (4±2ºC). Under TEM, all 
liposomes were appeared as spherical and regular vesicles. 
 
The in vitro dialysis and human epidermal skin release study showed a significant 
prolongation of drug release from liposomes compared to that of free drug solution 
indicating that liposomal formulations may act as sustained release delivery vehicle. 
Incorporation of cholesterol caused the liposomal bilayer more rigid and provided a 
slow drug release compared to that of elastic liposomes prepared from either Tween 
80 or sodium cholate. Moreover release of IBU was faster from all liposomes 
compared to the release of NaFl concluding that drug entrapped inside the core 
shows slow release. 
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Elastic liposomes improved in vitro topical delivery of IBU across human epidermis 
compared to conventional liposomes and free drug solution. Inclusion of surfactants 
and ethanol into elastic liposomes were found to play major role in enhancing IBU 
permeation when vesicles were applied under non-occluded condition. No significant 
difference in enhancement was observed in between the  elastic liposomes. Better 
IBU drug deposition in the stratum corneum was obtained from elastic liposomes 
indicating that these delivery vehicles may show depot forming ability and localize 
IBU at the targeted tissue. Conventional liposomes failed to achieve significant 
improvement in drug permeation compared to control drug solution due to the 
absence of penetration enhancers in their composition. Results from the skin 
penetration study indicate that elastic liposomal formulations are better topical 
delivery system for IBU in comparison to conventional liposomes and the control. 
This delivery system has a great potential for the delivery of other potential 
therapeutic molecules to achieve the local pharmacological effects.  
 
4.3. Scope for future work 
The current study revealed that elastic liposomes showed better penetration of IBU, 
but no mechanistic study was drawn. The possible mechanism by which elastic 
liposomes enhance dermal penetration is still not very clear.  Different mechanisms 
have been proposed and discussed in  this thesis. Elastic liposomes work either as 
drug carrier systems and/or as penetration enhancers. In the case of the former 
mechanism, intact vesicles are proposed to enter the stratum corneum. Therefore, a 
skin distribution study needs to be investigated in future to support this mechanism. 
To evaluate elastic liposomes as penetration enhancers, pre-treatment with empty 
elastic vesicles followed by drug application and liposomes with drug outside (i.e. 
non-entrapped) will be worthwhile to investigate the penetration enhancing 
mechanism.  
Some investigators have reported that conventional liposomes work better under 
occluded condition, as there is no transdermal hydration gradient operating at this 
condition. Therefore, a separate in vitro skin penetration study should be conducted 
under occluded condition to investigate how conventional liposomes show IBU 
transport through the stratum corneum and should be compared with that of elastic 
liposomes applied under non-occluded condition. 
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In the current study, a single type of phospholipid was used to prepare all liposomes, 
i.e. PC. Utilization of other lipids, for example, charge imparting agents as well as 
skin lipids could be used to investigate if they can also be used to prepare elastic 
liposomes and to enhance the drug skin penetration. Utilization of other surfactants, 
for example Span series could also be done to see how it influences epidermal 
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